bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags sequence	text stringlengths 5 72.4k	tokens sequence	types sequence
Pionierzeit is an umlsterm, Replantation is an umlsterm, Extremitaet is an umlsterm, Schmerzen is an umlsterm, Replantation is an umlsterm, Unfallmechanismus is an umlsterm, Replantation is an umlsterm, Patienten is an umlsterm	DerUnfallchirurg.71000694.ger.abstr_task0	Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .	[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]	[ "umlsterm" ]
Pionierzeit is an umlsterm, Replantation is an umlsterm, Extremitaet is an umlsterm, Schmerzen is an umlsterm, Replantation is an umlsterm, Unfallmechanismus is an umlsterm, Replantation is an umlsterm, Patienten is an umlsterm	DerUnfallchirurg.71000694.ger.abstr_task1	Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please typing these entity words according to sentence: Pionierzeit, Replantation, Extremitaet, Schmerzen, Replantation, Unfallmechanismus, Replantation, Patienten Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .	[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]	[ "umlsterm" ]
Pionierzeit, Replantation, Extremitaet, Schmerzen, Replantation, Unfallmechanismus, Replantation, Patienten	DerUnfallchirurg.71000694.ger.abstr_task2	Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .	[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]	[ "umlsterm" ]
transfer is an umlsterm, safety is an umlsterm, interaction is an umlsterm, teleradiology is an umlsterm, selection is an umlsterm	DerRadiologe.70370336.eng.abstr_task0	Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .	[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]	[ "umlsterm" ]
transfer is an umlsterm, safety is an umlsterm, interaction is an umlsterm, teleradiology is an umlsterm, selection is an umlsterm	DerRadiologe.70370336.eng.abstr_task1	Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please typing these entity words according to sentence: transfer, safety, interaction, teleradiology, selection Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .	[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]	[ "umlsterm" ]
transfer, safety, interaction, teleradiology, selection	DerRadiologe.70370336.eng.abstr_task2	Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .	[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]	[ "umlsterm" ]
Drucksenkung is an umlsterm, Glaukomaugen is an umlsterm	DerOpthalmologe.70940665.ger.abstr_task0	Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?	[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]	[ "umlsterm" ]
Drucksenkung is an umlsterm, Glaukomaugen is an umlsterm	DerOpthalmologe.70940665.ger.abstr_task1	Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please typing these entity words according to sentence: Drucksenkung, Glaukomaugen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?	[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]	[ "umlsterm" ]
Drucksenkung, Glaukomaugen	DerOpthalmologe.70940665.ger.abstr_task2	Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?	[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]	[ "umlsterm" ]
man is an umlsterm, giant - cell is an umlsterm, tumor is an umlsterm, right is an umlsterm, temporomandibular joint is an umlsterm, growth is an umlsterm, treatment is an umlsterm, endotracheal anesthesia is an umlsterm, recurrence is an umlsterm, Differential diagnosis is an umlsterm, therapy is an umlsterm	MundKieferGesichtschirurgie.80020279.eng.abstr_task0	Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .	[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]	[ "umlsterm" ]
man is an umlsterm, giant - cell is an umlsterm, tumor is an umlsterm, right is an umlsterm, temporomandibular joint is an umlsterm, growth is an umlsterm, treatment is an umlsterm, endotracheal anesthesia is an umlsterm, recurrence is an umlsterm, Differential diagnosis is an umlsterm, therapy is an umlsterm	MundKieferGesichtschirurgie.80020279.eng.abstr_task1	Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please typing these entity words according to sentence: man, giant - cell, tumor, right, temporomandibular joint, growth, treatment, endotracheal anesthesia, recurrence, Differential diagnosis, therapy Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .	[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]	[ "umlsterm" ]
man, giant - cell, tumor, right, temporomandibular joint, growth, treatment, endotracheal anesthesia, recurrence, Differential diagnosis, therapy	MundKieferGesichtschirurgie.80020279.eng.abstr_task2	Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .	[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]	[ "umlsterm" ]
Metoclopramide is a DRUG, MONUROL is a BRAND, metoclopramide is a DRUG, fosfomycin is a DRUG, Cimetidine is a DRUG, Cimetidine is a DRUG, fosfomycin is a DRUG, MONUROL is a BRAND	Fosfomycin_ddi_task0	Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: BRAND, DRUG	[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]	Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.	[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]	[ "DRUG", "BRAND" ]
Metoclopramide is a DRUG, MONUROL is a BRAND, metoclopramide is a DRUG, fosfomycin is a DRUG, Cimetidine is a DRUG, Cimetidine is a DRUG, fosfomycin is a DRUG, MONUROL is a BRAND	Fosfomycin_ddi_task1	Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please typing these entity words according to sentence: Metoclopramide, MONUROL, metoclopramide, fosfomycin, Cimetidine, Cimetidine, fosfomycin, MONUROL Options: BRAND, DRUG	[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]	Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.	[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]	[ "DRUG", "BRAND" ]
Metoclopramide, MONUROL, metoclopramide, fosfomycin, Cimetidine, Cimetidine, fosfomycin, MONUROL	Fosfomycin_ddi_task2	Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please extract entity words from the input sentence	[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]	Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.	[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]	[ "DRUG", "BRAND" ]
I - DOX is a chemical, TTR is a protein, FAP is a disease	1.0alpha7.train.194_task0	Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: disease, chemical, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]	The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.	[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]	[ "chemical", "protein", "disease" ]
I - DOX is a chemical, TTR is a protein, FAP is a disease	1.0alpha7.train.194_task1	Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please typing these entity words according to sentence: I - DOX, TTR, FAP Options: disease, chemical, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]	The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.	[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]	[ "chemical", "protein", "disease" ]
I - DOX, TTR, FAP	1.0alpha7.train.194_task2	Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]	The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.	[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]	[ "chemical", "protein", "disease" ]
prostaglandin is a CHEMICAL	12713596_task0	Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.	[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
prostaglandin is a CHEMICAL	12713596_task1	Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please typing these entity words according to sentence: prostaglandin Options: CHEMICAL	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.	[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
prostaglandin	12713596_task2	Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please extract entity words from the input sentence	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.	[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
I kappaB alpha is a Protein, serines 32 and 36 is a Entity, I kappaB alpha is a Protein, p50 is a Protein, relA is a Protein, I kappaB alpha is a Protein, I kappaB alpha is a Protein, Tax is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein, I kappaB alpha is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein	9032271_task0	Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]	Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.	[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]	[ "Entity", "Protein" ]
I kappaB alpha is a Protein, serines 32 and 36 is a Entity, I kappaB alpha is a Protein, p50 is a Protein, relA is a Protein, I kappaB alpha is a Protein, I kappaB alpha is a Protein, Tax is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein, I kappaB alpha is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein	9032271_task1	Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please typing these entity words according to sentence: I kappaB alpha, serines 32 and 36, I kappaB alpha, p50, relA, I kappaB alpha, I kappaB alpha, Tax, I kappaB beta, I kappaB epsilon, I kappaB alpha, I kappaB beta, I kappaB epsilon Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]	Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.	[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]	[ "Entity", "Protein" ]
I kappaB alpha, serines 32 and 36, I kappaB alpha, p50, relA, I kappaB alpha, I kappaB alpha, Tax, I kappaB beta, I kappaB epsilon, I kappaB alpha, I kappaB beta, I kappaB epsilon	9032271_task2	Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]	Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.	[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]	[ "Entity", "Protein" ]
Toxicities , including thromboembolism is an outcome, overall survival is an outcome	892_task0	Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome	[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]	Toxicities , including thromboembolism , and overall survival were similar .	[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]	[ "outcome" ]
Toxicities , including thromboembolism is an outcome, overall survival is an outcome	892_task1	Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please typing these entity words according to sentence: Toxicities , including thromboembolism, overall survival Options: outcome	[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]	Toxicities , including thromboembolism , and overall survival were similar .	[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]	[ "outcome" ]
Toxicities , including thromboembolism, overall survival	892_task2	Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please extract entity words from the input sentence	[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]	Toxicities , including thromboembolism , and overall survival were similar .	[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]	[ "outcome" ]
hypertension is a Participant_Condition, reduced sodium intake is a Intervention_Physical, Dietary Approaches to Stop Hypertension ( DASH ) diet is a Intervention_Other, blood pressure ( BP ) is a Outcome_Physical, Adults is a Participant_Age, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg is a Participant_Condition, DASH diet is a Intervention_Educational, typical American ( control ) diet is a Intervention_Control, BP control is a Outcome_Physical, increased BP control is a Outcome_Physical, maximum BP control rate is a Outcome_Physical, DASH / lower sodium diet is a Intervention_Educational, control / lower sodium diet is a Intervention_Control	17841_task0	Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Intervention_Control, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical	[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .	[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]	[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]
hypertension is a Participant_Condition, reduced sodium intake is a Intervention_Physical, Dietary Approaches to Stop Hypertension ( DASH ) diet is a Intervention_Other, blood pressure ( BP ) is a Outcome_Physical, Adults is a Participant_Age, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg is a Participant_Condition, DASH diet is a Intervention_Educational, typical American ( control ) diet is a Intervention_Control, BP control is a Outcome_Physical, increased BP control is a Outcome_Physical, maximum BP control rate is a Outcome_Physical, DASH / lower sodium diet is a Intervention_Educational, control / lower sodium diet is a Intervention_Control	17841_task1	Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please typing these entity words according to sentence: hypertension, reduced sodium intake, Dietary Approaches to Stop Hypertension ( DASH ) diet, blood pressure ( BP ), Adults, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg, DASH diet, typical American ( control ) diet, BP control, increased BP control, maximum BP control rate, DASH / lower sodium diet, control / lower sodium diet Options: Intervention_Physical, Participant_Condition, Intervention_Control, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical	[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .	[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]	[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]
hypertension, reduced sodium intake, Dietary Approaches to Stop Hypertension ( DASH ) diet, blood pressure ( BP ), Adults, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg, DASH diet, typical American ( control ) diet, BP control, increased BP control, maximum BP control rate, DASH / lower sodium diet, control / lower sodium diet	17841_task2	Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .	[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]	[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]
CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene	225_task0	Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.	[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]	[ "Gene" ]
CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene	225_task1	Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please typing these entity words according to sentence: CHH, CHH, CHH, CHH, CHH Options: Gene	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.	[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]	[ "Gene" ]
CHH, CHH, CHH, CHH, CHH	225_task2	Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.	[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]	[ "Gene" ]
urologic surgery is a Procedure	NCT02805504_inc_task0	Sentence: Patients undergoing urologic surgery. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Procedure	[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]	Patients undergoing urologic surgery.	[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]	[ "Procedure" ]
urologic surgery is a Procedure	NCT02805504_inc_task1	Sentence: Patients undergoing urologic surgery. Instructions: please typing these entity words according to sentence: urologic surgery Options: Procedure	[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]	Patients undergoing urologic surgery.	[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]	[ "Procedure" ]
urologic surgery	NCT02805504_inc_task2	Sentence: Patients undergoing urologic surgery. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]	Patients undergoing urologic surgery.	[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]	[ "Procedure" ]
Embryonenschutzgesetz is an umlsterm, Forschung is an umlsterm, Embryonen is an umlsterm, Deutschland is an umlsterm, Zellen is an umlsterm, Embryo is an umlsterm, Stammzellen is an umlsterm, Embryos is an umlsterm, Embryonenschutzgesetz is an umlsterm, selbst is an umlsterm, Embryo is an umlsterm, Zellen is an umlsterm, Zellkerntransfer is an umlsterm, Eizellen is an umlsterm, Stammzellen is an umlsterm, Technik is an umlsterm, Zellen is an umlsterm, Menschen is an umlsterm, Deutschland is an umlsterm, Stammzellen is an umlsterm, Gewebe is an umlsterm, Feten is an umlsterm, Gewebeentnahme is an umlsterm, Verwendung is an umlsterm, Zellen is an umlsterm, Gewebe is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Deutschland is an umlsterm, Standards is an umlsterm, Lebenswerten is an umlsterm, Gesundheit is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Stammzellen is an umlsterm, Eizellen is an umlsterm, Embryonen is an umlsterm, Klonen is an umlsterm, Menschen is an umlsterm, Menschen is an umlsterm, Stammzellen is an umlsterm	Reproduktionsmedizin.90150159.ger.abstr_task0	Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .	[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]	[ "umlsterm" ]
Embryonenschutzgesetz is an umlsterm, Forschung is an umlsterm, Embryonen is an umlsterm, Deutschland is an umlsterm, Zellen is an umlsterm, Embryo is an umlsterm, Stammzellen is an umlsterm, Embryos is an umlsterm, Embryonenschutzgesetz is an umlsterm, selbst is an umlsterm, Embryo is an umlsterm, Zellen is an umlsterm, Zellkerntransfer is an umlsterm, Eizellen is an umlsterm, Stammzellen is an umlsterm, Technik is an umlsterm, Zellen is an umlsterm, Menschen is an umlsterm, Deutschland is an umlsterm, Stammzellen is an umlsterm, Gewebe is an umlsterm, Feten is an umlsterm, Gewebeentnahme is an umlsterm, Verwendung is an umlsterm, Zellen is an umlsterm, Gewebe is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Deutschland is an umlsterm, Standards is an umlsterm, Lebenswerten is an umlsterm, Gesundheit is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Stammzellen is an umlsterm, Eizellen is an umlsterm, Embryonen is an umlsterm, Klonen is an umlsterm, Menschen is an umlsterm, Menschen is an umlsterm, Stammzellen is an umlsterm	Reproduktionsmedizin.90150159.ger.abstr_task1	Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please typing these entity words according to sentence: Embryonenschutzgesetz, Forschung, Embryonen, Deutschland, Zellen, Embryo, Stammzellen, Embryos, Embryonenschutzgesetz, selbst, Embryo, Zellen, Zellkerntransfer, Eizellen, Stammzellen, Technik, Zellen, Menschen, Deutschland, Stammzellen, Gewebe, Feten, Gewebeentnahme, Verwendung, Zellen, Gewebe, Forschung, Stammzellen, Deutschland, Standards, Lebenswerten, Gesundheit, Forschung, Stammzellen, Stammzellen, Eizellen, Embryonen, Klonen, Menschen, Menschen, Stammzellen Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .	[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]	[ "umlsterm" ]
Embryonenschutzgesetz, Forschung, Embryonen, Deutschland, Zellen, Embryo, Stammzellen, Embryos, Embryonenschutzgesetz, selbst, Embryo, Zellen, Zellkerntransfer, Eizellen, Stammzellen, Technik, Zellen, Menschen, Deutschland, Stammzellen, Gewebe, Feten, Gewebeentnahme, Verwendung, Zellen, Gewebe, Forschung, Stammzellen, Deutschland, Standards, Lebenswerten, Gesundheit, Forschung, Stammzellen, Stammzellen, Eizellen, Embryonen, Klonen, Menschen, Menschen, Stammzellen	Reproduktionsmedizin.90150159.ger.abstr_task2	Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .	[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]	[ "umlsterm" ]
neurotoxicity is a ADVERSE	example-381_task0	Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]	Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.	[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]	[ "ADVERSE" ]
neurotoxicity is a ADVERSE	example-381_task1	Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please typing these entity words according to sentence: neurotoxicity Options: ADVERSE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]	Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.	[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]	[ "ADVERSE" ]
neurotoxicity	example-381_task2	Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]	Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.	[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]	[ "ADVERSE" ]
alpha - UBF antibody is a reagent, UBF is a protein, rDNA is a DNA, FISH is an assay	1.0alpha7.train.1055_task0	Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: assay, DNA, reagent, protein	[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).	[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]	[ "reagent", "DNA", "assay", "protein" ]
alpha - UBF antibody is a reagent, UBF is a protein, rDNA is a DNA, FISH is an assay	1.0alpha7.train.1055_task1	Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please typing these entity words according to sentence: alpha - UBF antibody, UBF, rDNA, FISH Options: assay, DNA, reagent, protein	[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).	[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]	[ "reagent", "DNA", "assay", "protein" ]
alpha - UBF antibody, UBF, rDNA, FISH	1.0alpha7.train.1055_task2	Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).	[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]	[ "reagent", "DNA", "assay", "protein" ]
Sp family members is a protein_family_or_group, promoter proximal repeat is a DNA_domain_or_region, HTLV - I enhancer is a DNA_domain_or_region	62654_task0	Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, DNA_domain_or_region	[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]	Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.	[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]	[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]
Sp family members is a protein_family_or_group, promoter proximal repeat is a DNA_domain_or_region, HTLV - I enhancer is a DNA_domain_or_region	62654_task1	Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please typing these entity words according to sentence: Sp family members, promoter proximal repeat, HTLV - I enhancer Options: protein_family_or_group, DNA_domain_or_region	[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]	Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.	[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]	[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]
Sp family members, promoter proximal repeat, HTLV - I enhancer	62654_task2	Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please extract entity words from the input sentence	[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]	Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.	[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]	[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]
Surgery is an umlsterm, therapeutic is an umlsterm, treatment is an umlsterm, tumors is an umlsterm, head is an umlsterm, neck is an umlsterm, dates is an umlsterm, lymph node dissection is an umlsterm, surgery is an umlsterm, plastic is an umlsterm, reconstructive surgery is an umlsterm, surgical is an umlsterm, patients is an umlsterm, development is an umlsterm, reconstructive surgery is an umlsterm, stages is an umlsterm, secondary is an umlsterm, flaps is an umlsterm, The change is an umlsterm, skin is an umlsterm, flaps is an umlsterm, flaps is an umlsterm, tissue is an umlsterm, transfer is an umlsterm, bone grafting is an umlsterm, bone grafting is an umlsterm, bone is an umlsterm, transfer is an umlsterm, donor is an umlsterm, five - year - survival is an umlsterm, carcinoma is an umlsterm, oral cavity is an umlsterm, tumor is an umlsterm, surgery is an umlsterm, imaging techniques is an umlsterm, surgical is an umlsterm, techniques is an umlsterm, guidelines is an umlsterm, surgery is an umlsterm, Surgical is an umlsterm, morbidity is an umlsterm, role is an umlsterm, tumors is an umlsterm, Tumors is an umlsterm, viscerocranium is an umlsterm, skull base is an umlsterm, osteotomy is an umlsterm, morbidity is an umlsterm, neck is an umlsterm, dissection is an umlsterm, techniques is an umlsterm, procedure is an umlsterm, inquiries is an umlsterm, surgical procedures is an umlsterm, surgical is an umlsterm, carcinomas is an umlsterm	MundKieferGesichtschirurgie.0004s142.eng.abstr_task0	Sentence: Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification .	[ "Surgery", "is", "still", "the", "primary", "therapeutic", "approach", "in", "treatment", "of", "tumors", "in", "the", "head", "and", "neck", "area", ",", "dating", "back", "to", "the", "early", "nineteenth", "century", ".", "More", "than", "150", "years", "ago", ",", "hemimaxillectomies", "and", "mandibular", "resections", "as", "well", "as", "hemiglossectomies", "were", "already", "performed", "by", "leading", "surgeons", ".", "The", "block", "principle", "we", "are", "now", "following", "dates", "back", "to", "Crile", ",", "who", "also", "established", "the", "principle", "of", "cervical", "lymph", "node", "dissection", ".", "Ablative", "oncologic", "surgery", "has", "always", "been", "closely", "linked", "with", "plastic", "and", "reconstructive", "surgery", ",", "rendering", "radical", "surgical", "interventions", "possible", "without", "disfiguring", "patients", ".", "The", "development", "of", "facial", "reconstructive", "surgery", "proceeded", "in", "stages", ",", "in", "the", "first", "instance", "as", "secondary", "reconstruction", "using", "tube", "pedicled", "flaps", ".", "The", "change", "to", "the", "concept", "of", "primary", "reconstruction", "occurred", "via", "arterialized", "skin", "flaps", "and", "myocutaneous", "flaps", "to", "the", "widely", "accepted", "and", "performed", "free", "tissue", "transfer", ".", "Free", "bone", "grafting", ",", "inaugurated", "earlier", "and", "still", "representing", "the", "majority", "of", "bone", "grafting", ",", "has", "been", "supplemented", "for", "certain", "reconstructive", "purposes", "by", "free", "vascularized", "bone", "transfer", "from", "various", "donor", "sites", ".", "Although", "the", "five", "-", "year", "-", "survival", "rate", "of", "carcinoma", "of", "the", "oral", "cavity", "has", "remained", "unchanged", "in", "the", "past", "30", "years", ",", "distinctive", "improvements", "in", "tumor", "surgery", "can", "be", "recorded", ".", "This", "is", "primarily", "based", "on", "improved", "diagnostics", "such", "as", "modern", "imaging", "techniques", "and", "the", "refinement", "of", "surgical", "techniques", ".", "The", "DOeSAK", "has", "worked", "out", "distinctive", "guidelines", "for", "effective", "ablative", "oncologic", "surgery", ".", "Surgical", "approaches", "offering", "wide", "exposure", "and", "carrying", "low", "morbidity", "play", "a", "decisive", "role", "in", "radical", "resections", ".", "For", "this", "reason", ",", "midfacial", "degloving", "offers", "an", "essential", "improvement", "for", "the", "resection", "of", "midface", "tumors", ",", "especially", "from", "an", "aesthetic", "point", "of", "view", ".", "Tumors", "situated", "deep", "behind", "the", "viscerocranium", "at", "the", "skull", "base", "can", "be", "clearly", "exposed", "either", "through", "a", "lateral", "approach", "following", "a", "temporary", "osteotomy", "of", "the", "mandibular", "ramus", "or", "a", "transmandibular", ",", "transmaxillar", ",", "or", "transfacial", "approach", "with", "minimal", "morbidity", ".", "Concerning", "the", "concept", "of", "neck", "dissection", ",", "radical", "techniques", "are", "more", "and", "more", "abandoned", "in", "favor", "of", "a", "more", "conservative", "procedure", ".", "Actual", "inquiries", "concerning", "present", "surgical", "procedures", "as", "to", "the", "surgical", "strategy", "in", "\"", "No", "-", "neck", "\"", "or", "marginal", "and", "segmental", "resection", "in", "mandibular", "adherent", "carcinomas", "demand", "scientific", "clarification", "." ]	[ "umlsterm" ]
Surgery is an umlsterm, therapeutic is an umlsterm, treatment is an umlsterm, tumors is an umlsterm, head is an umlsterm, neck is an umlsterm, dates is an umlsterm, lymph node dissection is an umlsterm, surgery is an umlsterm, plastic is an umlsterm, reconstructive surgery is an umlsterm, surgical is an umlsterm, patients is an umlsterm, development is an umlsterm, reconstructive surgery is an umlsterm, stages is an umlsterm, secondary is an umlsterm, flaps is an umlsterm, The change is an umlsterm, skin is an umlsterm, flaps is an umlsterm, flaps is an umlsterm, tissue is an umlsterm, transfer is an umlsterm, bone grafting is an umlsterm, bone grafting is an umlsterm, bone is an umlsterm, transfer is an umlsterm, donor is an umlsterm, five - year - survival is an umlsterm, carcinoma is an umlsterm, oral cavity is an umlsterm, tumor is an umlsterm, surgery is an umlsterm, imaging techniques is an umlsterm, surgical is an umlsterm, techniques is an umlsterm, guidelines is an umlsterm, surgery is an umlsterm, Surgical is an umlsterm, morbidity is an umlsterm, role is an umlsterm, tumors is an umlsterm, Tumors is an umlsterm, viscerocranium is an umlsterm, skull base is an umlsterm, osteotomy is an umlsterm, morbidity is an umlsterm, neck is an umlsterm, dissection is an umlsterm, techniques is an umlsterm, procedure is an umlsterm, inquiries is an umlsterm, surgical procedures is an umlsterm, surgical is an umlsterm, carcinomas is an umlsterm	MundKieferGesichtschirurgie.0004s142.eng.abstr_task1	Sentence: Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification . Instructions: please typing these entity words according to sentence: Surgery, therapeutic, treatment, tumors, head, neck, dates, lymph node dissection, surgery, plastic, reconstructive surgery, surgical, patients, development, reconstructive surgery, stages, secondary, flaps, The change, skin, flaps, flaps, tissue, transfer, bone grafting, bone grafting, bone, transfer, donor, five - year - survival, carcinoma, oral cavity, tumor, surgery, imaging techniques, surgical, techniques, guidelines, surgery, Surgical, morbidity, role, tumors, Tumors, viscerocranium, skull base, osteotomy, morbidity, neck, dissection, techniques, procedure, inquiries, surgical procedures, surgical, carcinomas Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification .	[ "Surgery", "is", "still", "the", "primary", "therapeutic", "approach", "in", "treatment", "of", "tumors", "in", "the", "head", "and", "neck", "area", ",", "dating", "back", "to", "the", "early", "nineteenth", "century", ".", "More", "than", "150", "years", "ago", ",", "hemimaxillectomies", "and", "mandibular", "resections", "as", "well", "as", "hemiglossectomies", "were", "already", "performed", "by", "leading", "surgeons", ".", "The", "block", "principle", "we", "are", "now", "following", "dates", "back", "to", "Crile", ",", "who", "also", "established", "the", "principle", "of", "cervical", "lymph", "node", "dissection", ".", "Ablative", "oncologic", "surgery", "has", "always", "been", "closely", "linked", "with", "plastic", "and", "reconstructive", "surgery", ",", "rendering", "radical", "surgical", "interventions", "possible", "without", "disfiguring", "patients", ".", "The", "development", "of", "facial", "reconstructive", "surgery", "proceeded", "in", "stages", ",", "in", "the", "first", "instance", "as", "secondary", "reconstruction", "using", "tube", "pedicled", "flaps", ".", "The", "change", "to", "the", "concept", "of", "primary", "reconstruction", "occurred", "via", "arterialized", "skin", "flaps", "and", "myocutaneous", "flaps", "to", "the", "widely", "accepted", "and", "performed", "free", "tissue", "transfer", ".", "Free", "bone", "grafting", ",", "inaugurated", "earlier", "and", "still", "representing", "the", "majority", "of", "bone", "grafting", ",", "has", "been", "supplemented", "for", "certain", "reconstructive", "purposes", "by", "free", "vascularized", "bone", "transfer", "from", "various", "donor", "sites", ".", "Although", "the", "five", "-", "year", "-", "survival", "rate", "of", "carcinoma", "of", "the", "oral", "cavity", "has", "remained", "unchanged", "in", "the", "past", "30", "years", ",", "distinctive", "improvements", "in", "tumor", "surgery", "can", "be", "recorded", ".", "This", "is", "primarily", "based", "on", "improved", "diagnostics", "such", "as", "modern", "imaging", "techniques", "and", "the", "refinement", "of", "surgical", "techniques", ".", "The", "DOeSAK", "has", "worked", "out", "distinctive", "guidelines", "for", "effective", "ablative", "oncologic", "surgery", ".", "Surgical", "approaches", "offering", "wide", "exposure", "and", "carrying", "low", "morbidity", "play", "a", "decisive", "role", "in", "radical", "resections", ".", "For", "this", "reason", ",", "midfacial", "degloving", "offers", "an", "essential", "improvement", "for", "the", "resection", "of", "midface", "tumors", ",", "especially", "from", "an", "aesthetic", "point", "of", "view", ".", "Tumors", "situated", "deep", "behind", "the", "viscerocranium", "at", "the", "skull", "base", "can", "be", "clearly", "exposed", "either", "through", "a", "lateral", "approach", "following", "a", "temporary", "osteotomy", "of", "the", "mandibular", "ramus", "or", "a", "transmandibular", ",", "transmaxillar", ",", "or", "transfacial", "approach", "with", "minimal", "morbidity", ".", "Concerning", "the", "concept", "of", "neck", "dissection", ",", "radical", "techniques", "are", "more", "and", "more", "abandoned", "in", "favor", "of", "a", "more", "conservative", "procedure", ".", "Actual", "inquiries", "concerning", "present", "surgical", "procedures", "as", "to", "the", "surgical", "strategy", "in", "\"", "No", "-", "neck", "\"", "or", "marginal", "and", "segmental", "resection", "in", "mandibular", "adherent", "carcinomas", "demand", "scientific", "clarification", "." ]	[ "umlsterm" ]
Surgery, therapeutic, treatment, tumors, head, neck, dates, lymph node dissection, surgery, plastic, reconstructive surgery, surgical, patients, development, reconstructive surgery, stages, secondary, flaps, The change, skin, flaps, flaps, tissue, transfer, bone grafting, bone grafting, bone, transfer, donor, five - year - survival, carcinoma, oral cavity, tumor, surgery, imaging techniques, surgical, techniques, guidelines, surgery, Surgical, morbidity, role, tumors, Tumors, viscerocranium, skull base, osteotomy, morbidity, neck, dissection, techniques, procedure, inquiries, surgical procedures, surgical, carcinomas	MundKieferGesichtschirurgie.0004s142.eng.abstr_task2	Sentence: Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification .	[ "Surgery", "is", "still", "the", "primary", "therapeutic", "approach", "in", "treatment", "of", "tumors", "in", "the", "head", "and", "neck", "area", ",", "dating", "back", "to", "the", "early", "nineteenth", "century", ".", "More", "than", "150", "years", "ago", ",", "hemimaxillectomies", "and", "mandibular", "resections", "as", "well", "as", "hemiglossectomies", "were", "already", "performed", "by", "leading", "surgeons", ".", "The", "block", "principle", "we", "are", "now", "following", "dates", "back", "to", "Crile", ",", "who", "also", "established", "the", "principle", "of", "cervical", "lymph", "node", "dissection", ".", "Ablative", "oncologic", "surgery", "has", "always", "been", "closely", "linked", "with", "plastic", "and", "reconstructive", "surgery", ",", "rendering", "radical", "surgical", "interventions", "possible", "without", "disfiguring", "patients", ".", "The", "development", "of", "facial", "reconstructive", "surgery", "proceeded", "in", "stages", ",", "in", "the", "first", "instance", "as", "secondary", "reconstruction", "using", "tube", "pedicled", "flaps", ".", "The", "change", "to", "the", "concept", "of", "primary", "reconstruction", "occurred", "via", "arterialized", "skin", "flaps", "and", "myocutaneous", "flaps", "to", "the", "widely", "accepted", "and", "performed", "free", "tissue", "transfer", ".", "Free", "bone", "grafting", ",", "inaugurated", "earlier", "and", "still", "representing", "the", "majority", "of", "bone", "grafting", ",", "has", "been", "supplemented", "for", "certain", "reconstructive", "purposes", "by", "free", "vascularized", "bone", "transfer", "from", "various", "donor", "sites", ".", "Although", "the", "five", "-", "year", "-", "survival", "rate", "of", "carcinoma", "of", "the", "oral", "cavity", "has", "remained", "unchanged", "in", "the", "past", "30", "years", ",", "distinctive", "improvements", "in", "tumor", "surgery", "can", "be", "recorded", ".", "This", "is", "primarily", "based", "on", "improved", "diagnostics", "such", "as", "modern", "imaging", "techniques", "and", "the", "refinement", "of", "surgical", "techniques", ".", "The", "DOeSAK", "has", "worked", "out", "distinctive", "guidelines", "for", "effective", "ablative", "oncologic", "surgery", ".", "Surgical", "approaches", "offering", "wide", "exposure", "and", "carrying", "low", "morbidity", "play", "a", "decisive", "role", "in", "radical", "resections", ".", "For", "this", "reason", ",", "midfacial", "degloving", "offers", "an", "essential", "improvement", "for", "the", "resection", "of", "midface", "tumors", ",", "especially", "from", "an", "aesthetic", "point", "of", "view", ".", "Tumors", "situated", "deep", "behind", "the", "viscerocranium", "at", "the", "skull", "base", "can", "be", "clearly", "exposed", "either", "through", "a", "lateral", "approach", "following", "a", "temporary", "osteotomy", "of", "the", "mandibular", "ramus", "or", "a", "transmandibular", ",", "transmaxillar", ",", "or", "transfacial", "approach", "with", "minimal", "morbidity", ".", "Concerning", "the", "concept", "of", "neck", "dissection", ",", "radical", "techniques", "are", "more", "and", "more", "abandoned", "in", "favor", "of", "a", "more", "conservative", "procedure", ".", "Actual", "inquiries", "concerning", "present", "surgical", "procedures", "as", "to", "the", "surgical", "strategy", "in", "\"", "No", "-", "neck", "\"", "or", "marginal", "and", "segmental", "resection", "in", "mandibular", "adherent", "carcinomas", "demand", "scientific", "clarification", "." ]	[ "umlsterm" ]
CCL3 is a GENE-Y, CCR1 is a GENE-Y	23059626_task0	Sentence: The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.	[ "The", "effect", "of", "CCL3", "and", "CCR1", "in", "bone", "remodeling", "induced", "by", "mechanical", "loading", "during", "orthodontic", "tooth", "movement", "in", "mice", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
CCL3 is a GENE-Y, CCR1 is a GENE-Y	23059626_task1	Sentence: The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice. Instructions: please typing these entity words according to sentence: CCL3, CCR1 Options: GENE-Y	[ "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.	[ "The", "effect", "of", "CCL3", "and", "CCR1", "in", "bone", "remodeling", "induced", "by", "mechanical", "loading", "during", "orthodontic", "tooth", "movement", "in", "mice", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
CCL3, CCR1	23059626_task2	Sentence: The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.	[ "The", "effect", "of", "CCL3", "and", "CCR1", "in", "bone", "remodeling", "induced", "by", "mechanical", "loading", "during", "orthodontic", "tooth", "movement", "in", "mice", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Ramipril is an intervention, progression is an outcome	512_task0	Sentence: Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome	[ "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) .	[ "Ramipril", "reduced", "the", "risk", "for", "any", "progression", "(", "OR", ",", "0.87", ";", "95", "%", "CI", ",", "0.78", "to", "0.97", ";", "P", "=", "0.0146", ")", "." ]	[ "outcome", "intervention" ]
Ramipril is an intervention, progression is an outcome	512_task1	Sentence: Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) . Instructions: please typing these entity words according to sentence: Ramipril, progression Options: intervention, outcome	[ "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) .	[ "Ramipril", "reduced", "the", "risk", "for", "any", "progression", "(", "OR", ",", "0.87", ";", "95", "%", "CI", ",", "0.78", "to", "0.97", ";", "P", "=", "0.0146", ")", "." ]	[ "outcome", "intervention" ]
Ramipril, progression	512_task2	Sentence: Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) . Instructions: please extract entity words from the input sentence	[ "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) .	[ "Ramipril", "reduced", "the", "risk", "for", "any", "progression", "(", "OR", ",", "0.87", ";", "95", "%", "CI", ",", "0.78", "to", "0.97", ";", "P", "=", "0.0146", ")", "." ]	[ "outcome", "intervention" ]
cisplatin is a CHEMICAL	16876126_task0	Sentence: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]	RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.	[ "RNA", "interference", "-", "triggered", "reversal", "of", "ABCC2-dependent", "cisplatin", "resistance", "in", "human", "cancer", "cells", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
cisplatin is a CHEMICAL	16876126_task1	Sentence: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Instructions: please typing these entity words according to sentence: cisplatin Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]	RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.	[ "RNA", "interference", "-", "triggered", "reversal", "of", "ABCC2-dependent", "cisplatin", "resistance", "in", "human", "cancer", "cells", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
cisplatin	16876126_task2	Sentence: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]	RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.	[ "RNA", "interference", "-", "triggered", "reversal", "of", "ABCC2-dependent", "cisplatin", "resistance", "in", "human", "cancer", "cells", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Mn SOD is a Protein, Mn superoxide dismutase is a Protein, Cu , Zn SOD is a Protein, catalase is a Protein, Mn SOD is a Protein, human monocyte nuclear factor - kappaB is a Entity, Mn SOD is a Protein, tumor necrosis factor - alpha is a Protein, macrophage inflammatory protein-1alpha is a Protein, Mn SOD is a Protein, Mn SOD is a Protein, tumor necrosis factor - alpha is a Protein	105_task0	Sentence: Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase.	[ "Induction", "of", "Mn", "SOD", "in", "human", "monocytes", "without", "inflammatory", "cytokine", "production", "by", "a", "mutant", "endotoxin", ".", "\n", "Endotoxin", "selectively", "induces", "monocyte", "Mn", "superoxide", "dismutase", "(", "SOD", ")", "without", "affecting", "levels", "of", "Cu", ",", "Zn", "SOD", ",", "catalase", ",", "or", "glutathione", "peroxidase", ".", "However", ",", "little", "is", "known", "about", "the", "structure", "-", "activity", "relationship", "and", "the", "mechanism", "by", "which", "endotoxin", "induces", "Mn", "SOD", ".", "In", "this", "study", "we", "demonstrated", "that", "a", "mutant", "Escherichia", "coli", "endotoxin", "lacking", "myristoyl", "fatty", "acid", "at", "the", "3", "'", "R-3-hydroxymyristate", "position", "of", "the", "lipid", "A", "moiety", "retained", "its", "full", "capacity", "to", "coagulate", "Limulus", "amoebocyte", "lysate", "compared", "with", "the", "wild", "-", "type", "E.", "coli", "endotoxin", "and", "markedly", "stimulated", "the", "activation", "of", "human", "monocyte", "nuclear", "factor", "-", "kappaB", "and", "the", "induction", "of", "Mn", "SOD", "mRNA", "and", "enzyme", "activity", ".", "However", ",", "in", "contrast", "to", "the", "wild", "-", "type", "endotoxin", ",", "it", "failed", "to", "induce", "significant", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", "and", "macrophage", "inflammatory", "protein-1alpha", "by", "monocytes", "and", "did", "not", "induce", "the", "phosphorylation", "and", "nuclear", "translocation", "of", "mitogen", "-", "activated", "protein", "kinase", ".", "These", "results", "suggest", "that", "1", ")", "lipid", "A", "myristoyl", "fatty", "acid", ",", "although", "it", "is", "important", "for", "the", "induction", "of", "inflammatory", "cytokine", "production", "by", "human", "monocytes", ",", "is", "not", "necessary", "for", "the", "induction", "of", "Mn", "SOD", ",", "2", ")", "endotoxin", "-", "mediated", "induction", "of", "Mn", "SOD", "and", "inflammatory", "cytokines", "are", "regulated", ",", "at", "least", "in", "part", ",", "through", "different", "signal", "transduction", "pathways", ",", "and", "3", ")", "failure", "of", "the", "mutant", "endotoxin", "to", "induce", "tumor", "necrosis", "factor", "-", "alpha", "production", "is", ",", "at", "least", "in", "part", ",", "due", "to", "its", "inability", "to", "activate", "mitogen", "-", "activated", "protein", "kinase", ".", "\n" ]	[ "Protein", "Entity" ]
Mn SOD is a Protein, Mn superoxide dismutase is a Protein, Cu , Zn SOD is a Protein, catalase is a Protein, Mn SOD is a Protein, human monocyte nuclear factor - kappaB is a Entity, Mn SOD is a Protein, tumor necrosis factor - alpha is a Protein, macrophage inflammatory protein-1alpha is a Protein, Mn SOD is a Protein, Mn SOD is a Protein, tumor necrosis factor - alpha is a Protein	105_task1	Sentence: Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase. Instructions: please typing these entity words according to sentence: Mn SOD, Mn superoxide dismutase, Cu , Zn SOD, catalase, Mn SOD, human monocyte nuclear factor - kappaB, Mn SOD, tumor necrosis factor - alpha, macrophage inflammatory protein-1alpha, Mn SOD, Mn SOD, tumor necrosis factor - alpha Options: Entity, Protein	[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase.	[ "Induction", "of", "Mn", "SOD", "in", "human", "monocytes", "without", "inflammatory", "cytokine", "production", "by", "a", "mutant", "endotoxin", ".", "\n", "Endotoxin", "selectively", "induces", "monocyte", "Mn", "superoxide", "dismutase", "(", "SOD", ")", "without", "affecting", "levels", "of", "Cu", ",", "Zn", "SOD", ",", "catalase", ",", "or", "glutathione", "peroxidase", ".", "However", ",", "little", "is", "known", "about", "the", "structure", "-", "activity", "relationship", "and", "the", "mechanism", "by", "which", "endotoxin", "induces", "Mn", "SOD", ".", "In", "this", "study", "we", "demonstrated", "that", "a", "mutant", "Escherichia", "coli", "endotoxin", "lacking", "myristoyl", "fatty", "acid", "at", "the", "3", "'", "R-3-hydroxymyristate", "position", "of", "the", "lipid", "A", "moiety", "retained", "its", "full", "capacity", "to", "coagulate", "Limulus", "amoebocyte", "lysate", "compared", "with", "the", "wild", "-", "type", "E.", "coli", "endotoxin", "and", "markedly", "stimulated", "the", "activation", "of", "human", "monocyte", "nuclear", "factor", "-", "kappaB", "and", "the", "induction", "of", "Mn", "SOD", "mRNA", "and", "enzyme", "activity", ".", "However", ",", "in", "contrast", "to", "the", "wild", "-", "type", "endotoxin", ",", "it", "failed", "to", "induce", "significant", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", "and", "macrophage", "inflammatory", "protein-1alpha", "by", "monocytes", "and", "did", "not", "induce", "the", "phosphorylation", "and", "nuclear", "translocation", "of", "mitogen", "-", "activated", "protein", "kinase", ".", "These", "results", "suggest", "that", "1", ")", "lipid", "A", "myristoyl", "fatty", "acid", ",", "although", "it", "is", "important", "for", "the", "induction", "of", "inflammatory", "cytokine", "production", "by", "human", "monocytes", ",", "is", "not", "necessary", "for", "the", "induction", "of", "Mn", "SOD", ",", "2", ")", "endotoxin", "-", "mediated", "induction", "of", "Mn", "SOD", "and", "inflammatory", "cytokines", "are", "regulated", ",", "at", "least", "in", "part", ",", "through", "different", "signal", "transduction", "pathways", ",", "and", "3", ")", "failure", "of", "the", "mutant", "endotoxin", "to", "induce", "tumor", "necrosis", "factor", "-", "alpha", "production", "is", ",", "at", "least", "in", "part", ",", "due", "to", "its", "inability", "to", "activate", "mitogen", "-", "activated", "protein", "kinase", ".", "\n" ]	[ "Protein", "Entity" ]
Mn SOD, Mn superoxide dismutase, Cu , Zn SOD, catalase, Mn SOD, human monocyte nuclear factor - kappaB, Mn SOD, tumor necrosis factor - alpha, macrophage inflammatory protein-1alpha, Mn SOD, Mn SOD, tumor necrosis factor - alpha	105_task2	Sentence: Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase.	[ "Induction", "of", "Mn", "SOD", "in", "human", "monocytes", "without", "inflammatory", "cytokine", "production", "by", "a", "mutant", "endotoxin", ".", "\n", "Endotoxin", "selectively", "induces", "monocyte", "Mn", "superoxide", "dismutase", "(", "SOD", ")", "without", "affecting", "levels", "of", "Cu", ",", "Zn", "SOD", ",", "catalase", ",", "or", "glutathione", "peroxidase", ".", "However", ",", "little", "is", "known", "about", "the", "structure", "-", "activity", "relationship", "and", "the", "mechanism", "by", "which", "endotoxin", "induces", "Mn", "SOD", ".", "In", "this", "study", "we", "demonstrated", "that", "a", "mutant", "Escherichia", "coli", "endotoxin", "lacking", "myristoyl", "fatty", "acid", "at", "the", "3", "'", "R-3-hydroxymyristate", "position", "of", "the", "lipid", "A", "moiety", "retained", "its", "full", "capacity", "to", "coagulate", "Limulus", "amoebocyte", "lysate", "compared", "with", "the", "wild", "-", "type", "E.", "coli", "endotoxin", "and", "markedly", "stimulated", "the", "activation", "of", "human", "monocyte", "nuclear", "factor", "-", "kappaB", "and", "the", "induction", "of", "Mn", "SOD", "mRNA", "and", "enzyme", "activity", ".", "However", ",", "in", "contrast", "to", "the", "wild", "-", "type", "endotoxin", ",", "it", "failed", "to", "induce", "significant", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", "and", "macrophage", "inflammatory", "protein-1alpha", "by", "monocytes", "and", "did", "not", "induce", "the", "phosphorylation", "and", "nuclear", "translocation", "of", "mitogen", "-", "activated", "protein", "kinase", ".", "These", "results", "suggest", "that", "1", ")", "lipid", "A", "myristoyl", "fatty", "acid", ",", "although", "it", "is", "important", "for", "the", "induction", "of", "inflammatory", "cytokine", "production", "by", "human", "monocytes", ",", "is", "not", "necessary", "for", "the", "induction", "of", "Mn", "SOD", ",", "2", ")", "endotoxin", "-", "mediated", "induction", "of", "Mn", "SOD", "and", "inflammatory", "cytokines", "are", "regulated", ",", "at", "least", "in", "part", ",", "through", "different", "signal", "transduction", "pathways", ",", "and", "3", ")", "failure", "of", "the", "mutant", "endotoxin", "to", "induce", "tumor", "necrosis", "factor", "-", "alpha", "production", "is", ",", "at", "least", "in", "part", ",", "due", "to", "its", "inability", "to", "activate", "mitogen", "-", "activated", "protein", "kinase", ".", "\n" ]	[ "Protein", "Entity" ]
Surgery is an umlsterm, hyperparathyroidism is an umlsterm, standard is an umlsterm, therapy is an umlsterm, frequency is an umlsterm, testing is an umlsterm, surgery is an umlsterm, evaluation is an umlsterm, surgical is an umlsterm, safety is an umlsterm, retrospective is an umlsterm, analysis is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, female is an umlsterm, age is an umlsterm, patients is an umlsterm, sonography is an umlsterm, adenoma is an umlsterm, catheterization is an umlsterm, analysis is an umlsterm, patients is an umlsterm, patients is an umlsterm, procedures is an umlsterm, ultrasound is an umlsterm, catheterization is an umlsterm, Postoperative is an umlsterm, morbidity is an umlsterm, recurrent laryngeal nerve is an umlsterm, palsy is an umlsterm, patients is an umlsterm, hemorrhage is an umlsterm, reoperation is an umlsterm, hypoparathyroidism is an umlsterm, supplementation is an umlsterm, patients is an umlsterm, hypoparathyroidism is an umlsterm, postoperative is an umlsterm, mortality is an umlsterm, Risk is an umlsterm, factor analysis is an umlsterm, morbidity is an umlsterm, Surgery is an umlsterm, safety is an umlsterm, patients is an umlsterm, patients is an umlsterm, surgery is an umlsterm	DerChirurg.70680141.eng.abstr_task0	Sentence: Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery .	[ "Surgery", "for", "symptomatic", "hyperparathyroidism", "remains", "the", "standard", "therapy", ".", "Asymptomatic", "primary", "hyperparathyroidsm", "(", "pHPT", ")", "is", "being", "diagnosed", "with", "increasing", "frequency", "owing", "to", "broad", "serum", "testing", ".", "Indications", "for", "surgery", "in", "this", "setting", "are", "controversial", ".", "For", "evaluation", "of", "surgical", "safety", "we", "performed", "a", "retrospective", "analysis", "of", "our", "patients", "who", "were", "being", "operated", "on", "for", "asymptomatic", "pHPT", ".", "From", "January", "1988", "until", "August", "1995", ",", "243", "patients", "were", "treated", "for", "pHPT", "and", "registered", "prospectively", "at", "our", "unit", ".", "Seventy", "-", "six", "patients", "were", "classified", "as", "asymptomatic", ".", "In", "all", ",", "75", "%", "of", "the", "patients", "were", "female", ";", "the", "mean", "age", "was", "62", "years", ".", "In", "this", "group", ",", "87", "%", "of", "the", "patients", "had", "cervical", "sonography", "in", "order", "to", "localize", "the", "adenoma", ".", "Highly", "selective", "venous", "catheterization", "was", "required", "in", "cervical", "reexplorations", ".", "Statistical", "analysis", "for", "potential", "prognostic", "factors", "for", "the", "clinical", "outcome", "was", "performed", ".", "Successful", "cervical", "exploration", "was", "possible", "in", "71", "patients", "(", "94.7", "%", ")", ".", "With", "4", "patients", "remaining", "hypercalcemic", ",", "the", "rate", "of", "persistency", "was", "5.2", "%", ".", "Localization", "procedures", "were", "correct", "in", "58", "%", "for", "cervical", "ultrasound", "and", "77", "%", "for", "selective", "venous", "catheterization", ".", "Postoperative", "morbidity", "included", "one", "permanent", "recurrent", "laryngeal", "nerve", "palsy", "and", "2", "patients", "with", "hemorrhage", "who", "were", "treated", "by", "reoperation", ".", "While", "one", "case", "of", "permanent", "hypoparathyroidism", "was", "well", "controlled", "by", "oral", "supplementation", ",", "18", "patients", "recovered", "from", "temporary", "hypoparathyroidism", ".", "No", "postoperative", "mortality", "occurred", ".", "Risk", "factor", "analysis", "revealed", "only", "cervical", "reexplorations", "for", "HPT", "to", "be", "associated", "with", "a", "higher", "morbidity", "(", "P", "=", "0.02", ")", ".", "Surgery", "for", "asymptomatic", "pHPT", "can", "be", "performed", "with", "reasonable", "safety", ".", "Cervical", "reexplorations", "in", "asymptomatic", "patients", "should", "be", "reserved", "for", "special", "indications", ".", "Apart", "from", "this", "small", "group", ",", "all", "patients", "should", "be", "evaluated", "for", "surgery", "." ]	[ "umlsterm" ]
Surgery is an umlsterm, hyperparathyroidism is an umlsterm, standard is an umlsterm, therapy is an umlsterm, frequency is an umlsterm, testing is an umlsterm, surgery is an umlsterm, evaluation is an umlsterm, surgical is an umlsterm, safety is an umlsterm, retrospective is an umlsterm, analysis is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, female is an umlsterm, age is an umlsterm, patients is an umlsterm, sonography is an umlsterm, adenoma is an umlsterm, catheterization is an umlsterm, analysis is an umlsterm, patients is an umlsterm, patients is an umlsterm, procedures is an umlsterm, ultrasound is an umlsterm, catheterization is an umlsterm, Postoperative is an umlsterm, morbidity is an umlsterm, recurrent laryngeal nerve is an umlsterm, palsy is an umlsterm, patients is an umlsterm, hemorrhage is an umlsterm, reoperation is an umlsterm, hypoparathyroidism is an umlsterm, supplementation is an umlsterm, patients is an umlsterm, hypoparathyroidism is an umlsterm, postoperative is an umlsterm, mortality is an umlsterm, Risk is an umlsterm, factor analysis is an umlsterm, morbidity is an umlsterm, Surgery is an umlsterm, safety is an umlsterm, patients is an umlsterm, patients is an umlsterm, surgery is an umlsterm	DerChirurg.70680141.eng.abstr_task1	Sentence: Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery . Instructions: please typing these entity words according to sentence: Surgery, hyperparathyroidism, standard, therapy, frequency, testing, surgery, evaluation, surgical, safety, retrospective, analysis, patients, patients, patients, patients, female, age, patients, sonography, adenoma, catheterization, analysis, patients, patients, procedures, ultrasound, catheterization, Postoperative, morbidity, recurrent laryngeal nerve, palsy, patients, hemorrhage, reoperation, hypoparathyroidism, supplementation, patients, hypoparathyroidism, postoperative, mortality, Risk, factor analysis, morbidity, Surgery, safety, patients, patients, surgery Options: umlsterm	[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery .	[ "Surgery", "for", "symptomatic", "hyperparathyroidism", "remains", "the", "standard", "therapy", ".", "Asymptomatic", "primary", "hyperparathyroidsm", "(", "pHPT", ")", "is", "being", "diagnosed", "with", "increasing", "frequency", "owing", "to", "broad", "serum", "testing", ".", "Indications", "for", "surgery", "in", "this", "setting", "are", "controversial", ".", "For", "evaluation", "of", "surgical", "safety", "we", "performed", "a", "retrospective", "analysis", "of", "our", "patients", "who", "were", "being", "operated", "on", "for", "asymptomatic", "pHPT", ".", "From", "January", "1988", "until", "August", "1995", ",", "243", "patients", "were", "treated", "for", "pHPT", "and", "registered", "prospectively", "at", "our", "unit", ".", "Seventy", "-", "six", "patients", "were", "classified", "as", "asymptomatic", ".", "In", "all", ",", "75", "%", "of", "the", "patients", "were", "female", ";", "the", "mean", "age", "was", "62", "years", ".", "In", "this", "group", ",", "87", "%", "of", "the", "patients", "had", "cervical", "sonography", "in", "order", "to", "localize", "the", "adenoma", ".", "Highly", "selective", "venous", "catheterization", "was", "required", "in", "cervical", "reexplorations", ".", "Statistical", "analysis", "for", "potential", "prognostic", "factors", "for", "the", "clinical", "outcome", "was", "performed", ".", "Successful", "cervical", "exploration", "was", "possible", "in", "71", "patients", "(", "94.7", "%", ")", ".", "With", "4", "patients", "remaining", "hypercalcemic", ",", "the", "rate", "of", "persistency", "was", "5.2", "%", ".", "Localization", "procedures", "were", "correct", "in", "58", "%", "for", "cervical", "ultrasound", "and", "77", "%", "for", "selective", "venous", "catheterization", ".", "Postoperative", "morbidity", "included", "one", "permanent", "recurrent", "laryngeal", "nerve", "palsy", "and", "2", "patients", "with", "hemorrhage", "who", "were", "treated", "by", "reoperation", ".", "While", "one", "case", "of", "permanent", "hypoparathyroidism", "was", "well", "controlled", "by", "oral", "supplementation", ",", "18", "patients", "recovered", "from", "temporary", "hypoparathyroidism", ".", "No", "postoperative", "mortality", "occurred", ".", "Risk", "factor", "analysis", "revealed", "only", "cervical", "reexplorations", "for", "HPT", "to", "be", "associated", "with", "a", "higher", "morbidity", "(", "P", "=", "0.02", ")", ".", "Surgery", "for", "asymptomatic", "pHPT", "can", "be", "performed", "with", "reasonable", "safety", ".", "Cervical", "reexplorations", "in", "asymptomatic", "patients", "should", "be", "reserved", "for", "special", "indications", ".", "Apart", "from", "this", "small", "group", ",", "all", "patients", "should", "be", "evaluated", "for", "surgery", "." ]	[ "umlsterm" ]
Surgery, hyperparathyroidism, standard, therapy, frequency, testing, surgery, evaluation, surgical, safety, retrospective, analysis, patients, patients, patients, patients, female, age, patients, sonography, adenoma, catheterization, analysis, patients, patients, procedures, ultrasound, catheterization, Postoperative, morbidity, recurrent laryngeal nerve, palsy, patients, hemorrhage, reoperation, hypoparathyroidism, supplementation, patients, hypoparathyroidism, postoperative, mortality, Risk, factor analysis, morbidity, Surgery, safety, patients, patients, surgery	DerChirurg.70680141.eng.abstr_task2	Sentence: Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery .	[ "Surgery", "for", "symptomatic", "hyperparathyroidism", "remains", "the", "standard", "therapy", ".", "Asymptomatic", "primary", "hyperparathyroidsm", "(", "pHPT", ")", "is", "being", "diagnosed", "with", "increasing", "frequency", "owing", "to", "broad", "serum", "testing", ".", "Indications", "for", "surgery", "in", "this", "setting", "are", "controversial", ".", "For", "evaluation", "of", "surgical", "safety", "we", "performed", "a", "retrospective", "analysis", "of", "our", "patients", "who", "were", "being", "operated", "on", "for", "asymptomatic", "pHPT", ".", "From", "January", "1988", "until", "August", "1995", ",", "243", "patients", "were", "treated", "for", "pHPT", "and", "registered", "prospectively", "at", "our", "unit", ".", "Seventy", "-", "six", "patients", "were", "classified", "as", "asymptomatic", ".", "In", "all", ",", "75", "%", "of", "the", "patients", "were", "female", ";", "the", "mean", "age", "was", "62", "years", ".", "In", "this", "group", ",", "87", "%", "of", "the", "patients", "had", "cervical", "sonography", "in", "order", "to", "localize", "the", "adenoma", ".", "Highly", "selective", "venous", "catheterization", "was", "required", "in", "cervical", "reexplorations", ".", "Statistical", "analysis", "for", "potential", "prognostic", "factors", "for", "the", "clinical", "outcome", "was", "performed", ".", "Successful", "cervical", "exploration", "was", "possible", "in", "71", "patients", "(", "94.7", "%", ")", ".", "With", "4", "patients", "remaining", "hypercalcemic", ",", "the", "rate", "of", "persistency", "was", "5.2", "%", ".", "Localization", "procedures", "were", "correct", "in", "58", "%", "for", "cervical", "ultrasound", "and", "77", "%", "for", "selective", "venous", "catheterization", ".", "Postoperative", "morbidity", "included", "one", "permanent", "recurrent", "laryngeal", "nerve", "palsy", "and", "2", "patients", "with", "hemorrhage", "who", "were", "treated", "by", "reoperation", ".", "While", "one", "case", "of", "permanent", "hypoparathyroidism", "was", "well", "controlled", "by", "oral", "supplementation", ",", "18", "patients", "recovered", "from", "temporary", "hypoparathyroidism", ".", "No", "postoperative", "mortality", "occurred", ".", "Risk", "factor", "analysis", "revealed", "only", "cervical", "reexplorations", "for", "HPT", "to", "be", "associated", "with", "a", "higher", "morbidity", "(", "P", "=", "0.02", ")", ".", "Surgery", "for", "asymptomatic", "pHPT", "can", "be", "performed", "with", "reasonable", "safety", ".", "Cervical", "reexplorations", "in", "asymptomatic", "patients", "should", "be", "reserved", "for", "special", "indications", ".", "Apart", "from", "this", "small", "group", ",", "all", "patients", "should", "be", "evaluated", "for", "surgery", "." ]	[ "umlsterm" ]
Wachstum is an umlsterm, Schaedelkorrekturen is an umlsterm, Kraniosynostosen is an umlsterm, Schaedelkonfiguration is an umlsterm, Krankengut is an umlsterm, Kindern is an umlsterm, maennliche is an umlsterm, weibliche is an umlsterm, syndromale is an umlsterm, Kraniosynostosen is an umlsterm, Kraniosynostose is an umlsterm, Kopfumfang is an umlsterm, Kraniotomie is an umlsterm, Bandes is an umlsterm, Kraniosynostosen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kraniosynostosen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kraniosynostosen is an umlsterm, Wachstum is an umlsterm, gegebenen is an umlsterm, Kopfform is an umlsterm, Wachstumsverhalten is an umlsterm, Kraniosynostosen is an umlsterm	MundKieferGesichtschirurgie.8002s049.ger.abstr_task0	Sentence: Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht .	[ "Ziel", "der", "prospektiven", "Studie", "war", "es", "zu", "untersuchen", ",", "ob", "das", "postoperative", "Wachstum", "nach", "Schaedelkorrekturen", "bei", "Kraniosynostosen", "perzentilengerecht", "im", "Verhaeltnis", "zu", "einem", "Normalkollektiv", "weiterverlaeuft", ",", "da", "durch", "die", "Operation", "eine", "normale", "\"", "Schaedelkonfiguration", "\"", "erreicht", "wird", ".", "Das", "Krankengut", "setzte", "sich", "aus", "71", "Kindern", "zusammen", ",", "von", "denen", "57", "(", "36", "maennliche", "und", "21", "weibliche", ")", "mehr", "als", "12", "Monate", "postoperativ", "nachkontrolliert", "werden", "konnten", ";", "36", "betrafen", "unbehandelte", ",", "nicht", "syndromale", "und", "21", "syndromale", "Kraniosynostosen", ".", "In", "11", "Faellen", "erfolgte", "die", "Korrektur", "einer", "okzipitalen", "Kraniosynostose", ".", "Das", "Alter", "bei", "der", "Operation", "lag", "zwischen", "16", "und", "27", "Monaten", ".", "Der", "frontookzipitale", "Kopfumfang", "wurde", "auf", "der", "Perzentilentabelle", "nach", "Prader", "et", "al", ".", "[", "2", "]", "eingetragen", ".", "Die", "einheitliche", "Operation", "bestand", "aus", "einer", "frontoparietalen", "Kraniotomie", ",", "der", "Entfernung", "und", "Neuformung", "des", "frontoorbitalen", "Bandes", "sowie", "der", "Kranioplastik", ".", "Nach", "frontoorbitalem", "Advancement", "isolierter", "Kraniosynostosen", "blieben", "13", "Patienten", "im", "Verlauf", "auf", "der", "postoperativ", "eingenommenen", "Perzentilenkurve", ".", "13", "Patienten", "zeigten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", ".", "Bei", "den", "syndromalen", "Kraniosynostosen", "blieben", "10", "Patienten", "auf", "der", "postoperativ", "eingenommen", "Perzentilenkurve", ",", "waehrend", "8", "Patienten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", "zeigten", ".", "Nach", "der", "Korrektur", "von", "Kraniosynostosen", "kommt", "es", "damit", "zu", "einem", "weiteren", "Wachstum", "in", "der", "durch", "die", "Operation", "gegebenen", "Kopfform", ",", "wobei", "kein", "signifikanter", "Unterschied", "im", "Wachstumsverhalten", "zwischen", "syndromalen", "und", "isolierten", "Kraniosynostosen", "besteht", "." ]	[ "umlsterm" ]
Wachstum is an umlsterm, Schaedelkorrekturen is an umlsterm, Kraniosynostosen is an umlsterm, Schaedelkonfiguration is an umlsterm, Krankengut is an umlsterm, Kindern is an umlsterm, maennliche is an umlsterm, weibliche is an umlsterm, syndromale is an umlsterm, Kraniosynostosen is an umlsterm, Kraniosynostose is an umlsterm, Kopfumfang is an umlsterm, Kraniotomie is an umlsterm, Bandes is an umlsterm, Kraniosynostosen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kraniosynostosen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kraniosynostosen is an umlsterm, Wachstum is an umlsterm, gegebenen is an umlsterm, Kopfform is an umlsterm, Wachstumsverhalten is an umlsterm, Kraniosynostosen is an umlsterm	MundKieferGesichtschirurgie.8002s049.ger.abstr_task1	Sentence: Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht . Instructions: please typing these entity words according to sentence: Wachstum, Schaedelkorrekturen, Kraniosynostosen, Schaedelkonfiguration, Krankengut, Kindern, maennliche, weibliche, syndromale, Kraniosynostosen, Kraniosynostose, Kopfumfang, Kraniotomie, Bandes, Kraniosynostosen, Patienten, Patienten, Patient, Kraniosynostosen, Patienten, Patienten, Patient, Kraniosynostosen, Wachstum, gegebenen, Kopfform, Wachstumsverhalten, Kraniosynostosen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht .	[ "Ziel", "der", "prospektiven", "Studie", "war", "es", "zu", "untersuchen", ",", "ob", "das", "postoperative", "Wachstum", "nach", "Schaedelkorrekturen", "bei", "Kraniosynostosen", "perzentilengerecht", "im", "Verhaeltnis", "zu", "einem", "Normalkollektiv", "weiterverlaeuft", ",", "da", "durch", "die", "Operation", "eine", "normale", "\"", "Schaedelkonfiguration", "\"", "erreicht", "wird", ".", "Das", "Krankengut", "setzte", "sich", "aus", "71", "Kindern", "zusammen", ",", "von", "denen", "57", "(", "36", "maennliche", "und", "21", "weibliche", ")", "mehr", "als", "12", "Monate", "postoperativ", "nachkontrolliert", "werden", "konnten", ";", "36", "betrafen", "unbehandelte", ",", "nicht", "syndromale", "und", "21", "syndromale", "Kraniosynostosen", ".", "In", "11", "Faellen", "erfolgte", "die", "Korrektur", "einer", "okzipitalen", "Kraniosynostose", ".", "Das", "Alter", "bei", "der", "Operation", "lag", "zwischen", "16", "und", "27", "Monaten", ".", "Der", "frontookzipitale", "Kopfumfang", "wurde", "auf", "der", "Perzentilentabelle", "nach", "Prader", "et", "al", ".", "[", "2", "]", "eingetragen", ".", "Die", "einheitliche", "Operation", "bestand", "aus", "einer", "frontoparietalen", "Kraniotomie", ",", "der", "Entfernung", "und", "Neuformung", "des", "frontoorbitalen", "Bandes", "sowie", "der", "Kranioplastik", ".", "Nach", "frontoorbitalem", "Advancement", "isolierter", "Kraniosynostosen", "blieben", "13", "Patienten", "im", "Verlauf", "auf", "der", "postoperativ", "eingenommenen", "Perzentilenkurve", ".", "13", "Patienten", "zeigten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", ".", "Bei", "den", "syndromalen", "Kraniosynostosen", "blieben", "10", "Patienten", "auf", "der", "postoperativ", "eingenommen", "Perzentilenkurve", ",", "waehrend", "8", "Patienten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", "zeigten", ".", "Nach", "der", "Korrektur", "von", "Kraniosynostosen", "kommt", "es", "damit", "zu", "einem", "weiteren", "Wachstum", "in", "der", "durch", "die", "Operation", "gegebenen", "Kopfform", ",", "wobei", "kein", "signifikanter", "Unterschied", "im", "Wachstumsverhalten", "zwischen", "syndromalen", "und", "isolierten", "Kraniosynostosen", "besteht", "." ]	[ "umlsterm" ]
Wachstum, Schaedelkorrekturen, Kraniosynostosen, Schaedelkonfiguration, Krankengut, Kindern, maennliche, weibliche, syndromale, Kraniosynostosen, Kraniosynostose, Kopfumfang, Kraniotomie, Bandes, Kraniosynostosen, Patienten, Patienten, Patient, Kraniosynostosen, Patienten, Patienten, Patient, Kraniosynostosen, Wachstum, gegebenen, Kopfform, Wachstumsverhalten, Kraniosynostosen	MundKieferGesichtschirurgie.8002s049.ger.abstr_task2	Sentence: Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]	Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht .	[ "Ziel", "der", "prospektiven", "Studie", "war", "es", "zu", "untersuchen", ",", "ob", "das", "postoperative", "Wachstum", "nach", "Schaedelkorrekturen", "bei", "Kraniosynostosen", "perzentilengerecht", "im", "Verhaeltnis", "zu", "einem", "Normalkollektiv", "weiterverlaeuft", ",", "da", "durch", "die", "Operation", "eine", "normale", "\"", "Schaedelkonfiguration", "\"", "erreicht", "wird", ".", "Das", "Krankengut", "setzte", "sich", "aus", "71", "Kindern", "zusammen", ",", "von", "denen", "57", "(", "36", "maennliche", "und", "21", "weibliche", ")", "mehr", "als", "12", "Monate", "postoperativ", "nachkontrolliert", "werden", "konnten", ";", "36", "betrafen", "unbehandelte", ",", "nicht", "syndromale", "und", "21", "syndromale", "Kraniosynostosen", ".", "In", "11", "Faellen", "erfolgte", "die", "Korrektur", "einer", "okzipitalen", "Kraniosynostose", ".", "Das", "Alter", "bei", "der", "Operation", "lag", "zwischen", "16", "und", "27", "Monaten", ".", "Der", "frontookzipitale", "Kopfumfang", "wurde", "auf", "der", "Perzentilentabelle", "nach", "Prader", "et", "al", ".", "[", "2", "]", "eingetragen", ".", "Die", "einheitliche", "Operation", "bestand", "aus", "einer", "frontoparietalen", "Kraniotomie", ",", "der", "Entfernung", "und", "Neuformung", "des", "frontoorbitalen", "Bandes", "sowie", "der", "Kranioplastik", ".", "Nach", "frontoorbitalem", "Advancement", "isolierter", "Kraniosynostosen", "blieben", "13", "Patienten", "im", "Verlauf", "auf", "der", "postoperativ", "eingenommenen", "Perzentilenkurve", ".", "13", "Patienten", "zeigten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", ".", "Bei", "den", "syndromalen", "Kraniosynostosen", "blieben", "10", "Patienten", "auf", "der", "postoperativ", "eingenommen", "Perzentilenkurve", ",", "waehrend", "8", "Patienten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", "zeigten", ".", "Nach", "der", "Korrektur", "von", "Kraniosynostosen", "kommt", "es", "damit", "zu", "einem", "weiteren", "Wachstum", "in", "der", "durch", "die", "Operation", "gegebenen", "Kopfform", ",", "wobei", "kein", "signifikanter", "Unterschied", "im", "Wachstumsverhalten", "zwischen", "syndromalen", "und", "isolierten", "Kraniosynostosen", "besteht", "." ]	[ "umlsterm" ]
actin is a protein-family	1.0alpha7.train.98_task0	Sentence: This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O" ]	This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin.	[ "This", "is", "contrary", "to", "what", "one", "would", "expect", "if", "high", "ionic", "strength", "decreases", "the", "effect", "of", "the", "mutation", "on", "the", "binding", "of", "the", "regulatory", "complex", "to", "actin", "." ]	[ "protein-family" ]
actin is a protein-family	1.0alpha7.train.98_task1	Sentence: This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin. Instructions: please typing these entity words according to sentence: actin Options: protein-family	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O" ]	This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin.	[ "This", "is", "contrary", "to", "what", "one", "would", "expect", "if", "high", "ionic", "strength", "decreases", "the", "effect", "of", "the", "mutation", "on", "the", "binding", "of", "the", "regulatory", "complex", "to", "actin", "." ]	[ "protein-family" ]
actin	1.0alpha7.train.98_task2	Sentence: This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O" ]	This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin.	[ "This", "is", "contrary", "to", "what", "one", "would", "expect", "if", "high", "ionic", "strength", "decreases", "the", "effect", "of", "the", "mutation", "on", "the", "binding", "of", "the", "regulatory", "complex", "to", "actin", "." ]	[ "protein-family" ]
AT1 receptor is a GENE-Y, BDNF is a GENE-Y	23211364_task0	Sentence: AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O" ]	AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.	[ "AT1", "receptor", "antagonism", "is", "proangiogenic", "in", "the", "brain", ":", "BDNF", "a", "novel", "mediator", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
AT1 receptor is a GENE-Y, BDNF is a GENE-Y	23211364_task1	Sentence: AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. Instructions: please typing these entity words according to sentence: AT1 receptor, BDNF Options: GENE-Y	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O" ]	AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.	[ "AT1", "receptor", "antagonism", "is", "proangiogenic", "in", "the", "brain", ":", "BDNF", "a", "novel", "mediator", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
AT1 receptor, BDNF	23211364_task2	Sentence: AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. Instructions: please extract entity words from the input sentence	[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O" ]	AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.	[ "AT1", "receptor", "antagonism", "is", "proangiogenic", "in", "the", "brain", ":", "BDNF", "a", "novel", "mediator", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Paola is a NOMBRE_SUJETO_ASISTENCIA, Barba Vega is a NOMBRE_SUJETO_ASISTENCIA, 4387459 is a ID_SUJETO_ASISTENCIA, 83 56740786 47 is a ID_ASEGURAMIENTO, Calle Puchaicela , 34 is a CALLE, Madrid is a TERRITORIO, 31250 is a TERRITORIO, 21/07/1981 is a FECHAS, España is a PAIS, 34 años is a EDAD_SUJETO_ASISTENCIA, 10/11/2015 is a FECHAS, Ana M. Calvo Benito is a NOMBRE_PERSONAL_SANITARIO, 31 31 20250 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 34 años is a EDAD_SUJETO_ASISTENCIA, Ana M. Calvo Benito is a NOMBRE_PERSONAL_SANITARIO, Hospital de Navarra is a HOSPITAL, C/ Irunlarrea , 3 is a CALLE, 31008 is a TERRITORIO, Pamplona is a TERRITORIO, 848 422179 is a NUMERO_TELEFONO	359_task0	Sentence: Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179 Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, HOSPITAL, CALLE, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O" ]	Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Paola", ".", "\n", "Apellidos", ":", "Barba", "Vega", ".", "\n", "NHC", ":", "4387459", ".", "\n", "NASS", ":", "83", "56740786", "47", ".", "\n", "Domicilio", ":", "Calle", "Puchaicela", ",", "34", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "31250", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1981", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "34", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "10/11/2015", ".", "\n", "Médico", ":", "Ana", "M.", "Calvo", "Benito", "NºCol", ":", "31", "31", "20250", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "34", "años", ",", "embarazada", "de", "18", "semanas", ",", "que", "acudió", "a", "urgencias", "porque", "durante", "un", "episodio", "de", "hiperémesis", "gravídica", "con", "vómitos", "proyectivos", "presentó", "de", "forma", "súbita", "tumefacción", "supraorbitaria", "derecha", "con", "proptosis", "ocular", "y", "alteraciones", "visuales", "del", "ojo", "derecho", ".", "La", "paciente", "no", "presentaba", "antecedentes", "personales", "de", "interés", ",", "no", "tomaba", "ninguna", "medicación", "habitual", "ni", "había", "sufrido", "ningún", "traumatismo", "previamente", ".", "\n", "A", "la", "exploración", "oftalmológica", "destacaba", "la", "presencia", "de", "exoftalmos", "con", "hipoftalmos", "del", "ojo", "derecho", ",", "midriasis", "derecha", "de", "7", "mm", "con", "disminución", "de", "la", "reactividad", "pupilar", ",", "limitación", "de", "la", "supraducción", "y", "supraversión", "con", "diplopia", ",", "miodesopsias", "y", "edema", "palpebral", "superior", "doloroso", "a", "la", "palpación", ".", "La", "exploración", "del", "fondo", "de", "ojo", "fue", "normal", "con", "presión", "intraocular", "de", "24", "mmHg", ".", "No", "se", "observó", "edema", "ni", "anomalías", "vasculares", "en", "la", "conjuntiva", ".", "\n", "Debido", "a", "que", "la", "paciente", "estaba", "embarazada", ",", "se", "solicitó", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "orbitaria", "urgente", "cuyos", "hallazgos", "fueron", "compatibles", "con", "el", "diagnóstico", "de", "hematoma", "intraorbitario", "extraconal", "derecho", ".", "Un", "análisis", "sanguíneo", "basado", "en", "hemograma", ",", "bioquímica", "y", "coagulación", "de", "rutina", "no", "mostró", "ninguna", "alteración", "que", "pudiese", "haber", "precipitado", "el", "cuadro", ".", "\n", "Dada", "la", "repercusión", "clínica", "y", "las", "alteraciones", ",", "cada", "vez", "más", "evidentes", "en", "la", "visión", "de", "la", "paciente", ",", "se", "decidió", "intervenir", "quirúrgicamente", "de", "forma", "urgente", "para", "evacuar", "el", "hematoma", "y", "descomprimir", "la", "órbita", "bajo", "anestesia", "general", ".", "Se", "realizó", "una", "abordaje", "de", "blefaroplastia", "superior", "derecho", ",", "disecando", "el", "músculo", "orbicular", "del", "ojo", "y", "el", "periostio", ",", "hasta", "alcanzar", "el", "reborde", "óseo", "súpero", "-", "externo", "orbitario", ".", "Al", "incidir", "el", "periostio", "a", "nivel", "de", "la", "cara", "orbitaria", "del", "hueso", "frontal", ",", "se", "produjo", "la", "salida", "a", "presión", "de", "coágulos", "y", "sangre", "procedentes", "del", "hematoma", "extraconal", ".", "Tras", "la", "evacuación", "del", "hematoma", "no", "se", "objetivaron", "puntos", "sangrantes", "de", "ningún", "vaso", "de", "la", "región", ".", "Se", "colocó", "un", "drenaje", "fino", "tipo", "Penrose", "y", "se", "instauró", "tratamiento", "para", "la", "hiperémesis", "gravídica", "con", "piridoxina", "10", "mg/8", "h", "iv+tiamina", "100", "mg/24", "h", "iv", "+", "metoclopramida", "10", "mg/8", "h", "iv", ".", "\n", "La", "paciente", "evolucionó", "favorablemente", "tras", "la", "cirugía", ",", "desapareciendo", "la", "midriasis", "y", "las", "alteraciones", "visuales", "en", "las", "primeras", "horas", "postoperatorias", ",", "retirándose", "el", "drenaje", "a", "las", "48", "h", ",", "actualmente", ",", "3", "meses", "después", "de", "la", "cirugía", ",", "la", "paciente", "se", "encuentra", "asintomática", "y", "sin", "secuelas", ".", "\n", "Responsable", "clínico", ":", "Ana", "M.", "Calvo", "Benito", "Servicio", "Cirugía", "General", "y", "Aparato", "Digestivo", "Hospital", "de", "Navarra", "C/", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848", "422179", "\n" ]	[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NUMERO_TELEFONO", "FECHAS", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Paola is a NOMBRE_SUJETO_ASISTENCIA, Barba Vega is a NOMBRE_SUJETO_ASISTENCIA, 4387459 is a ID_SUJETO_ASISTENCIA, 83 56740786 47 is a ID_ASEGURAMIENTO, Calle Puchaicela , 34 is a CALLE, Madrid is a TERRITORIO, 31250 is a TERRITORIO, 21/07/1981 is a FECHAS, España is a PAIS, 34 años is a EDAD_SUJETO_ASISTENCIA, 10/11/2015 is a FECHAS, Ana M. Calvo Benito is a NOMBRE_PERSONAL_SANITARIO, 31 31 20250 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 34 años is a EDAD_SUJETO_ASISTENCIA, Ana M. Calvo Benito is a NOMBRE_PERSONAL_SANITARIO, Hospital de Navarra is a HOSPITAL, C/ Irunlarrea , 3 is a CALLE, 31008 is a TERRITORIO, Pamplona is a TERRITORIO, 848 422179 is a NUMERO_TELEFONO	359_task1	Sentence: Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179 Instructions: please typing these entity words according to sentence: Paola, Barba Vega, 4387459, 83 56740786 47, Calle Puchaicela , 34, Madrid, 31250, 21/07/1981, España, 34 años, 10/11/2015, Ana M. Calvo Benito, 31 31 20250, Mujer, 34 años, Ana M. Calvo Benito, Hospital de Navarra, C/ Irunlarrea , 3, 31008, Pamplona, 848 422179 Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, HOSPITAL, CALLE, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O" ]	Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Paola", ".", "\n", "Apellidos", ":", "Barba", "Vega", ".", "\n", "NHC", ":", "4387459", ".", "\n", "NASS", ":", "83", "56740786", "47", ".", "\n", "Domicilio", ":", "Calle", "Puchaicela", ",", "34", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "31250", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1981", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "34", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "10/11/2015", ".", "\n", "Médico", ":", "Ana", "M.", "Calvo", "Benito", "NºCol", ":", "31", "31", "20250", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "34", "años", ",", "embarazada", "de", "18", "semanas", ",", "que", "acudió", "a", "urgencias", "porque", "durante", "un", "episodio", "de", "hiperémesis", "gravídica", "con", "vómitos", "proyectivos", "presentó", "de", "forma", "súbita", "tumefacción", "supraorbitaria", "derecha", "con", "proptosis", "ocular", "y", "alteraciones", "visuales", "del", "ojo", "derecho", ".", "La", "paciente", "no", "presentaba", "antecedentes", "personales", "de", "interés", ",", "no", "tomaba", "ninguna", "medicación", "habitual", "ni", "había", "sufrido", "ningún", "traumatismo", "previamente", ".", "\n", "A", "la", "exploración", "oftalmológica", "destacaba", "la", "presencia", "de", "exoftalmos", "con", "hipoftalmos", "del", "ojo", "derecho", ",", "midriasis", "derecha", "de", "7", "mm", "con", "disminución", "de", "la", "reactividad", "pupilar", ",", "limitación", "de", "la", "supraducción", "y", "supraversión", "con", "diplopia", ",", "miodesopsias", "y", "edema", "palpebral", "superior", "doloroso", "a", "la", "palpación", ".", "La", "exploración", "del", "fondo", "de", "ojo", "fue", "normal", "con", "presión", "intraocular", "de", "24", "mmHg", ".", "No", "se", "observó", "edema", "ni", "anomalías", "vasculares", "en", "la", "conjuntiva", ".", "\n", "Debido", "a", "que", "la", "paciente", "estaba", "embarazada", ",", "se", "solicitó", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "orbitaria", "urgente", "cuyos", "hallazgos", "fueron", "compatibles", "con", "el", "diagnóstico", "de", "hematoma", "intraorbitario", "extraconal", "derecho", ".", "Un", "análisis", "sanguíneo", "basado", "en", "hemograma", ",", "bioquímica", "y", "coagulación", "de", "rutina", "no", "mostró", "ninguna", "alteración", "que", "pudiese", "haber", "precipitado", "el", "cuadro", ".", "\n", "Dada", "la", "repercusión", "clínica", "y", "las", "alteraciones", ",", "cada", "vez", "más", "evidentes", "en", "la", "visión", "de", "la", "paciente", ",", "se", "decidió", "intervenir", "quirúrgicamente", "de", "forma", "urgente", "para", "evacuar", "el", "hematoma", "y", "descomprimir", "la", "órbita", "bajo", "anestesia", "general", ".", "Se", "realizó", "una", "abordaje", "de", "blefaroplastia", "superior", "derecho", ",", "disecando", "el", "músculo", "orbicular", "del", "ojo", "y", "el", "periostio", ",", "hasta", "alcanzar", "el", "reborde", "óseo", "súpero", "-", "externo", "orbitario", ".", "Al", "incidir", "el", "periostio", "a", "nivel", "de", "la", "cara", "orbitaria", "del", "hueso", "frontal", ",", "se", "produjo", "la", "salida", "a", "presión", "de", "coágulos", "y", "sangre", "procedentes", "del", "hematoma", "extraconal", ".", "Tras", "la", "evacuación", "del", "hematoma", "no", "se", "objetivaron", "puntos", "sangrantes", "de", "ningún", "vaso", "de", "la", "región", ".", "Se", "colocó", "un", "drenaje", "fino", "tipo", "Penrose", "y", "se", "instauró", "tratamiento", "para", "la", "hiperémesis", "gravídica", "con", "piridoxina", "10", "mg/8", "h", "iv+tiamina", "100", "mg/24", "h", "iv", "+", "metoclopramida", "10", "mg/8", "h", "iv", ".", "\n", "La", "paciente", "evolucionó", "favorablemente", "tras", "la", "cirugía", ",", "desapareciendo", "la", "midriasis", "y", "las", "alteraciones", "visuales", "en", "las", "primeras", "horas", "postoperatorias", ",", "retirándose", "el", "drenaje", "a", "las", "48", "h", ",", "actualmente", ",", "3", "meses", "después", "de", "la", "cirugía", ",", "la", "paciente", "se", "encuentra", "asintomática", "y", "sin", "secuelas", ".", "\n", "Responsable", "clínico", ":", "Ana", "M.", "Calvo", "Benito", "Servicio", "Cirugía", "General", "y", "Aparato", "Digestivo", "Hospital", "de", "Navarra", "C/", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848", "422179", "\n" ]	[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NUMERO_TELEFONO", "FECHAS", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Paola, Barba Vega, 4387459, 83 56740786 47, Calle Puchaicela , 34, Madrid, 31250, 21/07/1981, España, 34 años, 10/11/2015, Ana M. Calvo Benito, 31 31 20250, Mujer, 34 años, Ana M. Calvo Benito, Hospital de Navarra, C/ Irunlarrea , 3, 31008, Pamplona, 848 422179	359_task2	Sentence: Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179 Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O" ]	Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179	[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Paola", ".", "\n", "Apellidos", ":", "Barba", "Vega", ".", "\n", "NHC", ":", "4387459", ".", "\n", "NASS", ":", "83", "56740786", "47", ".", "\n", "Domicilio", ":", "Calle", "Puchaicela", ",", "34", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "31250", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1981", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "34", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "10/11/2015", ".", "\n", "Médico", ":", "Ana", "M.", "Calvo", "Benito", "NºCol", ":", "31", "31", "20250", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "34", "años", ",", "embarazada", "de", "18", "semanas", ",", "que", "acudió", "a", "urgencias", "porque", "durante", "un", "episodio", "de", "hiperémesis", "gravídica", "con", "vómitos", "proyectivos", "presentó", "de", "forma", "súbita", "tumefacción", "supraorbitaria", "derecha", "con", "proptosis", "ocular", "y", "alteraciones", "visuales", "del", "ojo", "derecho", ".", "La", "paciente", "no", "presentaba", "antecedentes", "personales", "de", "interés", ",", "no", "tomaba", "ninguna", "medicación", "habitual", "ni", "había", "sufrido", "ningún", "traumatismo", "previamente", ".", "\n", "A", "la", "exploración", "oftalmológica", "destacaba", "la", "presencia", "de", "exoftalmos", "con", "hipoftalmos", "del", "ojo", "derecho", ",", "midriasis", "derecha", "de", "7", "mm", "con", "disminución", "de", "la", "reactividad", "pupilar", ",", "limitación", "de", "la", "supraducción", "y", "supraversión", "con", "diplopia", ",", "miodesopsias", "y", "edema", "palpebral", "superior", "doloroso", "a", "la", "palpación", ".", "La", "exploración", "del", "fondo", "de", "ojo", "fue", "normal", "con", "presión", "intraocular", "de", "24", "mmHg", ".", "No", "se", "observó", "edema", "ni", "anomalías", "vasculares", "en", "la", "conjuntiva", ".", "\n", "Debido", "a", "que", "la", "paciente", "estaba", "embarazada", ",", "se", "solicitó", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "orbitaria", "urgente", "cuyos", "hallazgos", "fueron", "compatibles", "con", "el", "diagnóstico", "de", "hematoma", "intraorbitario", "extraconal", "derecho", ".", "Un", "análisis", "sanguíneo", "basado", "en", "hemograma", ",", "bioquímica", "y", "coagulación", "de", "rutina", "no", "mostró", "ninguna", "alteración", "que", "pudiese", "haber", "precipitado", "el", "cuadro", ".", "\n", "Dada", "la", "repercusión", "clínica", "y", "las", "alteraciones", ",", "cada", "vez", "más", "evidentes", "en", "la", "visión", "de", "la", "paciente", ",", "se", "decidió", "intervenir", "quirúrgicamente", "de", "forma", "urgente", "para", "evacuar", "el", "hematoma", "y", "descomprimir", "la", "órbita", "bajo", "anestesia", "general", ".", "Se", "realizó", "una", "abordaje", "de", "blefaroplastia", "superior", "derecho", ",", "disecando", "el", "músculo", "orbicular", "del", "ojo", "y", "el", "periostio", ",", "hasta", "alcanzar", "el", "reborde", "óseo", "súpero", "-", "externo", "orbitario", ".", "Al", "incidir", "el", "periostio", "a", "nivel", "de", "la", "cara", "orbitaria", "del", "hueso", "frontal", ",", "se", "produjo", "la", "salida", "a", "presión", "de", "coágulos", "y", "sangre", "procedentes", "del", "hematoma", "extraconal", ".", "Tras", "la", "evacuación", "del", "hematoma", "no", "se", "objetivaron", "puntos", "sangrantes", "de", "ningún", "vaso", "de", "la", "región", ".", "Se", "colocó", "un", "drenaje", "fino", "tipo", "Penrose", "y", "se", "instauró", "tratamiento", "para", "la", "hiperémesis", "gravídica", "con", "piridoxina", "10", "mg/8", "h", "iv+tiamina", "100", "mg/24", "h", "iv", "+", "metoclopramida", "10", "mg/8", "h", "iv", ".", "\n", "La", "paciente", "evolucionó", "favorablemente", "tras", "la", "cirugía", ",", "desapareciendo", "la", "midriasis", "y", "las", "alteraciones", "visuales", "en", "las", "primeras", "horas", "postoperatorias", ",", "retirándose", "el", "drenaje", "a", "las", "48", "h", ",", "actualmente", ",", "3", "meses", "después", "de", "la", "cirugía", ",", "la", "paciente", "se", "encuentra", "asintomática", "y", "sin", "secuelas", ".", "\n", "Responsable", "clínico", ":", "Ana", "M.", "Calvo", "Benito", "Servicio", "Cirugía", "General", "y", "Aparato", "Digestivo", "Hospital", "de", "Navarra", "C/", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848", "422179", "\n" ]	[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NUMERO_TELEFONO", "FECHAS", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Stammzellen is an umlsterm, Wiederherstellung is an umlsterm, Haematopoese is an umlsterm, Therapie is an umlsterm, Behandlung is an umlsterm, Mangelsyndrome is an umlsterm, Stoffwechselkrankheiten is an umlsterm, Transportvehikel is an umlsterm, Gentherapie is an umlsterm, Stammzellen is an umlsterm, Knochenmark is an umlsterm, Blut is an umlsterm, Nabelschnurblut is an umlsterm, Biologie is an umlsterm, Stammzellen is an umlsterm, Zulassung is an umlsterm, Stammzellen is an umlsterm, Arzneimittel is an umlsterm, Person is an umlsterm, Gebrauch is an umlsterm	Bundesgesundheitsblatt.90420105.ger.abstr_task0	Sentence: Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden .	[ "Praeparationen", "haematopoetischer", "Stammzellen", "bieten", "prinzipiell", "eine", "unendliche", "Vielfalt", "klinischer", "Anwendungsmoeglichkeiten", "und", "Zukunftsperspektiven", ".", "Sie", "sind", "die", "Basis", "fuer", "Stammzelltransplantationen", ",", "d.h", ".", "fuer", "die", "Wiederherstellung", "der", "Haematopoese", "nach", "hochdosierter", "zytotoxischer", "Therapie", "und", "bilden", "die", "Grundlage", "der", "Behandlung", "immunologischer", "Mangelsyndrome", "sowie", "erblicher", "Stoffwechselkrankheiten", ".", "Weiterhin", "koennten", "sie", "in", "der", "Zukunft", "ein", "Transportvehikel", "fuer", "die", "Gentherapie", "darstellen", ".", "Stammzellen", "koennen", "vom", "Knochenmark", ",", "vom", "peripheren", "Blut", "oder", "aus", "Nabelschnurblut", "gewonnen", "werden", ".", "Der", "vorliegende", "Artikel", "vermittelt", "einen", "Ueberblick", "ueber", "die", "Biologie", "der", "Stammzellen", "ueber", "Verfahren", ",", "ihrer", "Gewinnung", ",", "die", "gesetzliche", "Grundlage", "fuer", "die", "Herstellung", "von", "Stammzellpraeparationen", "sowie", "ueber", "die", "Grundzuege", "der", "Anforderungen", "fuer", "deren", "Zulassung", ".", "Nach", "der", "deutschen", "Rechtslage", "sind", "Stammzellen", "dann", "zulassungspflichtige", "Arzneimittel", ",", "wenn", "sie", "nicht", "fuer", "eine", "bestimmte", "erkrankte", "Person", "hergestellt", "werden", ",", "sondern", "im", "voraus", "produziert", "und", "-", "bis", "zu", "ihrem", "Gebrauch", "-", "in", "sogenannten", "Zellbanken", "gelagert", "werden", "." ]	[ "umlsterm" ]
Stammzellen is an umlsterm, Wiederherstellung is an umlsterm, Haematopoese is an umlsterm, Therapie is an umlsterm, Behandlung is an umlsterm, Mangelsyndrome is an umlsterm, Stoffwechselkrankheiten is an umlsterm, Transportvehikel is an umlsterm, Gentherapie is an umlsterm, Stammzellen is an umlsterm, Knochenmark is an umlsterm, Blut is an umlsterm, Nabelschnurblut is an umlsterm, Biologie is an umlsterm, Stammzellen is an umlsterm, Zulassung is an umlsterm, Stammzellen is an umlsterm, Arzneimittel is an umlsterm, Person is an umlsterm, Gebrauch is an umlsterm	Bundesgesundheitsblatt.90420105.ger.abstr_task1	Sentence: Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden . Instructions: please typing these entity words according to sentence: Stammzellen, Wiederherstellung, Haematopoese, Therapie, Behandlung, Mangelsyndrome, Stoffwechselkrankheiten, Transportvehikel, Gentherapie, Stammzellen, Knochenmark, Blut, Nabelschnurblut, Biologie, Stammzellen, Zulassung, Stammzellen, Arzneimittel, Person, Gebrauch Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden .	[ "Praeparationen", "haematopoetischer", "Stammzellen", "bieten", "prinzipiell", "eine", "unendliche", "Vielfalt", "klinischer", "Anwendungsmoeglichkeiten", "und", "Zukunftsperspektiven", ".", "Sie", "sind", "die", "Basis", "fuer", "Stammzelltransplantationen", ",", "d.h", ".", "fuer", "die", "Wiederherstellung", "der", "Haematopoese", "nach", "hochdosierter", "zytotoxischer", "Therapie", "und", "bilden", "die", "Grundlage", "der", "Behandlung", "immunologischer", "Mangelsyndrome", "sowie", "erblicher", "Stoffwechselkrankheiten", ".", "Weiterhin", "koennten", "sie", "in", "der", "Zukunft", "ein", "Transportvehikel", "fuer", "die", "Gentherapie", "darstellen", ".", "Stammzellen", "koennen", "vom", "Knochenmark", ",", "vom", "peripheren", "Blut", "oder", "aus", "Nabelschnurblut", "gewonnen", "werden", ".", "Der", "vorliegende", "Artikel", "vermittelt", "einen", "Ueberblick", "ueber", "die", "Biologie", "der", "Stammzellen", "ueber", "Verfahren", ",", "ihrer", "Gewinnung", ",", "die", "gesetzliche", "Grundlage", "fuer", "die", "Herstellung", "von", "Stammzellpraeparationen", "sowie", "ueber", "die", "Grundzuege", "der", "Anforderungen", "fuer", "deren", "Zulassung", ".", "Nach", "der", "deutschen", "Rechtslage", "sind", "Stammzellen", "dann", "zulassungspflichtige", "Arzneimittel", ",", "wenn", "sie", "nicht", "fuer", "eine", "bestimmte", "erkrankte", "Person", "hergestellt", "werden", ",", "sondern", "im", "voraus", "produziert", "und", "-", "bis", "zu", "ihrem", "Gebrauch", "-", "in", "sogenannten", "Zellbanken", "gelagert", "werden", "." ]	[ "umlsterm" ]
Stammzellen, Wiederherstellung, Haematopoese, Therapie, Behandlung, Mangelsyndrome, Stoffwechselkrankheiten, Transportvehikel, Gentherapie, Stammzellen, Knochenmark, Blut, Nabelschnurblut, Biologie, Stammzellen, Zulassung, Stammzellen, Arzneimittel, Person, Gebrauch	Bundesgesundheitsblatt.90420105.ger.abstr_task2	Sentence: Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden .	[ "Praeparationen", "haematopoetischer", "Stammzellen", "bieten", "prinzipiell", "eine", "unendliche", "Vielfalt", "klinischer", "Anwendungsmoeglichkeiten", "und", "Zukunftsperspektiven", ".", "Sie", "sind", "die", "Basis", "fuer", "Stammzelltransplantationen", ",", "d.h", ".", "fuer", "die", "Wiederherstellung", "der", "Haematopoese", "nach", "hochdosierter", "zytotoxischer", "Therapie", "und", "bilden", "die", "Grundlage", "der", "Behandlung", "immunologischer", "Mangelsyndrome", "sowie", "erblicher", "Stoffwechselkrankheiten", ".", "Weiterhin", "koennten", "sie", "in", "der", "Zukunft", "ein", "Transportvehikel", "fuer", "die", "Gentherapie", "darstellen", ".", "Stammzellen", "koennen", "vom", "Knochenmark", ",", "vom", "peripheren", "Blut", "oder", "aus", "Nabelschnurblut", "gewonnen", "werden", ".", "Der", "vorliegende", "Artikel", "vermittelt", "einen", "Ueberblick", "ueber", "die", "Biologie", "der", "Stammzellen", "ueber", "Verfahren", ",", "ihrer", "Gewinnung", ",", "die", "gesetzliche", "Grundlage", "fuer", "die", "Herstellung", "von", "Stammzellpraeparationen", "sowie", "ueber", "die", "Grundzuege", "der", "Anforderungen", "fuer", "deren", "Zulassung", ".", "Nach", "der", "deutschen", "Rechtslage", "sind", "Stammzellen", "dann", "zulassungspflichtige", "Arzneimittel", ",", "wenn", "sie", "nicht", "fuer", "eine", "bestimmte", "erkrankte", "Person", "hergestellt", "werden", ",", "sondern", "im", "voraus", "produziert", "und", "-", "bis", "zu", "ihrem", "Gebrauch", "-", "in", "sogenannten", "Zellbanken", "gelagert", "werden", "." ]	[ "umlsterm" ]
Ifenprodil is a CHEMICAL, Fluorescein is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - Methyl - D - aspartate Receptor is a GENE-N	23532918_task0	Sentence: Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]	Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists.	[ "Synthesis", "and", "in", "Vitro", "Characterisation", "of", "Ifenprodil", "-", "Based", "Fluorescein", "Conjugates", "as", "GluN1", "/", "GluN2B", "N", "-", "Methyl", "-", "D", "-", "aspartate", "Receptor", "Antagonists", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Ifenprodil is a CHEMICAL, Fluorescein is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - Methyl - D - aspartate Receptor is a GENE-N	23532918_task1	Sentence: Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists. Instructions: please typing these entity words according to sentence: Ifenprodil, Fluorescein, GluN1, GluN2B, N - Methyl - D - aspartate Receptor Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]	Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists.	[ "Synthesis", "and", "in", "Vitro", "Characterisation", "of", "Ifenprodil", "-", "Based", "Fluorescein", "Conjugates", "as", "GluN1", "/", "GluN2B", "N", "-", "Methyl", "-", "D", "-", "aspartate", "Receptor", "Antagonists", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Ifenprodil, Fluorescein, GluN1, GluN2B, N - Methyl - D - aspartate Receptor	23532918_task2	Sentence: Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]	Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists.	[ "Synthesis", "and", "in", "Vitro", "Characterisation", "of", "Ifenprodil", "-", "Based", "Fluorescein", "Conjugates", "as", "GluN1", "/", "GluN2B", "N", "-", "Methyl", "-", "D", "-", "aspartate", "Receptor", "Antagonists", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
Fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, 4-hydroxytolbutamide is a DRUG_N, carboxytolbutamide is a DRUG_N, fluvoxamine is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, 4-hydroxytolbutamide is a DRUG_N, carboxytolbutamide is a DRUG_N, tolbutamide is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, Fluvoxamine is a DRUG	11180037_task0	Sentence: Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG_N, DRUG	[ "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo.	[ "Fluvoxamine", "inhibits", "the", "CYP2C9", "catalyzed", "biotransformation", "of", "tolbutamide", ".", "OBJECTIVE", ":", "Our", "objective", "was", "to", "examine", "the", "interaction", "between", "fluvoxamine", "and", "tolbutamide", "to", "confirm", "that", "fluvoxamine", "inhibits", "CYP2C9", ".", "METHODS", ":", "The", "study", "was", "carried", "out", "as", "an", "open", ",", "randomized", ",", "crossover", "design", "with", "14", "healthy", "participants", ".", "In", "period", "A", ",", "all", "volunteers", "took", "500", "mg", "of", "tolbutamide", "orally", ".", "In", "period", "B", ",", "the", "volunteers", "were", "randomly", "assigned", "to", "one", "of", "two", "groups", ".", "Each", "group", "took", "either", "150", "mg", "or", "75", "mg", "of", "fluvoxamine", "a", "day", "for", "5", "days", "(", "day", "-3", "to", "day", "2", ")", ".", "The", "groups", "then", "took", "500", "mg", "of", "tolbutamide", "as", "a", "single", "dose", "(", "day", "0", ")", ".", "In", "both", "periods", ",", "blood", "and", "urine", "were", "sampled", "at", "regular", "intervals", ".", "Plasma", "was", "analyzed", "for", "tolbutamide", ",", "and", "urine", "was", "analyzed", "for", "tolbutamide", "and", "its", "two", "metabolites", ",", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "by", "means", "of", "HPLC", ".", "RESULTS", ":", "During", "treatment", "with", "fluvoxamine", ",", "there", "was", "a", "statistically", "significant", "decrease", "in", "the", "median", "of", "the", "total", "clearance", "of", "tolbutamide", ",", "from", "845", "mL", "/", "h", "to", "688", "mL", "/", "h", ",", "among", "the", "volunteers", "who", "received", "75", "mg", "/", "d.", "There", "was", "a", "reduction", "that", "reached", "borderline", "statistical", "significance", "in", "the", "group", "that", "received", "150", "mg", "/", "d", "of", "tolbutamide", ".", "The", "clearance", "by", "means", "of", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "was", "significantly", "reduced", "in", "both", "groups", "(", "ie", ",", "from", "901", "mL", "/", "h", "to", "318", "mL", "/", "h", "in", "the", "group", "that", "received", "150", "mg", "of", "tolbutamide", "per", "day", "and", "from", "723", "mL", "/", "h", "to", "457", "mL", "/", "h", "in", "the", "group", "that", "received", "75", "mg", "of", "tolbutamide", "per", "day", ")", ".", "Thus", "there", "was", "a", "tendency", "toward", "a", "more", "pronounced", "inhibition", "of", "the", "4-hydroxylation", "during", "treatment", "with", "150", "mg", "/", "d", "of", "fluvoxamine", "compared", "with", "75", "mg", "/", "d", ",", "but", "the", "difference", "was", "not", "statistically", "significant", ".", "CONCLUSION", ":", "Fluvoxamine", "is", "a", "moderate", "inhibitor", "of", "CYP2C9", "in", "vivo", "." ]	[ "DRUG_N", "DRUG" ]
Fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, 4-hydroxytolbutamide is a DRUG_N, carboxytolbutamide is a DRUG_N, fluvoxamine is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, 4-hydroxytolbutamide is a DRUG_N, carboxytolbutamide is a DRUG_N, tolbutamide is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, Fluvoxamine is a DRUG	11180037_task1	Sentence: Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo. Instructions: please typing these entity words according to sentence: Fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, tolbutamide, tolbutamide, 4-hydroxytolbutamide, carboxytolbutamide, fluvoxamine, tolbutamide, tolbutamide, 4-hydroxytolbutamide, carboxytolbutamide, tolbutamide, tolbutamide, fluvoxamine, Fluvoxamine Options: DRUG_N, DRUG	[ "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo.	[ "Fluvoxamine", "inhibits", "the", "CYP2C9", "catalyzed", "biotransformation", "of", "tolbutamide", ".", "OBJECTIVE", ":", "Our", "objective", "was", "to", "examine", "the", "interaction", "between", "fluvoxamine", "and", "tolbutamide", "to", "confirm", "that", "fluvoxamine", "inhibits", "CYP2C9", ".", "METHODS", ":", "The", "study", "was", "carried", "out", "as", "an", "open", ",", "randomized", ",", "crossover", "design", "with", "14", "healthy", "participants", ".", "In", "period", "A", ",", "all", "volunteers", "took", "500", "mg", "of", "tolbutamide", "orally", ".", "In", "period", "B", ",", "the", "volunteers", "were", "randomly", "assigned", "to", "one", "of", "two", "groups", ".", "Each", "group", "took", "either", "150", "mg", "or", "75", "mg", "of", "fluvoxamine", "a", "day", "for", "5", "days", "(", "day", "-3", "to", "day", "2", ")", ".", "The", "groups", "then", "took", "500", "mg", "of", "tolbutamide", "as", "a", "single", "dose", "(", "day", "0", ")", ".", "In", "both", "periods", ",", "blood", "and", "urine", "were", "sampled", "at", "regular", "intervals", ".", "Plasma", "was", "analyzed", "for", "tolbutamide", ",", "and", "urine", "was", "analyzed", "for", "tolbutamide", "and", "its", "two", "metabolites", ",", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "by", "means", "of", "HPLC", ".", "RESULTS", ":", "During", "treatment", "with", "fluvoxamine", ",", "there", "was", "a", "statistically", "significant", "decrease", "in", "the", "median", "of", "the", "total", "clearance", "of", "tolbutamide", ",", "from", "845", "mL", "/", "h", "to", "688", "mL", "/", "h", ",", "among", "the", "volunteers", "who", "received", "75", "mg", "/", "d.", "There", "was", "a", "reduction", "that", "reached", "borderline", "statistical", "significance", "in", "the", "group", "that", "received", "150", "mg", "/", "d", "of", "tolbutamide", ".", "The", "clearance", "by", "means", "of", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "was", "significantly", "reduced", "in", "both", "groups", "(", "ie", ",", "from", "901", "mL", "/", "h", "to", "318", "mL", "/", "h", "in", "the", "group", "that", "received", "150", "mg", "of", "tolbutamide", "per", "day", "and", "from", "723", "mL", "/", "h", "to", "457", "mL", "/", "h", "in", "the", "group", "that", "received", "75", "mg", "of", "tolbutamide", "per", "day", ")", ".", "Thus", "there", "was", "a", "tendency", "toward", "a", "more", "pronounced", "inhibition", "of", "the", "4-hydroxylation", "during", "treatment", "with", "150", "mg", "/", "d", "of", "fluvoxamine", "compared", "with", "75", "mg", "/", "d", ",", "but", "the", "difference", "was", "not", "statistically", "significant", ".", "CONCLUSION", ":", "Fluvoxamine", "is", "a", "moderate", "inhibitor", "of", "CYP2C9", "in", "vivo", "." ]	[ "DRUG_N", "DRUG" ]
Fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, tolbutamide, tolbutamide, 4-hydroxytolbutamide, carboxytolbutamide, fluvoxamine, tolbutamide, tolbutamide, 4-hydroxytolbutamide, carboxytolbutamide, tolbutamide, tolbutamide, fluvoxamine, Fluvoxamine	11180037_task2	Sentence: Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo. Instructions: please extract entity words from the input sentence	[ "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo.	[ "Fluvoxamine", "inhibits", "the", "CYP2C9", "catalyzed", "biotransformation", "of", "tolbutamide", ".", "OBJECTIVE", ":", "Our", "objective", "was", "to", "examine", "the", "interaction", "between", "fluvoxamine", "and", "tolbutamide", "to", "confirm", "that", "fluvoxamine", "inhibits", "CYP2C9", ".", "METHODS", ":", "The", "study", "was", "carried", "out", "as", "an", "open", ",", "randomized", ",", "crossover", "design", "with", "14", "healthy", "participants", ".", "In", "period", "A", ",", "all", "volunteers", "took", "500", "mg", "of", "tolbutamide", "orally", ".", "In", "period", "B", ",", "the", "volunteers", "were", "randomly", "assigned", "to", "one", "of", "two", "groups", ".", "Each", "group", "took", "either", "150", "mg", "or", "75", "mg", "of", "fluvoxamine", "a", "day", "for", "5", "days", "(", "day", "-3", "to", "day", "2", ")", ".", "The", "groups", "then", "took", "500", "mg", "of", "tolbutamide", "as", "a", "single", "dose", "(", "day", "0", ")", ".", "In", "both", "periods", ",", "blood", "and", "urine", "were", "sampled", "at", "regular", "intervals", ".", "Plasma", "was", "analyzed", "for", "tolbutamide", ",", "and", "urine", "was", "analyzed", "for", "tolbutamide", "and", "its", "two", "metabolites", ",", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "by", "means", "of", "HPLC", ".", "RESULTS", ":", "During", "treatment", "with", "fluvoxamine", ",", "there", "was", "a", "statistically", "significant", "decrease", "in", "the", "median", "of", "the", "total", "clearance", "of", "tolbutamide", ",", "from", "845", "mL", "/", "h", "to", "688", "mL", "/", "h", ",", "among", "the", "volunteers", "who", "received", "75", "mg", "/", "d.", "There", "was", "a", "reduction", "that", "reached", "borderline", "statistical", "significance", "in", "the", "group", "that", "received", "150", "mg", "/", "d", "of", "tolbutamide", ".", "The", "clearance", "by", "means", "of", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "was", "significantly", "reduced", "in", "both", "groups", "(", "ie", ",", "from", "901", "mL", "/", "h", "to", "318", "mL", "/", "h", "in", "the", "group", "that", "received", "150", "mg", "of", "tolbutamide", "per", "day", "and", "from", "723", "mL", "/", "h", "to", "457", "mL", "/", "h", "in", "the", "group", "that", "received", "75", "mg", "of", "tolbutamide", "per", "day", ")", ".", "Thus", "there", "was", "a", "tendency", "toward", "a", "more", "pronounced", "inhibition", "of", "the", "4-hydroxylation", "during", "treatment", "with", "150", "mg", "/", "d", "of", "fluvoxamine", "compared", "with", "75", "mg", "/", "d", ",", "but", "the", "difference", "was", "not", "statistically", "significant", ".", "CONCLUSION", ":", "Fluvoxamine", "is", "a", "moderate", "inhibitor", "of", "CYP2C9", "in", "vivo", "." ]	[ "DRUG_N", "DRUG" ]
GrpL is a Protein, SLP-76 is a Protein, SH2 domain - containing protein 76 is a Protein, SLP-76 is a Protein, Vav is a Protein, Grb2-related protein of the lymphoid system is a Protein, GrpL is a Protein, GrpL is a Protein, Grb2 is a Protein, GrpL is a Protein, SLP-76 is a Protein, Sos1 is a Protein, Sos2 is a Protein, Grb2 is a Protein, Sos1 is a Protein, Sos2 is a Protein, SLP-76 is a Protein, tyrosine is a Entity, LAT is a Protein, pp36/38 is a Protein, Grb2 is a Protein, GrpL is a Protein, Grb2 is a Protein, GrpL is a Protein, SLP-76 is a Protein, GrpL is a Protein, SLP-76 is a Protein	152_task0	Sentence: GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells.	[ "GrpL", ",", "a", "Grb2-related", "adaptor", "protein", ",", "interacts", "with", "SLP-76", "to", "regulate", "nuclear", "factor", "of", "activated", "T", "cell", "activation", ".", "\n", "Propagation", "of", "signals", "from", "the", "T", "cell", "antigen", "receptor", "(", "TCR", ")", "involves", "a", "number", "of", "adaptor", "molecules", ".", "SH2", "domain", "-", "containing", "protein", "76", "(", "SLP-76", ")", "interacts", "with", "the", "guanine", "nucleotide", "exchange", "factor", "Vav", "to", "activate", "the", "nuclear", "factor", "of", "activated", "cells", "(", "NF", "-", "AT", ")", ",", "and", "its", "expression", "is", "required", "for", "normal", "T", "cell", "development", ".", "We", "report", "the", "cloning", "and", "characterization", "of", "a", "novel", "Grb2-like", "adaptor", "molecule", "designated", "as", "Grb2-related", "protein", "of", "the", "lymphoid", "system", "(", "GrpL", ")", ".", "Expression", "of", "GrpL", "is", "restricted", "to", "hematopoietic", "tissues", ",", "and", "it", "is", "distinguished", "from", "Grb2", "by", "having", "a", "proline", "-", "rich", "region", ".", "GrpL", "can", "be", "coimmunoprecipitated", "with", "SLP-76", "but", "not", "with", "Sos1", "or", "Sos2", "from", "Jurkat", "cell", "lysates", ".", "In", "contrast", ",", "Grb2", "can", "be", "coimmunoprecipitated", "with", "Sos1", "and", "Sos2", "but", "not", "with", "SLP-76", ".", "Moreover", ",", "tyrosine", "-", "phosphorylated", "LAT", "/", "pp36/38", "in", "detergent", "lysates", "prepared", "from", "anti", "-", "CD3", "stimulated", "T", "cells", "associated", "with", "Grb2", "but", "not", "GrpL.", "These", "data", "reveal", "the", "presence", "of", "distinct", "complexes", "involving", "GrpL", "and", "Grb2", "in", "T", "cells", ".", "A", "functional", "role", "of", "the", "GrpL", "-", "SLP-76", "complex", "is", "suggested", "by", "the", "ability", "of", "GrpL", "to", "act", "alone", "or", "in", "concert", "with", "SLP-76", "to", "augment", "NF", "-", "AT", "activation", "in", "Jurkat", "T", "cells", "." ]	[ "Protein", "Entity" ]
GrpL is a Protein, SLP-76 is a Protein, SH2 domain - containing protein 76 is a Protein, SLP-76 is a Protein, Vav is a Protein, Grb2-related protein of the lymphoid system is a Protein, GrpL is a Protein, GrpL is a Protein, Grb2 is a Protein, GrpL is a Protein, SLP-76 is a Protein, Sos1 is a Protein, Sos2 is a Protein, Grb2 is a Protein, Sos1 is a Protein, Sos2 is a Protein, SLP-76 is a Protein, tyrosine is a Entity, LAT is a Protein, pp36/38 is a Protein, Grb2 is a Protein, GrpL is a Protein, Grb2 is a Protein, GrpL is a Protein, SLP-76 is a Protein, GrpL is a Protein, SLP-76 is a Protein	152_task1	Sentence: GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells. Instructions: please typing these entity words according to sentence: GrpL, SLP-76, SH2 domain - containing protein 76, SLP-76, Vav, Grb2-related protein of the lymphoid system, GrpL, GrpL, Grb2, GrpL, SLP-76, Sos1, Sos2, Grb2, Sos1, Sos2, SLP-76, tyrosine, LAT, pp36/38, Grb2, GrpL, Grb2, GrpL, SLP-76, GrpL, SLP-76 Options: Entity, Protein	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells.	[ "GrpL", ",", "a", "Grb2-related", "adaptor", "protein", ",", "interacts", "with", "SLP-76", "to", "regulate", "nuclear", "factor", "of", "activated", "T", "cell", "activation", ".", "\n", "Propagation", "of", "signals", "from", "the", "T", "cell", "antigen", "receptor", "(", "TCR", ")", "involves", "a", "number", "of", "adaptor", "molecules", ".", "SH2", "domain", "-", "containing", "protein", "76", "(", "SLP-76", ")", "interacts", "with", "the", "guanine", "nucleotide", "exchange", "factor", "Vav", "to", "activate", "the", "nuclear", "factor", "of", "activated", "cells", "(", "NF", "-", "AT", ")", ",", "and", "its", "expression", "is", "required", "for", "normal", "T", "cell", "development", ".", "We", "report", "the", "cloning", "and", "characterization", "of", "a", "novel", "Grb2-like", "adaptor", "molecule", "designated", "as", "Grb2-related", "protein", "of", "the", "lymphoid", "system", "(", "GrpL", ")", ".", "Expression", "of", "GrpL", "is", "restricted", "to", "hematopoietic", "tissues", ",", "and", "it", "is", "distinguished", "from", "Grb2", "by", "having", "a", "proline", "-", "rich", "region", ".", "GrpL", "can", "be", "coimmunoprecipitated", "with", "SLP-76", "but", "not", "with", "Sos1", "or", "Sos2", "from", "Jurkat", "cell", "lysates", ".", "In", "contrast", ",", "Grb2", "can", "be", "coimmunoprecipitated", "with", "Sos1", "and", "Sos2", "but", "not", "with", "SLP-76", ".", "Moreover", ",", "tyrosine", "-", "phosphorylated", "LAT", "/", "pp36/38", "in", "detergent", "lysates", "prepared", "from", "anti", "-", "CD3", "stimulated", "T", "cells", "associated", "with", "Grb2", "but", "not", "GrpL.", "These", "data", "reveal", "the", "presence", "of", "distinct", "complexes", "involving", "GrpL", "and", "Grb2", "in", "T", "cells", ".", "A", "functional", "role", "of", "the", "GrpL", "-", "SLP-76", "complex", "is", "suggested", "by", "the", "ability", "of", "GrpL", "to", "act", "alone", "or", "in", "concert", "with", "SLP-76", "to", "augment", "NF", "-", "AT", "activation", "in", "Jurkat", "T", "cells", "." ]	[ "Protein", "Entity" ]
GrpL, SLP-76, SH2 domain - containing protein 76, SLP-76, Vav, Grb2-related protein of the lymphoid system, GrpL, GrpL, Grb2, GrpL, SLP-76, Sos1, Sos2, Grb2, Sos1, Sos2, SLP-76, tyrosine, LAT, pp36/38, Grb2, GrpL, Grb2, GrpL, SLP-76, GrpL, SLP-76	152_task2	Sentence: GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells. Instructions: please extract entity words from the input sentence	[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells.	[ "GrpL", ",", "a", "Grb2-related", "adaptor", "protein", ",", "interacts", "with", "SLP-76", "to", "regulate", "nuclear", "factor", "of", "activated", "T", "cell", "activation", ".", "\n", "Propagation", "of", "signals", "from", "the", "T", "cell", "antigen", "receptor", "(", "TCR", ")", "involves", "a", "number", "of", "adaptor", "molecules", ".", "SH2", "domain", "-", "containing", "protein", "76", "(", "SLP-76", ")", "interacts", "with", "the", "guanine", "nucleotide", "exchange", "factor", "Vav", "to", "activate", "the", "nuclear", "factor", "of", "activated", "cells", "(", "NF", "-", "AT", ")", ",", "and", "its", "expression", "is", "required", "for", "normal", "T", "cell", "development", ".", "We", "report", "the", "cloning", "and", "characterization", "of", "a", "novel", "Grb2-like", "adaptor", "molecule", "designated", "as", "Grb2-related", "protein", "of", "the", "lymphoid", "system", "(", "GrpL", ")", ".", "Expression", "of", "GrpL", "is", "restricted", "to", "hematopoietic", "tissues", ",", "and", "it", "is", "distinguished", "from", "Grb2", "by", "having", "a", "proline", "-", "rich", "region", ".", "GrpL", "can", "be", "coimmunoprecipitated", "with", "SLP-76", "but", "not", "with", "Sos1", "or", "Sos2", "from", "Jurkat", "cell", "lysates", ".", "In", "contrast", ",", "Grb2", "can", "be", "coimmunoprecipitated", "with", "Sos1", "and", "Sos2", "but", "not", "with", "SLP-76", ".", "Moreover", ",", "tyrosine", "-", "phosphorylated", "LAT", "/", "pp36/38", "in", "detergent", "lysates", "prepared", "from", "anti", "-", "CD3", "stimulated", "T", "cells", "associated", "with", "Grb2", "but", "not", "GrpL.", "These", "data", "reveal", "the", "presence", "of", "distinct", "complexes", "involving", "GrpL", "and", "Grb2", "in", "T", "cells", ".", "A", "functional", "role", "of", "the", "GrpL", "-", "SLP-76", "complex", "is", "suggested", "by", "the", "ability", "of", "GrpL", "to", "act", "alone", "or", "in", "concert", "with", "SLP-76", "to", "augment", "NF", "-", "AT", "activation", "in", "Jurkat", "T", "cells", "." ]	[ "Protein", "Entity" ]
células tumorales malignas is a MORFOLOGIA_NEOPLASIA	647_task0	Sentence: Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético.	[ "Anamnesis", "\n", "Acude", "a", "Urgencias", "al", "4º", "día", "del", "1er", "ciclo", ",", "por", "cuadro", "de", "24", "horas", "de", "evolución", "consistente", "en", "palpitaciones", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "reposo", ".", "Afebril", "en", "domicilio", ",", "sin", "dolor", "torácico", ",", "ni", "otra", "sintomatología", "acompañante", ".", "\n", "Ante", "hipotensión", "marcada", ",", "precisa", "la", "instauración", "de", "aminas", "en", "Urgencias", "(", "noradrenalina", "y", "dobutamina", ")", "para", "mantener", "la", "tensión", "arterial", ".", "Se", "avisa", "a", "Cardiología", "y", "UCI", "para", "valoración", ",", "realizando", "ecocardiograma", "donde", "se", "evidencia", "disfunción", "biventricular", "grave", ",", "decidiéndose", "ingreso", "en", "UCI", ".", "\n\n", "Exploración", "física", "\n", "Destaca", "mal", "estado", "general", "y", "mala", "perfusión", "periférica", "con", "relleno", "capilar", "lento", ".", "TA", "85/45", "mm", "Hg", ",", "taquicardia", "sinusal", "a", "170", "lpm", ",", "febril", "con", "Tª", "39", "ºC", ",", "SatO2", "94", "%", "con", "gafas", "nasales", "2", "lpm", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "analítica", "realizada", "en", "Urgencias", "existía", "un", "ligero", "aumento", "de", "transaminasas", "(", "GPT", "102", ")", ",", "incremento", "de", "marcadores", "de", "insuficiencia", "cardiaca", "(", "proBNP", "27885", ")", ",", "mínima", "alteración", "de", "enzimas", "cardiacas", "(", "TnTus", "59", ")", ",", "leucocitosis", "con", "neutrofilia", ",", "coagulopatía", "con", "TP", "61", "%", "y", "gasometría", "arterial", "sin", "hallazgos", ".", "En", "el", "electrocardiograma", "se", "muestra", "taquicardia", "sinusal", "a", "180", "lpm", ",", "sin", "signos", "de", "isquemia", "aguda", "ni", "alteraciones", "de", "la", "repolarización", ".", "\n", "En", "cuanto", "a", "los", "estudios", "de", "imagen", ",", "la", "radiografía", "de", "tórax", "mostraba", "derrame", "pleural", "derecho", ".", "Se", "solicita", "una", "angio", "-", "TC", "por", "la", "sospecha", "de", "TEP", "ante", "la", "aparición", "de", "disnea", "súbita", ",", "que", "se", "descarta", ",", "destacando", "en", "dicha", "TC", "derrame", "pleural", "derecho", "junto", "con", "infiltrados", "en", "lóbulo", "superior", "derecho", ",", "medio", "y", "língula", ".", "\n", "Respecto", "al", "ecocardiograma", "de", "Urgencias", ",", "destaca", "FEVI", "estimada", "visualmente", "de", "10", "-", "15", "%", "con", "hipocinesia", "-", "aquinesia", "difusa", ",", "presentando", "cierta", "contractilidad", "únicamente", "en", "segmentos", "basales", ".", "Se", "extrajeron", "hemocultivos", "y", "se", "realizó", "toracocentesis", "derecha", "diagnóstica", "con", "resultado", "de", "líquido", "trasudativo", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", "de", "un", "shock", "cardiogénico", "asociado", "a", "disfunción", "biventricular", "grave", "secundaria", "a", "cardiotoxicidad", "aguda", "en", "probable", "relación", "a", "infusión", "de", "fluorouracilo", ";", "además", "de", "disfunción", "hepática", "secundaria", "a", "congestión", "hepática", "por", "fallo", "de", "ventrículo", "derecho", "más", "bajo", "gasto", "cardiaco", ".", "\n\n", "Tratamiento", "\n", "A", "su", "llegada", "a", "UCI", "se", "procede", "a", "monitorización", ",", "vitamina", "K", "y", "canalización", "ecoguiada", "para", "monitorización", "con", "catéter", "de", "arteria", "pulmonar", ".", "Se", "realiza", "ajuste", "de", "aminas", "vasoactivas", ",", "diuréticos", ",", "sueroterapia", "con", "ajuste", "de", "iones", "y", "antibioterapia", "empírica", "con", "meropenem", "y", "linezolid", ".", "\n\n", "Evolución", "\n", "Mejoría", "hemodinámica", "en", "las", "primeras", "24", "horas", "de", "evolución", "en", "UCI", ",", "con", "soporte", "con", "dobutamina", "y", "noradrenalina", ",", "manteniendo", "buenos", "niveles", "tensionales", "y", "diuresis", "conservada", "con", "balance", "negativo", "diario", ".", "\n", "En", "primera", "eco", "-", "cardio", "de", "control", ",", "función", "sistólica", "global", "ligera", "-", "moderadamente", "deprimida", "FEVI", "40", "%", "con", "hipoquinesia", "generalizada", ".", "En", "analíticas", "de", "UCI", ",", "destaca", "elevación", "de", "enzimas", "hepáticas", ",", "llegando", "a", "un", "pico", "de", "GPT", "de", "4.282", ",", "LDH", "6.041", ",", "TP", "29", "%", "y", "TTPA30", ".", "\n", "Se", "planteó", "la", "posibilidad", "de", "traslado", "a", "otro", "centro", "con", "disponibilidad", "de", "extracorporeal", "membrane", "oxygenation", "(", "ECMO", ")", "como", "sistema", "de", "asistencia", "mecánica", "circulatoria", "de", "corta", "duración", ",", "pero", "finalmente", "se", "desestimó", ".", "\n", "Se", "colocó", "Pleurocath", "®", ",", "por", "presencia", "de", "derrame", "pleural", "en", "estudios", "de", "imagen", ",", "con", "salida", "de", "1", "l", "de", "líquido", "pleural", "seroso", "retirado", "a", "las", "24", "h", "con", "descenso", "de", "taquipnea", "sin", "llegar", "a", "precisar", "ventilación", "mecánica", ".", "\n", "Los", "resultados", "de", "los", "hemocultivos", "fueron", "negativos", ",", "con", "leucocitosis", "en", "descenso", ",", "por", "lo", "que", ",", "tras", "un", "ciclo", "corto", "de", "cobertura", "empírica", "con", "meropenem", "y", "linezolid", ",", "se", "suspenden", ".", "Mejoría", "progresiva", "de", "enzimas", "hepáticas", "(", "GPT", "302", ")", ",", "ausencia", "de", "leucocitosis", "(", "5.980", "con", "49", "%", "neutrófilos", ")", "y", "coagulopatía", "corregida", "(", "INR", ":", "1,1", ";", "TTPA", "32,5", "s", ")", ".", "La", "citología", "de", "líquido", "pleural", "fue", "negativa", "para", "células", "tumorales", "malignas", ".", "\n", "Dada", "la", "estabilidad", "hemodinámica", ",", "se", "traslada", "a", "planta", "de", "Cardiología", "donde", "se", "ajusta", "tratamiento", "con", "IECA", ",", "beta", "-", "bloqueantes", "y", "espironolactona", "con", "buena", "tolerancia", "clínica", ".", "Ecocardiograma", "con", "recuperación", "de", "FEVI", "(", "60", "%", ")", ",", "por", "lo", "que", "se", "procede", "al", "alta", ".", "\n", "Valorada", "de", "nuevo", "en", "consulta", "de", "Oncología", ",", "se", "muestra", "asintomática", "con", "controles", "y", "ajuste", "de", "tratamiento", "por", "Cardiología", ".", "Dada", "la", "toxicidad", "grave", "desarrollada", ",", "con", "shock", "cardiogénico", "tras", "primera", "infusión", "de", "fluorouracilo", ",", "que", "descarta", "su", "utilización", "posterior", ",", "se", "pide", "TC", "de", "reevaluación", "sin", "adenopatías", "macroscópicas", "ni", "otros", "hallazgos", "de", "enfermedad", "activa", ";", "se", "da", "por", "finalizada", "la", "adyuvancia", ",", "y", "pasa", "a", "control", "estrecho", ".", "Está", "pendiente", "de", "los", "resultados", "del", "Consejo", "Genético", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
células tumorales malignas is a MORFOLOGIA_NEOPLASIA	647_task1	Sentence: Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético. Instructions: please typing these entity words according to sentence: células tumorales malignas Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético.	[ "Anamnesis", "\n", "Acude", "a", "Urgencias", "al", "4º", "día", "del", "1er", "ciclo", ",", "por", "cuadro", "de", "24", "horas", "de", "evolución", "consistente", "en", "palpitaciones", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "reposo", ".", "Afebril", "en", "domicilio", ",", "sin", "dolor", "torácico", ",", "ni", "otra", "sintomatología", "acompañante", ".", "\n", "Ante", "hipotensión", "marcada", ",", "precisa", "la", "instauración", "de", "aminas", "en", "Urgencias", "(", "noradrenalina", "y", "dobutamina", ")", "para", "mantener", "la", "tensión", "arterial", ".", "Se", "avisa", "a", "Cardiología", "y", "UCI", "para", "valoración", ",", "realizando", "ecocardiograma", "donde", "se", "evidencia", "disfunción", "biventricular", "grave", ",", "decidiéndose", "ingreso", "en", "UCI", ".", "\n\n", "Exploración", "física", "\n", "Destaca", "mal", "estado", "general", "y", "mala", "perfusión", "periférica", "con", "relleno", "capilar", "lento", ".", "TA", "85/45", "mm", "Hg", ",", "taquicardia", "sinusal", "a", "170", "lpm", ",", "febril", "con", "Tª", "39", "ºC", ",", "SatO2", "94", "%", "con", "gafas", "nasales", "2", "lpm", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "analítica", "realizada", "en", "Urgencias", "existía", "un", "ligero", "aumento", "de", "transaminasas", "(", "GPT", "102", ")", ",", "incremento", "de", "marcadores", "de", "insuficiencia", "cardiaca", "(", "proBNP", "27885", ")", ",", "mínima", "alteración", "de", "enzimas", "cardiacas", "(", "TnTus", "59", ")", ",", "leucocitosis", "con", "neutrofilia", ",", "coagulopatía", "con", "TP", "61", "%", "y", "gasometría", "arterial", "sin", "hallazgos", ".", "En", "el", "electrocardiograma", "se", "muestra", "taquicardia", "sinusal", "a", "180", "lpm", ",", "sin", "signos", "de", "isquemia", "aguda", "ni", "alteraciones", "de", "la", "repolarización", ".", "\n", "En", "cuanto", "a", "los", "estudios", "de", "imagen", ",", "la", "radiografía", "de", "tórax", "mostraba", "derrame", "pleural", "derecho", ".", "Se", "solicita", "una", "angio", "-", "TC", "por", "la", "sospecha", "de", "TEP", "ante", "la", "aparición", "de", "disnea", "súbita", ",", "que", "se", "descarta", ",", "destacando", "en", "dicha", "TC", "derrame", "pleural", "derecho", "junto", "con", "infiltrados", "en", "lóbulo", "superior", "derecho", ",", "medio", "y", "língula", ".", "\n", "Respecto", "al", "ecocardiograma", "de", "Urgencias", ",", "destaca", "FEVI", "estimada", "visualmente", "de", "10", "-", "15", "%", "con", "hipocinesia", "-", "aquinesia", "difusa", ",", "presentando", "cierta", "contractilidad", "únicamente", "en", "segmentos", "basales", ".", "Se", "extrajeron", "hemocultivos", "y", "se", "realizó", "toracocentesis", "derecha", "diagnóstica", "con", "resultado", "de", "líquido", "trasudativo", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", "de", "un", "shock", "cardiogénico", "asociado", "a", "disfunción", "biventricular", "grave", "secundaria", "a", "cardiotoxicidad", "aguda", "en", "probable", "relación", "a", "infusión", "de", "fluorouracilo", ";", "además", "de", "disfunción", "hepática", "secundaria", "a", "congestión", "hepática", "por", "fallo", "de", "ventrículo", "derecho", "más", "bajo", "gasto", "cardiaco", ".", "\n\n", "Tratamiento", "\n", "A", "su", "llegada", "a", "UCI", "se", "procede", "a", "monitorización", ",", "vitamina", "K", "y", "canalización", "ecoguiada", "para", "monitorización", "con", "catéter", "de", "arteria", "pulmonar", ".", "Se", "realiza", "ajuste", "de", "aminas", "vasoactivas", ",", "diuréticos", ",", "sueroterapia", "con", "ajuste", "de", "iones", "y", "antibioterapia", "empírica", "con", "meropenem", "y", "linezolid", ".", "\n\n", "Evolución", "\n", "Mejoría", "hemodinámica", "en", "las", "primeras", "24", "horas", "de", "evolución", "en", "UCI", ",", "con", "soporte", "con", "dobutamina", "y", "noradrenalina", ",", "manteniendo", "buenos", "niveles", "tensionales", "y", "diuresis", "conservada", "con", "balance", "negativo", "diario", ".", "\n", "En", "primera", "eco", "-", "cardio", "de", "control", ",", "función", "sistólica", "global", "ligera", "-", "moderadamente", "deprimida", "FEVI", "40", "%", "con", "hipoquinesia", "generalizada", ".", "En", "analíticas", "de", "UCI", ",", "destaca", "elevación", "de", "enzimas", "hepáticas", ",", "llegando", "a", "un", "pico", "de", "GPT", "de", "4.282", ",", "LDH", "6.041", ",", "TP", "29", "%", "y", "TTPA30", ".", "\n", "Se", "planteó", "la", "posibilidad", "de", "traslado", "a", "otro", "centro", "con", "disponibilidad", "de", "extracorporeal", "membrane", "oxygenation", "(", "ECMO", ")", "como", "sistema", "de", "asistencia", "mecánica", "circulatoria", "de", "corta", "duración", ",", "pero", "finalmente", "se", "desestimó", ".", "\n", "Se", "colocó", "Pleurocath", "®", ",", "por", "presencia", "de", "derrame", "pleural", "en", "estudios", "de", "imagen", ",", "con", "salida", "de", "1", "l", "de", "líquido", "pleural", "seroso", "retirado", "a", "las", "24", "h", "con", "descenso", "de", "taquipnea", "sin", "llegar", "a", "precisar", "ventilación", "mecánica", ".", "\n", "Los", "resultados", "de", "los", "hemocultivos", "fueron", "negativos", ",", "con", "leucocitosis", "en", "descenso", ",", "por", "lo", "que", ",", "tras", "un", "ciclo", "corto", "de", "cobertura", "empírica", "con", "meropenem", "y", "linezolid", ",", "se", "suspenden", ".", "Mejoría", "progresiva", "de", "enzimas", "hepáticas", "(", "GPT", "302", ")", ",", "ausencia", "de", "leucocitosis", "(", "5.980", "con", "49", "%", "neutrófilos", ")", "y", "coagulopatía", "corregida", "(", "INR", ":", "1,1", ";", "TTPA", "32,5", "s", ")", ".", "La", "citología", "de", "líquido", "pleural", "fue", "negativa", "para", "células", "tumorales", "malignas", ".", "\n", "Dada", "la", "estabilidad", "hemodinámica", ",", "se", "traslada", "a", "planta", "de", "Cardiología", "donde", "se", "ajusta", "tratamiento", "con", "IECA", ",", "beta", "-", "bloqueantes", "y", "espironolactona", "con", "buena", "tolerancia", "clínica", ".", "Ecocardiograma", "con", "recuperación", "de", "FEVI", "(", "60", "%", ")", ",", "por", "lo", "que", "se", "procede", "al", "alta", ".", "\n", "Valorada", "de", "nuevo", "en", "consulta", "de", "Oncología", ",", "se", "muestra", "asintomática", "con", "controles", "y", "ajuste", "de", "tratamiento", "por", "Cardiología", ".", "Dada", "la", "toxicidad", "grave", "desarrollada", ",", "con", "shock", "cardiogénico", "tras", "primera", "infusión", "de", "fluorouracilo", ",", "que", "descarta", "su", "utilización", "posterior", ",", "se", "pide", "TC", "de", "reevaluación", "sin", "adenopatías", "macroscópicas", "ni", "otros", "hallazgos", "de", "enfermedad", "activa", ";", "se", "da", "por", "finalizada", "la", "adyuvancia", ",", "y", "pasa", "a", "control", "estrecho", ".", "Está", "pendiente", "de", "los", "resultados", "del", "Consejo", "Genético", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
células tumorales malignas	647_task2	Sentence: Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético.	[ "Anamnesis", "\n", "Acude", "a", "Urgencias", "al", "4º", "día", "del", "1er", "ciclo", ",", "por", "cuadro", "de", "24", "horas", "de", "evolución", "consistente", "en", "palpitaciones", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "reposo", ".", "Afebril", "en", "domicilio", ",", "sin", "dolor", "torácico", ",", "ni", "otra", "sintomatología", "acompañante", ".", "\n", "Ante", "hipotensión", "marcada", ",", "precisa", "la", "instauración", "de", "aminas", "en", "Urgencias", "(", "noradrenalina", "y", "dobutamina", ")", "para", "mantener", "la", "tensión", "arterial", ".", "Se", "avisa", "a", "Cardiología", "y", "UCI", "para", "valoración", ",", "realizando", "ecocardiograma", "donde", "se", "evidencia", "disfunción", "biventricular", "grave", ",", "decidiéndose", "ingreso", "en", "UCI", ".", "\n\n", "Exploración", "física", "\n", "Destaca", "mal", "estado", "general", "y", "mala", "perfusión", "periférica", "con", "relleno", "capilar", "lento", ".", "TA", "85/45", "mm", "Hg", ",", "taquicardia", "sinusal", "a", "170", "lpm", ",", "febril", "con", "Tª", "39", "ºC", ",", "SatO2", "94", "%", "con", "gafas", "nasales", "2", "lpm", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "analítica", "realizada", "en", "Urgencias", "existía", "un", "ligero", "aumento", "de", "transaminasas", "(", "GPT", "102", ")", ",", "incremento", "de", "marcadores", "de", "insuficiencia", "cardiaca", "(", "proBNP", "27885", ")", ",", "mínima", "alteración", "de", "enzimas", "cardiacas", "(", "TnTus", "59", ")", ",", "leucocitosis", "con", "neutrofilia", ",", "coagulopatía", "con", "TP", "61", "%", "y", "gasometría", "arterial", "sin", "hallazgos", ".", "En", "el", "electrocardiograma", "se", "muestra", "taquicardia", "sinusal", "a", "180", "lpm", ",", "sin", "signos", "de", "isquemia", "aguda", "ni", "alteraciones", "de", "la", "repolarización", ".", "\n", "En", "cuanto", "a", "los", "estudios", "de", "imagen", ",", "la", "radiografía", "de", "tórax", "mostraba", "derrame", "pleural", "derecho", ".", "Se", "solicita", "una", "angio", "-", "TC", "por", "la", "sospecha", "de", "TEP", "ante", "la", "aparición", "de", "disnea", "súbita", ",", "que", "se", "descarta", ",", "destacando", "en", "dicha", "TC", "derrame", "pleural", "derecho", "junto", "con", "infiltrados", "en", "lóbulo", "superior", "derecho", ",", "medio", "y", "língula", ".", "\n", "Respecto", "al", "ecocardiograma", "de", "Urgencias", ",", "destaca", "FEVI", "estimada", "visualmente", "de", "10", "-", "15", "%", "con", "hipocinesia", "-", "aquinesia", "difusa", ",", "presentando", "cierta", "contractilidad", "únicamente", "en", "segmentos", "basales", ".", "Se", "extrajeron", "hemocultivos", "y", "se", "realizó", "toracocentesis", "derecha", "diagnóstica", "con", "resultado", "de", "líquido", "trasudativo", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", "de", "un", "shock", "cardiogénico", "asociado", "a", "disfunción", "biventricular", "grave", "secundaria", "a", "cardiotoxicidad", "aguda", "en", "probable", "relación", "a", "infusión", "de", "fluorouracilo", ";", "además", "de", "disfunción", "hepática", "secundaria", "a", "congestión", "hepática", "por", "fallo", "de", "ventrículo", "derecho", "más", "bajo", "gasto", "cardiaco", ".", "\n\n", "Tratamiento", "\n", "A", "su", "llegada", "a", "UCI", "se", "procede", "a", "monitorización", ",", "vitamina", "K", "y", "canalización", "ecoguiada", "para", "monitorización", "con", "catéter", "de", "arteria", "pulmonar", ".", "Se", "realiza", "ajuste", "de", "aminas", "vasoactivas", ",", "diuréticos", ",", "sueroterapia", "con", "ajuste", "de", "iones", "y", "antibioterapia", "empírica", "con", "meropenem", "y", "linezolid", ".", "\n\n", "Evolución", "\n", "Mejoría", "hemodinámica", "en", "las", "primeras", "24", "horas", "de", "evolución", "en", "UCI", ",", "con", "soporte", "con", "dobutamina", "y", "noradrenalina", ",", "manteniendo", "buenos", "niveles", "tensionales", "y", "diuresis", "conservada", "con", "balance", "negativo", "diario", ".", "\n", "En", "primera", "eco", "-", "cardio", "de", "control", ",", "función", "sistólica", "global", "ligera", "-", "moderadamente", "deprimida", "FEVI", "40", "%", "con", "hipoquinesia", "generalizada", ".", "En", "analíticas", "de", "UCI", ",", "destaca", "elevación", "de", "enzimas", "hepáticas", ",", "llegando", "a", "un", "pico", "de", "GPT", "de", "4.282", ",", "LDH", "6.041", ",", "TP", "29", "%", "y", "TTPA30", ".", "\n", "Se", "planteó", "la", "posibilidad", "de", "traslado", "a", "otro", "centro", "con", "disponibilidad", "de", "extracorporeal", "membrane", "oxygenation", "(", "ECMO", ")", "como", "sistema", "de", "asistencia", "mecánica", "circulatoria", "de", "corta", "duración", ",", "pero", "finalmente", "se", "desestimó", ".", "\n", "Se", "colocó", "Pleurocath", "®", ",", "por", "presencia", "de", "derrame", "pleural", "en", "estudios", "de", "imagen", ",", "con", "salida", "de", "1", "l", "de", "líquido", "pleural", "seroso", "retirado", "a", "las", "24", "h", "con", "descenso", "de", "taquipnea", "sin", "llegar", "a", "precisar", "ventilación", "mecánica", ".", "\n", "Los", "resultados", "de", "los", "hemocultivos", "fueron", "negativos", ",", "con", "leucocitosis", "en", "descenso", ",", "por", "lo", "que", ",", "tras", "un", "ciclo", "corto", "de", "cobertura", "empírica", "con", "meropenem", "y", "linezolid", ",", "se", "suspenden", ".", "Mejoría", "progresiva", "de", "enzimas", "hepáticas", "(", "GPT", "302", ")", ",", "ausencia", "de", "leucocitosis", "(", "5.980", "con", "49", "%", "neutrófilos", ")", "y", "coagulopatía", "corregida", "(", "INR", ":", "1,1", ";", "TTPA", "32,5", "s", ")", ".", "La", "citología", "de", "líquido", "pleural", "fue", "negativa", "para", "células", "tumorales", "malignas", ".", "\n", "Dada", "la", "estabilidad", "hemodinámica", ",", "se", "traslada", "a", "planta", "de", "Cardiología", "donde", "se", "ajusta", "tratamiento", "con", "IECA", ",", "beta", "-", "bloqueantes", "y", "espironolactona", "con", "buena", "tolerancia", "clínica", ".", "Ecocardiograma", "con", "recuperación", "de", "FEVI", "(", "60", "%", ")", ",", "por", "lo", "que", "se", "procede", "al", "alta", ".", "\n", "Valorada", "de", "nuevo", "en", "consulta", "de", "Oncología", ",", "se", "muestra", "asintomática", "con", "controles", "y", "ajuste", "de", "tratamiento", "por", "Cardiología", ".", "Dada", "la", "toxicidad", "grave", "desarrollada", ",", "con", "shock", "cardiogénico", "tras", "primera", "infusión", "de", "fluorouracilo", ",", "que", "descarta", "su", "utilización", "posterior", ",", "se", "pide", "TC", "de", "reevaluación", "sin", "adenopatías", "macroscópicas", "ni", "otros", "hallazgos", "de", "enfermedad", "activa", ";", "se", "da", "por", "finalizada", "la", "adyuvancia", ",", "y", "pasa", "a", "control", "estrecho", ".", "Está", "pendiente", "de", "los", "resultados", "del", "Consejo", "Genético", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
F is a Person, age is a Person, 18 to 70 is a Value, American Society of Anesthesiologists ( ASA ) is a Measurement, I e II is a Value, breast cancer is a Condition, DIN 2 e 3 , o LIN 2 e 3 sec . Tavassoli is a Scope, scheduled for is a Mood, nipple - sparing mastectomy is a Condition, simple mastectomy is a Condition, skin - sparing mastectomy is a Condition, skin - reducing mastectomy is a Condition, lymphnode biopsy is a Condition, axillary dissection is a Condition, immediate is a Qualifier, sub - pectoral prosthetic reconstruction is a Procedure	NCT02035904_inc_task0	Sentence: F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Procedure, Scope, Measurement, Mood	[ "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O" ]	F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent.	[ "F", ";", "age", "18", "to", "70", "\n", "American", "Society", "of", "Anesthesiologists", "(", "ASA", ")", "I", "e", "II", ";", "\n", "breast", "cancer", "(", "DIN", "2", "e", "3", ",", "o", "LIN", "2", "e", "3", "sec", ".", "Tavassoli", ")", "scheduled", "for", "nipple", "-", "sparing", "mastectomy", ",", "simple", "mastectomy", ",", "skin", "-", "sparing", "mastectomy", ",", "skin", "-", "reducing", "mastectomy", "c", ",", "lymphnode", "biopsy", "and", "axillary", "dissection", ";", "\n", "immediate", "sub", "-", "pectoral", "prosthetic", "reconstruction", ";", "\n", "signed", "informed", "consent", ".", "\n" ]	[ "Measurement", "Procedure", "Scope", "Condition", "Mood", "Value", "Qualifier", "Person" ]
F is a Person, age is a Person, 18 to 70 is a Value, American Society of Anesthesiologists ( ASA ) is a Measurement, I e II is a Value, breast cancer is a Condition, DIN 2 e 3 , o LIN 2 e 3 sec . Tavassoli is a Scope, scheduled for is a Mood, nipple - sparing mastectomy is a Condition, simple mastectomy is a Condition, skin - sparing mastectomy is a Condition, skin - reducing mastectomy is a Condition, lymphnode biopsy is a Condition, axillary dissection is a Condition, immediate is a Qualifier, sub - pectoral prosthetic reconstruction is a Procedure	NCT02035904_inc_task1	Sentence: F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent. Instructions: please typing these entity words according to sentence: F, age, 18 to 70, American Society of Anesthesiologists ( ASA ), I e II, breast cancer, DIN 2 e 3 , o LIN 2 e 3 sec . Tavassoli, scheduled for, nipple - sparing mastectomy, simple mastectomy, skin - sparing mastectomy, skin - reducing mastectomy, lymphnode biopsy, axillary dissection, immediate, sub - pectoral prosthetic reconstruction Options: Condition, Qualifier, Value, Person, Procedure, Scope, Measurement, Mood	[ "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O" ]	F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent.	[ "F", ";", "age", "18", "to", "70", "\n", "American", "Society", "of", "Anesthesiologists", "(", "ASA", ")", "I", "e", "II", ";", "\n", "breast", "cancer", "(", "DIN", "2", "e", "3", ",", "o", "LIN", "2", "e", "3", "sec", ".", "Tavassoli", ")", "scheduled", "for", "nipple", "-", "sparing", "mastectomy", ",", "simple", "mastectomy", ",", "skin", "-", "sparing", "mastectomy", ",", "skin", "-", "reducing", "mastectomy", "c", ",", "lymphnode", "biopsy", "and", "axillary", "dissection", ";", "\n", "immediate", "sub", "-", "pectoral", "prosthetic", "reconstruction", ";", "\n", "signed", "informed", "consent", ".", "\n" ]	[ "Measurement", "Procedure", "Scope", "Condition", "Mood", "Value", "Qualifier", "Person" ]
F, age, 18 to 70, American Society of Anesthesiologists ( ASA ), I e II, breast cancer, DIN 2 e 3 , o LIN 2 e 3 sec . Tavassoli, scheduled for, nipple - sparing mastectomy, simple mastectomy, skin - sparing mastectomy, skin - reducing mastectomy, lymphnode biopsy, axillary dissection, immediate, sub - pectoral prosthetic reconstruction	NCT02035904_inc_task2	Sentence: F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent. Instructions: please extract entity words from the input sentence	[ "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O" ]	F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent.	[ "F", ";", "age", "18", "to", "70", "\n", "American", "Society", "of", "Anesthesiologists", "(", "ASA", ")", "I", "e", "II", ";", "\n", "breast", "cancer", "(", "DIN", "2", "e", "3", ",", "o", "LIN", "2", "e", "3", "sec", ".", "Tavassoli", ")", "scheduled", "for", "nipple", "-", "sparing", "mastectomy", ",", "simple", "mastectomy", ",", "skin", "-", "sparing", "mastectomy", ",", "skin", "-", "reducing", "mastectomy", "c", ",", "lymphnode", "biopsy", "and", "axillary", "dissection", ";", "\n", "immediate", "sub", "-", "pectoral", "prosthetic", "reconstruction", ";", "\n", "signed", "informed", "consent", ".", "\n" ]	[ "Measurement", "Procedure", "Scope", "Condition", "Mood", "Value", "Qualifier", "Person" ]
YE1998 is a Protein, 2000 is a Protein, Plu0634 is a Protein, Plu0635 is a Protein, P. luminescens is a Organism, plu1330 is a Protein, 1369 is a Protein, plu3217 is a Protein, plu3324 is a Protein, plu4117 is a Protein, plu3668 is a Protein, Y. enterocolitica is a Organism, YE1322 is a Protein, P. luminescens is a Organism, Plu3209 is a Protein, X. nematophila is a Organism, Plu2288 is a Protein, Plu0359 is a Protein, YE2685 is a Protein, Y. enterocolitica is a Organism, YE2091 is a Protein, P. luminescens ssp . akhurstii strain W14 is a Organism, P. luminescens ssp . laumondii strain TT01 is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, Txp40 is a Protein, Xnp2 is a Protein, X. bovienii is a Organism, galA is a Protein, plu0840 is a Protein, Aeromonas hydrophila is a Organism, plu2400 is a Protein, plu2420 is a Protein, cipA is a Protein, cipB is a Protein, P. luminescens is a Organism, plu1537 is a Protein, Y. enterocolitica is a Organism, Pnf is a Protein, P. luminescens ssp . akhurstii strain W14 is a Organism, P. luminescens ssp . laumondii strain TT01 is a Organism, P. luminescens is a Organism, plu4092 is a Protein, plu4436 is a Protein, P. luminescens is a Organism, M. sexta is a Organism, mcf2 is a Protein, plu3128 is a Protein, Y. enterocolitica is a Organism, P. luminescens is a Organism, tobacco hornworm is a Organism, Y. enterocolitica is a Organism, Y. pestis is a Organism, YPO0339 is a Protein, Y. enterocolitica is a Organism, P. luminescens is a Organism, SopB is a Protein, human is a Organism, P. asymbiotica is a Organism, P. luminescens is a Organism, YE2447 is a Protein, SrfA is a Protein, PhoP is a Protein, S. typhimurium is a Organism, SrfA is a Protein, P. luminescens is a Organism, YE1604 is a Protein, 1606 is a Protein, ProP is a Protein, YE3594 is a Protein, YE4072 is a Protein, 4078 is a Protein, YE3228 is a Protein, 3235 is a Protein, AHL is a Chemical, ADP is a Chemical, ye2124 is a Protein, ye2123 is a Protein, Yersinia is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, Y. enterocolitica is a Organism	21_task0	Sentence: Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism, Chemical, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5.	[ "Repeats", "-", "in", "-", "toxin", "(", "RTX", ")", "and", "other", "toxins", "\n", "RTX", "proteins", "constitute", "another", "family", "of", "toxins", "that", "may", "contribute", "to", "the", "insecticidal", "activity", "of", "the", "two", "pathogens", ".", "A", "putative", "RTX", "-", "family", "toxin", "transporter", "is", "common", "to", "both", "pathogens", "(", "YE1998", "-", "2000", ",", "Plu0634", "/", "Plu0635", ")", ".", "The", "P.", "luminescens", "genome", "comprises", "a", "gene", "cluster", "encoding", "RTX", "proteins", ",", "namely", "plu1330", "-", "1369", ".", "Further", "RTX", "toxins", "are", "encoded", "by", "plu3217", ",", "plu3324", "(", "both", "RTX", "A", "-", "family", ")", ",", "plu4117", "(", "own", "family", ")", ",", "and", "plu3668", "(", "RTX", "cytotoxin", ")", ",", "none", "of", "which", "is", "present", "in", "Y.", "enterocolitica", ".", "This", "pathogen", "produces", "only", "one", "RTX", "protein", "(", "YE1322", ")", "for", "which", "a", "truncated", "homologue", "is", "found", "in", "P.", "luminescens", "(", "Plu3209", ")", ".", "Other", "examples", "of", "toxins", "common", "for", "both", "bacterial", "species", "compared", "here", "are", "homologues", "of", "XaxAB", ",", "an", "apoptotic", "AB", "toxin", "of", "X.", "nematophila", "[", "68", "]", ",", "and", "proteins", "encoded", "by", "the", "macrophage", "toxin", "(", "mt)-like", "genes", "Plu2288", "and", "Plu0359", "with", "high", "similarity", "to", "YE2685", ".", "cnf", "encoding", "the", "cytonecrosis", "factor", "-", "like", "toxin", "is", "present", "in", "Y.", "enterocolitica", "(", "YE2091", ")", "and", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", "(", "Fig", ".", "4", ")", ".", "P.", "luminescens", "produces", "a", "series", "of", "proteins", "similar", "to", "toxins", "that", "have", "been", "identified", "in", "other", "bacteria", ",", "but", "are", "absent", "in", "Y.", "enterocolitica", ".", "Examples", "identified", "are", "Txp40", ",", "a", "40", "kD", "insecticidal", "toxin", "[", "69", "]", ",", "the", "nematicidal", "toxin", "(", "Xnp2", ")", "first", "described", "in", "X.", "bovienii", "(", "accession", "number", "AJ296651.1", ")", ",", "galA", "(", "plu0840", ")", "similar", "to", "the", "enterotoxin", "Ast", "of", "Aeromonas", "hydrophila", "which", "is", "involved", "in", "carbohydrate", "transport", "and", "metabolism", "[", "70", "]", ",", "and", "two", "dermonecrotizing", "toxin-(dnt-", ")", "like", "factors", "(", "plu2400", "and", "plu2420", ")", ".", "In", "addition", ",", "neither", "the", "crystal", "proteins", "encoded", "by", "cipA", "and", "cipB", "in", "P.", "luminescens", "nor", "a", "Bt", "-", "like", "toxin", "(", "plu1537", ")", "could", "be", "found", "in", "Y.", "enterocolitica", ".", "A", "cytonecrosis", "factor", "(", "CNF)-like", "protein", ",", "Pnf", ",", "was", "identified", "in", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", ".", "In", "P.", "luminescens", ",", "the", "two", "paralogs", "plu4092", "and", "plu4436", "encode", "juvenile", "hormone", "esterases", "(", "JHE", ")", "for", "which", "insect", "toxicity", "has", "already", "been", "demonstrated", "[", "24", "]", ".", "Additionally", ",", "neither", "the", "locus", "mcf", "that", "confers", "insecticidal", "activity", "of", "P.", "luminescens", "towards", "M.", "sexta", "[", "71", "]", "by", "inducing", "apoptosis", "[", "72", "]", ",", "nor", "the", "homologous", "gene", "locus", "mcf2", "(", "plu3128", ")", "[", "73", "]", "are", "present", "in", "the", "genome", "of", "Y.", "enterocolitica", ".", "Most", "of", "these", "toxins", "probably", "contribute", "to", "the", "higher", "insect", "toxicity", "of", "P.", "luminescens", "against", "the", "tobacco", "hornworm", "in", "comparison", "with", "Y.", "enterocolitica", ".", "No", "homologues", "of", "the", "Y.", "pestis", "gene", "coding", "for", "enhancin", "(", "YPO0339", ")", "could", "be", "found", "for", "which", "a", "role", "in", "flea", "colonization", "was", "predicted", "[", "74", "]", ".", "We", "also", "identified", "several", "virulence", "genes", "and", "operons", "that", "are", "present", "in", "Y.", "enterocolitica", ",", "but", "not", "in", "P.", "luminescens", ",", "suggesting", "that", "they", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", "from", "other", "bacteria", "and", "do", "not", "play", "a", "role", "in", "bacteria", "-", "insect", "association", ".", "Examples", "are", "SopB", ",", "a", "host", "cell", "invasion", "factor", "translocated", "via", "the", "type", "-", "III", "secretion", "system", "that", "is", "present", "in", "the", "emerging", "human", "pathogen", "P.", "asymbiotica", ",", "but", "not", "in", "the", "insect", "pathogen", "P.", "luminescens", "[", "14", "]", ",", "a", "putative", "effector", "protein", "(", "YE2447", ")", "with", "proteolytic", "activity", ",", "and", "a", "homologue", "of", "SrfA", "which", "is", "negatively", "regulated", "by", "PhoP", "in", "S.", "typhimurium", "[", "75", "]", ".", "The", "SrfA", "homologue", "has", "been", "demonstrated", "to", "be", "up", "-", "regulated", "by", "environmental", "temperature", "[", "67", "]", ".", "Other", "virulence", "factors", "absent", "in", "P.", "luminescens", "are", "the", "opg", "cluster", "(", "YE1604", "-", "1606", ")", "and", "ProP", "(", "YE3594", ")", ",", "both", "involved", "in", "osmoprotection", "[", "76", "]", ",", "cellulose", "biosynthesis", "(", "YE4072", "-", "4078", ")", "associated", "with", "protection", "from", "chemical", "and", "mechanical", "stress", "[", "60", "]", ",", "the", "methionine", "-", "salvage", "pathway", "(", "YE3228", "-", "3235", ")", "also", "involved", "in", "AHL", "production", "[", "23", "]", ",", "the", "putative", "ADP", "-", "ribosyltransferase", "toxin", "encoded", "by", "ytxAB", "(", "ye2124", "/", "ye2123", ")", "[", "77", "]", ",", "and", "the", "Yersinia", "heat", "-", "stable", "toxin", "Yst", "[", "78", "]", "which", "is", "stronger", "expressed", "at", "28degreesC", "than", "at", "37degreesC", "(", "Table", "1", ")", ".", "Summarizing", ",", "the", "large", "variety", "of", "diverse", "toxins", "present", "in", "P.", "luminescens", ",", "but", "absent", "in", "Y.", "enterocolitica", ",", "might", "contribute", "to", "the", "higher", "toxicity", "towards", "insects", "of", "P.", "luminescens", "in", "comparison", "to", "Y.", "enterocolitica", ".", "Toxins", "only", "present", "in", "Y.", "enterocolitica", "are", "assumed", "to", "play", "a", "major", "role", "in", "its", "pathogenicity", "towards", "mammalians", ",", "and", "some", "of", "them", "might", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", ".", "Examples", "of", "those", "factors", "are", "shown", "in", "Fig", ".", "5", ".", "\n" ]	[ "Organism", "Protein", "Chemical" ]
YE1998 is a Protein, 2000 is a Protein, Plu0634 is a Protein, Plu0635 is a Protein, P. luminescens is a Organism, plu1330 is a Protein, 1369 is a Protein, plu3217 is a Protein, plu3324 is a Protein, plu4117 is a Protein, plu3668 is a Protein, Y. enterocolitica is a Organism, YE1322 is a Protein, P. luminescens is a Organism, Plu3209 is a Protein, X. nematophila is a Organism, Plu2288 is a Protein, Plu0359 is a Protein, YE2685 is a Protein, Y. enterocolitica is a Organism, YE2091 is a Protein, P. luminescens ssp . akhurstii strain W14 is a Organism, P. luminescens ssp . laumondii strain TT01 is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, Txp40 is a Protein, Xnp2 is a Protein, X. bovienii is a Organism, galA is a Protein, plu0840 is a Protein, Aeromonas hydrophila is a Organism, plu2400 is a Protein, plu2420 is a Protein, cipA is a Protein, cipB is a Protein, P. luminescens is a Organism, plu1537 is a Protein, Y. enterocolitica is a Organism, Pnf is a Protein, P. luminescens ssp . akhurstii strain W14 is a Organism, P. luminescens ssp . laumondii strain TT01 is a Organism, P. luminescens is a Organism, plu4092 is a Protein, plu4436 is a Protein, P. luminescens is a Organism, M. sexta is a Organism, mcf2 is a Protein, plu3128 is a Protein, Y. enterocolitica is a Organism, P. luminescens is a Organism, tobacco hornworm is a Organism, Y. enterocolitica is a Organism, Y. pestis is a Organism, YPO0339 is a Protein, Y. enterocolitica is a Organism, P. luminescens is a Organism, SopB is a Protein, human is a Organism, P. asymbiotica is a Organism, P. luminescens is a Organism, YE2447 is a Protein, SrfA is a Protein, PhoP is a Protein, S. typhimurium is a Organism, SrfA is a Protein, P. luminescens is a Organism, YE1604 is a Protein, 1606 is a Protein, ProP is a Protein, YE3594 is a Protein, YE4072 is a Protein, 4078 is a Protein, YE3228 is a Protein, 3235 is a Protein, AHL is a Chemical, ADP is a Chemical, ye2124 is a Protein, ye2123 is a Protein, Yersinia is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, Y. enterocolitica is a Organism	21_task1	Sentence: Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5. Instructions: please typing these entity words according to sentence: YE1998, 2000, Plu0634, Plu0635, P. luminescens, plu1330, 1369, plu3217, plu3324, plu4117, plu3668, Y. enterocolitica, YE1322, P. luminescens, Plu3209, X. nematophila, Plu2288, Plu0359, YE2685, Y. enterocolitica, YE2091, P. luminescens ssp . akhurstii strain W14, P. luminescens ssp . laumondii strain TT01, P. luminescens, Y. enterocolitica, Txp40, Xnp2, X. bovienii, galA, plu0840, Aeromonas hydrophila, plu2400, plu2420, cipA, cipB, P. luminescens, plu1537, Y. enterocolitica, Pnf, P. luminescens ssp . akhurstii strain W14, P. luminescens ssp . laumondii strain TT01, P. luminescens, plu4092, plu4436, P. luminescens, M. sexta, mcf2, plu3128, Y. enterocolitica, P. luminescens, tobacco hornworm, Y. enterocolitica, Y. pestis, YPO0339, Y. enterocolitica, P. luminescens, SopB, human, P. asymbiotica, P. luminescens, YE2447, SrfA, PhoP, S. typhimurium, SrfA, P. luminescens, YE1604, 1606, ProP, YE3594, YE4072, 4078, YE3228, 3235, AHL, ADP, ye2124, ye2123, Yersinia, P. luminescens, Y. enterocolitica, P. luminescens, Y. enterocolitica, Y. enterocolitica Options: Organism, Chemical, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5.	[ "Repeats", "-", "in", "-", "toxin", "(", "RTX", ")", "and", "other", "toxins", "\n", "RTX", "proteins", "constitute", "another", "family", "of", "toxins", "that", "may", "contribute", "to", "the", "insecticidal", "activity", "of", "the", "two", "pathogens", ".", "A", "putative", "RTX", "-", "family", "toxin", "transporter", "is", "common", "to", "both", "pathogens", "(", "YE1998", "-", "2000", ",", "Plu0634", "/", "Plu0635", ")", ".", "The", "P.", "luminescens", "genome", "comprises", "a", "gene", "cluster", "encoding", "RTX", "proteins", ",", "namely", "plu1330", "-", "1369", ".", "Further", "RTX", "toxins", "are", "encoded", "by", "plu3217", ",", "plu3324", "(", "both", "RTX", "A", "-", "family", ")", ",", "plu4117", "(", "own", "family", ")", ",", "and", "plu3668", "(", "RTX", "cytotoxin", ")", ",", "none", "of", "which", "is", "present", "in", "Y.", "enterocolitica", ".", "This", "pathogen", "produces", "only", "one", "RTX", "protein", "(", "YE1322", ")", "for", "which", "a", "truncated", "homologue", "is", "found", "in", "P.", "luminescens", "(", "Plu3209", ")", ".", "Other", "examples", "of", "toxins", "common", "for", "both", "bacterial", "species", "compared", "here", "are", "homologues", "of", "XaxAB", ",", "an", "apoptotic", "AB", "toxin", "of", "X.", "nematophila", "[", "68", "]", ",", "and", "proteins", "encoded", "by", "the", "macrophage", "toxin", "(", "mt)-like", "genes", "Plu2288", "and", "Plu0359", "with", "high", "similarity", "to", "YE2685", ".", "cnf", "encoding", "the", "cytonecrosis", "factor", "-", "like", "toxin", "is", "present", "in", "Y.", "enterocolitica", "(", "YE2091", ")", "and", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", "(", "Fig", ".", "4", ")", ".", "P.", "luminescens", "produces", "a", "series", "of", "proteins", "similar", "to", "toxins", "that", "have", "been", "identified", "in", "other", "bacteria", ",", "but", "are", "absent", "in", "Y.", "enterocolitica", ".", "Examples", "identified", "are", "Txp40", ",", "a", "40", "kD", "insecticidal", "toxin", "[", "69", "]", ",", "the", "nematicidal", "toxin", "(", "Xnp2", ")", "first", "described", "in", "X.", "bovienii", "(", "accession", "number", "AJ296651.1", ")", ",", "galA", "(", "plu0840", ")", "similar", "to", "the", "enterotoxin", "Ast", "of", "Aeromonas", "hydrophila", "which", "is", "involved", "in", "carbohydrate", "transport", "and", "metabolism", "[", "70", "]", ",", "and", "two", "dermonecrotizing", "toxin-(dnt-", ")", "like", "factors", "(", "plu2400", "and", "plu2420", ")", ".", "In", "addition", ",", "neither", "the", "crystal", "proteins", "encoded", "by", "cipA", "and", "cipB", "in", "P.", "luminescens", "nor", "a", "Bt", "-", "like", "toxin", "(", "plu1537", ")", "could", "be", "found", "in", "Y.", "enterocolitica", ".", "A", "cytonecrosis", "factor", "(", "CNF)-like", "protein", ",", "Pnf", ",", "was", "identified", "in", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", ".", "In", "P.", "luminescens", ",", "the", "two", "paralogs", "plu4092", "and", "plu4436", "encode", "juvenile", "hormone", "esterases", "(", "JHE", ")", "for", "which", "insect", "toxicity", "has", "already", "been", "demonstrated", "[", "24", "]", ".", "Additionally", ",", "neither", "the", "locus", "mcf", "that", "confers", "insecticidal", "activity", "of", "P.", "luminescens", "towards", "M.", "sexta", "[", "71", "]", "by", "inducing", "apoptosis", "[", "72", "]", ",", "nor", "the", "homologous", "gene", "locus", "mcf2", "(", "plu3128", ")", "[", "73", "]", "are", "present", "in", "the", "genome", "of", "Y.", "enterocolitica", ".", "Most", "of", "these", "toxins", "probably", "contribute", "to", "the", "higher", "insect", "toxicity", "of", "P.", "luminescens", "against", "the", "tobacco", "hornworm", "in", "comparison", "with", "Y.", "enterocolitica", ".", "No", "homologues", "of", "the", "Y.", "pestis", "gene", "coding", "for", "enhancin", "(", "YPO0339", ")", "could", "be", "found", "for", "which", "a", "role", "in", "flea", "colonization", "was", "predicted", "[", "74", "]", ".", "We", "also", "identified", "several", "virulence", "genes", "and", "operons", "that", "are", "present", "in", "Y.", "enterocolitica", ",", "but", "not", "in", "P.", "luminescens", ",", "suggesting", "that", "they", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", "from", "other", "bacteria", "and", "do", "not", "play", "a", "role", "in", "bacteria", "-", "insect", "association", ".", "Examples", "are", "SopB", ",", "a", "host", "cell", "invasion", "factor", "translocated", "via", "the", "type", "-", "III", "secretion", "system", "that", "is", "present", "in", "the", "emerging", "human", "pathogen", "P.", "asymbiotica", ",", "but", "not", "in", "the", "insect", "pathogen", "P.", "luminescens", "[", "14", "]", ",", "a", "putative", "effector", "protein", "(", "YE2447", ")", "with", "proteolytic", "activity", ",", "and", "a", "homologue", "of", "SrfA", "which", "is", "negatively", "regulated", "by", "PhoP", "in", "S.", "typhimurium", "[", "75", "]", ".", "The", "SrfA", "homologue", "has", "been", "demonstrated", "to", "be", "up", "-", "regulated", "by", "environmental", "temperature", "[", "67", "]", ".", "Other", "virulence", "factors", "absent", "in", "P.", "luminescens", "are", "the", "opg", "cluster", "(", "YE1604", "-", "1606", ")", "and", "ProP", "(", "YE3594", ")", ",", "both", "involved", "in", "osmoprotection", "[", "76", "]", ",", "cellulose", "biosynthesis", "(", "YE4072", "-", "4078", ")", "associated", "with", "protection", "from", "chemical", "and", "mechanical", "stress", "[", "60", "]", ",", "the", "methionine", "-", "salvage", "pathway", "(", "YE3228", "-", "3235", ")", "also", "involved", "in", "AHL", "production", "[", "23", "]", ",", "the", "putative", "ADP", "-", "ribosyltransferase", "toxin", "encoded", "by", "ytxAB", "(", "ye2124", "/", "ye2123", ")", "[", "77", "]", ",", "and", "the", "Yersinia", "heat", "-", "stable", "toxin", "Yst", "[", "78", "]", "which", "is", "stronger", "expressed", "at", "28degreesC", "than", "at", "37degreesC", "(", "Table", "1", ")", ".", "Summarizing", ",", "the", "large", "variety", "of", "diverse", "toxins", "present", "in", "P.", "luminescens", ",", "but", "absent", "in", "Y.", "enterocolitica", ",", "might", "contribute", "to", "the", "higher", "toxicity", "towards", "insects", "of", "P.", "luminescens", "in", "comparison", "to", "Y.", "enterocolitica", ".", "Toxins", "only", "present", "in", "Y.", "enterocolitica", "are", "assumed", "to", "play", "a", "major", "role", "in", "its", "pathogenicity", "towards", "mammalians", ",", "and", "some", "of", "them", "might", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", ".", "Examples", "of", "those", "factors", "are", "shown", "in", "Fig", ".", "5", ".", "\n" ]	[ "Organism", "Protein", "Chemical" ]
YE1998, 2000, Plu0634, Plu0635, P. luminescens, plu1330, 1369, plu3217, plu3324, plu4117, plu3668, Y. enterocolitica, YE1322, P. luminescens, Plu3209, X. nematophila, Plu2288, Plu0359, YE2685, Y. enterocolitica, YE2091, P. luminescens ssp . akhurstii strain W14, P. luminescens ssp . laumondii strain TT01, P. luminescens, Y. enterocolitica, Txp40, Xnp2, X. bovienii, galA, plu0840, Aeromonas hydrophila, plu2400, plu2420, cipA, cipB, P. luminescens, plu1537, Y. enterocolitica, Pnf, P. luminescens ssp . akhurstii strain W14, P. luminescens ssp . laumondii strain TT01, P. luminescens, plu4092, plu4436, P. luminescens, M. sexta, mcf2, plu3128, Y. enterocolitica, P. luminescens, tobacco hornworm, Y. enterocolitica, Y. pestis, YPO0339, Y. enterocolitica, P. luminescens, SopB, human, P. asymbiotica, P. luminescens, YE2447, SrfA, PhoP, S. typhimurium, SrfA, P. luminescens, YE1604, 1606, ProP, YE3594, YE4072, 4078, YE3228, 3235, AHL, ADP, ye2124, ye2123, Yersinia, P. luminescens, Y. enterocolitica, P. luminescens, Y. enterocolitica, Y. enterocolitica	21_task2	Sentence: Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5.	[ "Repeats", "-", "in", "-", "toxin", "(", "RTX", ")", "and", "other", "toxins", "\n", "RTX", "proteins", "constitute", "another", "family", "of", "toxins", "that", "may", "contribute", "to", "the", "insecticidal", "activity", "of", "the", "two", "pathogens", ".", "A", "putative", "RTX", "-", "family", "toxin", "transporter", "is", "common", "to", "both", "pathogens", "(", "YE1998", "-", "2000", ",", "Plu0634", "/", "Plu0635", ")", ".", "The", "P.", "luminescens", "genome", "comprises", "a", "gene", "cluster", "encoding", "RTX", "proteins", ",", "namely", "plu1330", "-", "1369", ".", "Further", "RTX", "toxins", "are", "encoded", "by", "plu3217", ",", "plu3324", "(", "both", "RTX", "A", "-", "family", ")", ",", "plu4117", "(", "own", "family", ")", ",", "and", "plu3668", "(", "RTX", "cytotoxin", ")", ",", "none", "of", "which", "is", "present", "in", "Y.", "enterocolitica", ".", "This", "pathogen", "produces", "only", "one", "RTX", "protein", "(", "YE1322", ")", "for", "which", "a", "truncated", "homologue", "is", "found", "in", "P.", "luminescens", "(", "Plu3209", ")", ".", "Other", "examples", "of", "toxins", "common", "for", "both", "bacterial", "species", "compared", "here", "are", "homologues", "of", "XaxAB", ",", "an", "apoptotic", "AB", "toxin", "of", "X.", "nematophila", "[", "68", "]", ",", "and", "proteins", "encoded", "by", "the", "macrophage", "toxin", "(", "mt)-like", "genes", "Plu2288", "and", "Plu0359", "with", "high", "similarity", "to", "YE2685", ".", "cnf", "encoding", "the", "cytonecrosis", "factor", "-", "like", "toxin", "is", "present", "in", "Y.", "enterocolitica", "(", "YE2091", ")", "and", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", "(", "Fig", ".", "4", ")", ".", "P.", "luminescens", "produces", "a", "series", "of", "proteins", "similar", "to", "toxins", "that", "have", "been", "identified", "in", "other", "bacteria", ",", "but", "are", "absent", "in", "Y.", "enterocolitica", ".", "Examples", "identified", "are", "Txp40", ",", "a", "40", "kD", "insecticidal", "toxin", "[", "69", "]", ",", "the", "nematicidal", "toxin", "(", "Xnp2", ")", "first", "described", "in", "X.", "bovienii", "(", "accession", "number", "AJ296651.1", ")", ",", "galA", "(", "plu0840", ")", "similar", "to", "the", "enterotoxin", "Ast", "of", "Aeromonas", "hydrophila", "which", "is", "involved", "in", "carbohydrate", "transport", "and", "metabolism", "[", "70", "]", ",", "and", "two", "dermonecrotizing", "toxin-(dnt-", ")", "like", "factors", "(", "plu2400", "and", "plu2420", ")", ".", "In", "addition", ",", "neither", "the", "crystal", "proteins", "encoded", "by", "cipA", "and", "cipB", "in", "P.", "luminescens", "nor", "a", "Bt", "-", "like", "toxin", "(", "plu1537", ")", "could", "be", "found", "in", "Y.", "enterocolitica", ".", "A", "cytonecrosis", "factor", "(", "CNF)-like", "protein", ",", "Pnf", ",", "was", "identified", "in", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", ".", "In", "P.", "luminescens", ",", "the", "two", "paralogs", "plu4092", "and", "plu4436", "encode", "juvenile", "hormone", "esterases", "(", "JHE", ")", "for", "which", "insect", "toxicity", "has", "already", "been", "demonstrated", "[", "24", "]", ".", "Additionally", ",", "neither", "the", "locus", "mcf", "that", "confers", "insecticidal", "activity", "of", "P.", "luminescens", "towards", "M.", "sexta", "[", "71", "]", "by", "inducing", "apoptosis", "[", "72", "]", ",", "nor", "the", "homologous", "gene", "locus", "mcf2", "(", "plu3128", ")", "[", "73", "]", "are", "present", "in", "the", "genome", "of", "Y.", "enterocolitica", ".", "Most", "of", "these", "toxins", "probably", "contribute", "to", "the", "higher", "insect", "toxicity", "of", "P.", "luminescens", "against", "the", "tobacco", "hornworm", "in", "comparison", "with", "Y.", "enterocolitica", ".", "No", "homologues", "of", "the", "Y.", "pestis", "gene", "coding", "for", "enhancin", "(", "YPO0339", ")", "could", "be", "found", "for", "which", "a", "role", "in", "flea", "colonization", "was", "predicted", "[", "74", "]", ".", "We", "also", "identified", "several", "virulence", "genes", "and", "operons", "that", "are", "present", "in", "Y.", "enterocolitica", ",", "but", "not", "in", "P.", "luminescens", ",", "suggesting", "that", "they", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", "from", "other", "bacteria", "and", "do", "not", "play", "a", "role", "in", "bacteria", "-", "insect", "association", ".", "Examples", "are", "SopB", ",", "a", "host", "cell", "invasion", "factor", "translocated", "via", "the", "type", "-", "III", "secretion", "system", "that", "is", "present", "in", "the", "emerging", "human", "pathogen", "P.", "asymbiotica", ",", "but", "not", "in", "the", "insect", "pathogen", "P.", "luminescens", "[", "14", "]", ",", "a", "putative", "effector", "protein", "(", "YE2447", ")", "with", "proteolytic", "activity", ",", "and", "a", "homologue", "of", "SrfA", "which", "is", "negatively", "regulated", "by", "PhoP", "in", "S.", "typhimurium", "[", "75", "]", ".", "The", "SrfA", "homologue", "has", "been", "demonstrated", "to", "be", "up", "-", "regulated", "by", "environmental", "temperature", "[", "67", "]", ".", "Other", "virulence", "factors", "absent", "in", "P.", "luminescens", "are", "the", "opg", "cluster", "(", "YE1604", "-", "1606", ")", "and", "ProP", "(", "YE3594", ")", ",", "both", "involved", "in", "osmoprotection", "[", "76", "]", ",", "cellulose", "biosynthesis", "(", "YE4072", "-", "4078", ")", "associated", "with", "protection", "from", "chemical", "and", "mechanical", "stress", "[", "60", "]", ",", "the", "methionine", "-", "salvage", "pathway", "(", "YE3228", "-", "3235", ")", "also", "involved", "in", "AHL", "production", "[", "23", "]", ",", "the", "putative", "ADP", "-", "ribosyltransferase", "toxin", "encoded", "by", "ytxAB", "(", "ye2124", "/", "ye2123", ")", "[", "77", "]", ",", "and", "the", "Yersinia", "heat", "-", "stable", "toxin", "Yst", "[", "78", "]", "which", "is", "stronger", "expressed", "at", "28degreesC", "than", "at", "37degreesC", "(", "Table", "1", ")", ".", "Summarizing", ",", "the", "large", "variety", "of", "diverse", "toxins", "present", "in", "P.", "luminescens", ",", "but", "absent", "in", "Y.", "enterocolitica", ",", "might", "contribute", "to", "the", "higher", "toxicity", "towards", "insects", "of", "P.", "luminescens", "in", "comparison", "to", "Y.", "enterocolitica", ".", "Toxins", "only", "present", "in", "Y.", "enterocolitica", "are", "assumed", "to", "play", "a", "major", "role", "in", "its", "pathogenicity", "towards", "mammalians", ",", "and", "some", "of", "them", "might", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", ".", "Examples", "of", "those", "factors", "are", "shown", "in", "Fig", ".", "5", ".", "\n" ]	[ "Organism", "Protein", "Chemical" ]
Monitoring is an umlsterm, pressure is an umlsterm	DerRadiologe.80380624.eng.abstr_task0	Sentence: Purpose : Monitoring of intraluminal pressure in standardized enteroclysis . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Purpose : Monitoring of intraluminal pressure in standardized enteroclysis .	[ "Purpose", ":", "Monitoring", "of", "intraluminal", "pressure", "in", "standardized", "enteroclysis", "." ]	[ "umlsterm" ]

Pionierzeit is an umlsterm, Replantation is an umlsterm, Extremitaet is an umlsterm, Schmerzen is an umlsterm, Replantation is an umlsterm, Unfallmechanismus is an umlsterm, Replantation is an umlsterm, Patienten is an umlsterm

DerUnfallchirurg.71000694.ger.abstr_task0

Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .

[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]

[ "umlsterm" ]

Pionierzeit is an umlsterm, Replantation is an umlsterm, Extremitaet is an umlsterm, Schmerzen is an umlsterm, Replantation is an umlsterm, Unfallmechanismus is an umlsterm, Replantation is an umlsterm, Patienten is an umlsterm

DerUnfallchirurg.71000694.ger.abstr_task1

Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please typing these entity words according to sentence: Pionierzeit, Replantation, Extremitaet, Schmerzen, Replantation, Unfallmechanismus, Replantation, Patienten Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .

[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]

[ "umlsterm" ]

Pionierzeit, Replantation, Extremitaet, Schmerzen, Replantation, Unfallmechanismus, Replantation, Patienten

DerUnfallchirurg.71000694.ger.abstr_task2

Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .

[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]

[ "umlsterm" ]

transfer is an umlsterm, safety is an umlsterm, interaction is an umlsterm, teleradiology is an umlsterm, selection is an umlsterm

DerRadiologe.70370336.eng.abstr_task0

Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .

[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]

[ "umlsterm" ]

transfer is an umlsterm, safety is an umlsterm, interaction is an umlsterm, teleradiology is an umlsterm, selection is an umlsterm

DerRadiologe.70370336.eng.abstr_task1

Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please typing these entity words according to sentence: transfer, safety, interaction, teleradiology, selection Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .

[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]

[ "umlsterm" ]

transfer, safety, interaction, teleradiology, selection

DerRadiologe.70370336.eng.abstr_task2

Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .

[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]

[ "umlsterm" ]

Drucksenkung is an umlsterm, Glaukomaugen is an umlsterm

DerOpthalmologe.70940665.ger.abstr_task0

Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?

[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]

[ "umlsterm" ]

Drucksenkung is an umlsterm, Glaukomaugen is an umlsterm

DerOpthalmologe.70940665.ger.abstr_task1

Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please typing these entity words according to sentence: Drucksenkung, Glaukomaugen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?

[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]

[ "umlsterm" ]

Drucksenkung, Glaukomaugen

DerOpthalmologe.70940665.ger.abstr_task2

Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?

[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]

[ "umlsterm" ]

man is an umlsterm, giant - cell is an umlsterm, tumor is an umlsterm, right is an umlsterm, temporomandibular joint is an umlsterm, growth is an umlsterm, treatment is an umlsterm, endotracheal anesthesia is an umlsterm, recurrence is an umlsterm, Differential diagnosis is an umlsterm, therapy is an umlsterm

MundKieferGesichtschirurgie.80020279.eng.abstr_task0

Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .

[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]

[ "umlsterm" ]

man is an umlsterm, giant - cell is an umlsterm, tumor is an umlsterm, right is an umlsterm, temporomandibular joint is an umlsterm, growth is an umlsterm, treatment is an umlsterm, endotracheal anesthesia is an umlsterm, recurrence is an umlsterm, Differential diagnosis is an umlsterm, therapy is an umlsterm

MundKieferGesichtschirurgie.80020279.eng.abstr_task1

Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please typing these entity words according to sentence: man, giant - cell, tumor, right, temporomandibular joint, growth, treatment, endotracheal anesthesia, recurrence, Differential diagnosis, therapy Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .

[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]

[ "umlsterm" ]

man, giant - cell, tumor, right, temporomandibular joint, growth, treatment, endotracheal anesthesia, recurrence, Differential diagnosis, therapy

MundKieferGesichtschirurgie.80020279.eng.abstr_task2

Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .

[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]

[ "umlsterm" ]

Metoclopramide is a DRUG, MONUROL is a BRAND, metoclopramide is a DRUG, fosfomycin is a DRUG, Cimetidine is a DRUG, Cimetidine is a DRUG, fosfomycin is a DRUG, MONUROL is a BRAND

Fosfomycin_ddi_task0

Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: BRAND, DRUG

[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]

Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.

[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]

[ "DRUG", "BRAND" ]

Metoclopramide is a DRUG, MONUROL is a BRAND, metoclopramide is a DRUG, fosfomycin is a DRUG, Cimetidine is a DRUG, Cimetidine is a DRUG, fosfomycin is a DRUG, MONUROL is a BRAND

Fosfomycin_ddi_task1

Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please typing these entity words according to sentence: Metoclopramide, MONUROL, metoclopramide, fosfomycin, Cimetidine, Cimetidine, fosfomycin, MONUROL Options: BRAND, DRUG

[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]

Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.

[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]

[ "DRUG", "BRAND" ]

Metoclopramide, MONUROL, metoclopramide, fosfomycin, Cimetidine, Cimetidine, fosfomycin, MONUROL

Fosfomycin_ddi_task2

Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please extract entity words from the input sentence

[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]

Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.

[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]

[ "DRUG", "BRAND" ]

I - DOX is a chemical, TTR is a protein, FAP is a disease

1.0alpha7.train.194_task0

Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: disease, chemical, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]

The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.

[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]

[ "chemical", "protein", "disease" ]

I - DOX is a chemical, TTR is a protein, FAP is a disease

1.0alpha7.train.194_task1

Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please typing these entity words according to sentence: I - DOX, TTR, FAP Options: disease, chemical, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]

The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.

[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]

[ "chemical", "protein", "disease" ]

I - DOX, TTR, FAP

1.0alpha7.train.194_task2

Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]

The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.

[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]

[ "chemical", "protein", "disease" ]

prostaglandin is a CHEMICAL

12713596_task0

Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.

[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

prostaglandin is a CHEMICAL

12713596_task1

Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please typing these entity words according to sentence: prostaglandin Options: CHEMICAL

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.

[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

prostaglandin

12713596_task2

Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please extract entity words from the input sentence

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.

[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

I kappaB alpha is a Protein, serines 32 and 36 is a Entity, I kappaB alpha is a Protein, p50 is a Protein, relA is a Protein, I kappaB alpha is a Protein, I kappaB alpha is a Protein, Tax is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein, I kappaB alpha is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein

9032271_task0

Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]

Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.

[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]

[ "Entity", "Protein" ]

I kappaB alpha is a Protein, serines 32 and 36 is a Entity, I kappaB alpha is a Protein, p50 is a Protein, relA is a Protein, I kappaB alpha is a Protein, I kappaB alpha is a Protein, Tax is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein, I kappaB alpha is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein

9032271_task1

Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please typing these entity words according to sentence: I kappaB alpha, serines 32 and 36, I kappaB alpha, p50, relA, I kappaB alpha, I kappaB alpha, Tax, I kappaB beta, I kappaB epsilon, I kappaB alpha, I kappaB beta, I kappaB epsilon Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]

Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.

[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]

[ "Entity", "Protein" ]

I kappaB alpha, serines 32 and 36, I kappaB alpha, p50, relA, I kappaB alpha, I kappaB alpha, Tax, I kappaB beta, I kappaB epsilon, I kappaB alpha, I kappaB beta, I kappaB epsilon

9032271_task2

Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]

Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.

[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]

[ "Entity", "Protein" ]

Toxicities , including thromboembolism is an outcome, overall survival is an outcome

892_task0

Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome

[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]

Toxicities , including thromboembolism , and overall survival were similar .

[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]

[ "outcome" ]

Toxicities , including thromboembolism is an outcome, overall survival is an outcome

892_task1

Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please typing these entity words according to sentence: Toxicities , including thromboembolism, overall survival Options: outcome

[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]

Toxicities , including thromboembolism , and overall survival were similar .

[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]

[ "outcome" ]

Toxicities , including thromboembolism, overall survival

892_task2

Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please extract entity words from the input sentence

[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]

Toxicities , including thromboembolism , and overall survival were similar .

[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]

[ "outcome" ]

hypertension is a Participant_Condition, reduced sodium intake is a Intervention_Physical, Dietary Approaches to Stop Hypertension ( DASH ) diet is a Intervention_Other, blood pressure ( BP ) is a Outcome_Physical, Adults is a Participant_Age, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg is a Participant_Condition, DASH diet is a Intervention_Educational, typical American ( control ) diet is a Intervention_Control, BP control is a Outcome_Physical, increased BP control is a Outcome_Physical, maximum BP control rate is a Outcome_Physical, DASH / lower sodium diet is a Intervention_Educational, control / lower sodium diet is a Intervention_Control

17841_task0

Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Intervention_Control, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical

[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .

[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]

[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]

hypertension is a Participant_Condition, reduced sodium intake is a Intervention_Physical, Dietary Approaches to Stop Hypertension ( DASH ) diet is a Intervention_Other, blood pressure ( BP ) is a Outcome_Physical, Adults is a Participant_Age, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg is a Participant_Condition, DASH diet is a Intervention_Educational, typical American ( control ) diet is a Intervention_Control, BP control is a Outcome_Physical, increased BP control is a Outcome_Physical, maximum BP control rate is a Outcome_Physical, DASH / lower sodium diet is a Intervention_Educational, control / lower sodium diet is a Intervention_Control

17841_task1

Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please typing these entity words according to sentence: hypertension, reduced sodium intake, Dietary Approaches to Stop Hypertension ( DASH ) diet, blood pressure ( BP ), Adults, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg, DASH diet, typical American ( control ) diet, BP control, increased BP control, maximum BP control rate, DASH / lower sodium diet, control / lower sodium diet Options: Intervention_Physical, Participant_Condition, Intervention_Control, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical

[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .

[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]

[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]

hypertension, reduced sodium intake, Dietary Approaches to Stop Hypertension ( DASH ) diet, blood pressure ( BP ), Adults, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg, DASH diet, typical American ( control ) diet, BP control, increased BP control, maximum BP control rate, DASH / lower sodium diet, control / lower sodium diet

17841_task2

Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .

[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]

[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]

CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene

225_task0

Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.

[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]

[ "Gene" ]

CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene

225_task1

Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please typing these entity words according to sentence: CHH, CHH, CHH, CHH, CHH Options: Gene

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.

[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]

[ "Gene" ]

CHH, CHH, CHH, CHH, CHH

225_task2

Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.

[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]

[ "Gene" ]

urologic surgery is a Procedure

NCT02805504_inc_task0

Sentence: Patients undergoing urologic surgery. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Procedure

[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]

Patients undergoing urologic surgery.

[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]

[ "Procedure" ]

urologic surgery is a Procedure

NCT02805504_inc_task1

Sentence: Patients undergoing urologic surgery. Instructions: please typing these entity words according to sentence: urologic surgery Options: Procedure

[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]

Patients undergoing urologic surgery.

[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]

[ "Procedure" ]

urologic surgery

NCT02805504_inc_task2

Sentence: Patients undergoing urologic surgery. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]

Patients undergoing urologic surgery.

[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]

[ "Procedure" ]

Embryonenschutzgesetz is an umlsterm, Forschung is an umlsterm, Embryonen is an umlsterm, Deutschland is an umlsterm, Zellen is an umlsterm, Embryo is an umlsterm, Stammzellen is an umlsterm, Embryos is an umlsterm, Embryonenschutzgesetz is an umlsterm, selbst is an umlsterm, Embryo is an umlsterm, Zellen is an umlsterm, Zellkerntransfer is an umlsterm, Eizellen is an umlsterm, Stammzellen is an umlsterm, Technik is an umlsterm, Zellen is an umlsterm, Menschen is an umlsterm, Deutschland is an umlsterm, Stammzellen is an umlsterm, Gewebe is an umlsterm, Feten is an umlsterm, Gewebeentnahme is an umlsterm, Verwendung is an umlsterm, Zellen is an umlsterm, Gewebe is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Deutschland is an umlsterm, Standards is an umlsterm, Lebenswerten is an umlsterm, Gesundheit is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Stammzellen is an umlsterm, Eizellen is an umlsterm, Embryonen is an umlsterm, Klonen is an umlsterm, Menschen is an umlsterm, Menschen is an umlsterm, Stammzellen is an umlsterm

Reproduktionsmedizin.90150159.ger.abstr_task0

Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .

[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]

[ "umlsterm" ]

Embryonenschutzgesetz is an umlsterm, Forschung is an umlsterm, Embryonen is an umlsterm, Deutschland is an umlsterm, Zellen is an umlsterm, Embryo is an umlsterm, Stammzellen is an umlsterm, Embryos is an umlsterm, Embryonenschutzgesetz is an umlsterm, selbst is an umlsterm, Embryo is an umlsterm, Zellen is an umlsterm, Zellkerntransfer is an umlsterm, Eizellen is an umlsterm, Stammzellen is an umlsterm, Technik is an umlsterm, Zellen is an umlsterm, Menschen is an umlsterm, Deutschland is an umlsterm, Stammzellen is an umlsterm, Gewebe is an umlsterm, Feten is an umlsterm, Gewebeentnahme is an umlsterm, Verwendung is an umlsterm, Zellen is an umlsterm, Gewebe is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Deutschland is an umlsterm, Standards is an umlsterm, Lebenswerten is an umlsterm, Gesundheit is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Stammzellen is an umlsterm, Eizellen is an umlsterm, Embryonen is an umlsterm, Klonen is an umlsterm, Menschen is an umlsterm, Menschen is an umlsterm, Stammzellen is an umlsterm

Reproduktionsmedizin.90150159.ger.abstr_task1

Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please typing these entity words according to sentence: Embryonenschutzgesetz, Forschung, Embryonen, Deutschland, Zellen, Embryo, Stammzellen, Embryos, Embryonenschutzgesetz, selbst, Embryo, Zellen, Zellkerntransfer, Eizellen, Stammzellen, Technik, Zellen, Menschen, Deutschland, Stammzellen, Gewebe, Feten, Gewebeentnahme, Verwendung, Zellen, Gewebe, Forschung, Stammzellen, Deutschland, Standards, Lebenswerten, Gesundheit, Forschung, Stammzellen, Stammzellen, Eizellen, Embryonen, Klonen, Menschen, Menschen, Stammzellen Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .

[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]

[ "umlsterm" ]

Embryonenschutzgesetz, Forschung, Embryonen, Deutschland, Zellen, Embryo, Stammzellen, Embryos, Embryonenschutzgesetz, selbst, Embryo, Zellen, Zellkerntransfer, Eizellen, Stammzellen, Technik, Zellen, Menschen, Deutschland, Stammzellen, Gewebe, Feten, Gewebeentnahme, Verwendung, Zellen, Gewebe, Forschung, Stammzellen, Deutschland, Standards, Lebenswerten, Gesundheit, Forschung, Stammzellen, Stammzellen, Eizellen, Embryonen, Klonen, Menschen, Menschen, Stammzellen

Reproduktionsmedizin.90150159.ger.abstr_task2

Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .

[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]

[ "umlsterm" ]

neurotoxicity is a ADVERSE

example-381_task0

Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]

Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.

[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]

[ "ADVERSE" ]

neurotoxicity is a ADVERSE

example-381_task1

Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please typing these entity words according to sentence: neurotoxicity Options: ADVERSE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]

Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.

[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]

[ "ADVERSE" ]

neurotoxicity

example-381_task2

Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]

Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.

[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]

[ "ADVERSE" ]

alpha - UBF antibody is a reagent, UBF is a protein, rDNA is a DNA, FISH is an assay

1.0alpha7.train.1055_task0

Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: assay, DNA, reagent, protein

[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).

[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]

[ "reagent", "DNA", "assay", "protein" ]

alpha - UBF antibody is a reagent, UBF is a protein, rDNA is a DNA, FISH is an assay

1.0alpha7.train.1055_task1

Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please typing these entity words according to sentence: alpha - UBF antibody, UBF, rDNA, FISH Options: assay, DNA, reagent, protein

[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).

[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]

[ "reagent", "DNA", "assay", "protein" ]

alpha - UBF antibody, UBF, rDNA, FISH

1.0alpha7.train.1055_task2

Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).

[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]

[ "reagent", "DNA", "assay", "protein" ]

Sp family members is a protein_family_or_group, promoter proximal repeat is a DNA_domain_or_region, HTLV - I enhancer is a DNA_domain_or_region

62654_task0

Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, DNA_domain_or_region

[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]

Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.

[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]

[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]

Sp family members is a protein_family_or_group, promoter proximal repeat is a DNA_domain_or_region, HTLV - I enhancer is a DNA_domain_or_region

62654_task1

Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please typing these entity words according to sentence: Sp family members, promoter proximal repeat, HTLV - I enhancer Options: protein_family_or_group, DNA_domain_or_region

[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]

Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.

[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]

[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]

Sp family members, promoter proximal repeat, HTLV - I enhancer

62654_task2

Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please extract entity words from the input sentence

[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]

Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.

[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]

[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]

Surgery is an umlsterm, therapeutic is an umlsterm, treatment is an umlsterm, tumors is an umlsterm, head is an umlsterm, neck is an umlsterm, dates is an umlsterm, lymph node dissection is an umlsterm, surgery is an umlsterm, plastic is an umlsterm, reconstructive surgery is an umlsterm, surgical is an umlsterm, patients is an umlsterm, development is an umlsterm, reconstructive surgery is an umlsterm, stages is an umlsterm, secondary is an umlsterm, flaps is an umlsterm, The change is an umlsterm, skin is an umlsterm, flaps is an umlsterm, flaps is an umlsterm, tissue is an umlsterm, transfer is an umlsterm, bone grafting is an umlsterm, bone grafting is an umlsterm, bone is an umlsterm, transfer is an umlsterm, donor is an umlsterm, five - year - survival is an umlsterm, carcinoma is an umlsterm, oral cavity is an umlsterm, tumor is an umlsterm, surgery is an umlsterm, imaging techniques is an umlsterm, surgical is an umlsterm, techniques is an umlsterm, guidelines is an umlsterm, surgery is an umlsterm, Surgical is an umlsterm, morbidity is an umlsterm, role is an umlsterm, tumors is an umlsterm, Tumors is an umlsterm, viscerocranium is an umlsterm, skull base is an umlsterm, osteotomy is an umlsterm, morbidity is an umlsterm, neck is an umlsterm, dissection is an umlsterm, techniques is an umlsterm, procedure is an umlsterm, inquiries is an umlsterm, surgical procedures is an umlsterm, surgical is an umlsterm, carcinomas is an umlsterm

MundKieferGesichtschirurgie.0004s142.eng.abstr_task0

Sentence: Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification .

[ "Surgery", "is", "still", "the", "primary", "therapeutic", "approach", "in", "treatment", "of", "tumors", "in", "the", "head", "and", "neck", "area", ",", "dating", "back", "to", "the", "early", "nineteenth", "century", ".", "More", "than", "150", "years", "ago", ",", "hemimaxillectomies", "and", "mandibular", "resections", "as", "well", "as", "hemiglossectomies", "were", "already", "performed", "by", "leading", "surgeons", ".", "The", "block", "principle", "we", "are", "now", "following", "dates", "back", "to", "Crile", ",", "who", "also", "established", "the", "principle", "of", "cervical", "lymph", "node", "dissection", ".", "Ablative", "oncologic", "surgery", "has", "always", "been", "closely", "linked", "with", "plastic", "and", "reconstructive", "surgery", ",", "rendering", "radical", "surgical", "interventions", "possible", "without", "disfiguring", "patients", ".", "The", "development", "of", "facial", "reconstructive", "surgery", "proceeded", "in", "stages", ",", "in", "the", "first", "instance", "as", "secondary", "reconstruction", "using", "tube", "pedicled", "flaps", ".", "The", "change", "to", "the", "concept", "of", "primary", "reconstruction", "occurred", "via", "arterialized", "skin", "flaps", "and", "myocutaneous", "flaps", "to", "the", "widely", "accepted", "and", "performed", "free", "tissue", "transfer", ".", "Free", "bone", "grafting", ",", "inaugurated", "earlier", "and", "still", "representing", "the", "majority", "of", "bone", "grafting", ",", "has", "been", "supplemented", "for", "certain", "reconstructive", "purposes", "by", "free", "vascularized", "bone", "transfer", "from", "various", "donor", "sites", ".", "Although", "the", "five", "-", "year", "-", "survival", "rate", "of", "carcinoma", "of", "the", "oral", "cavity", "has", "remained", "unchanged", "in", "the", "past", "30", "years", ",", "distinctive", "improvements", "in", "tumor", "surgery", "can", "be", "recorded", ".", "This", "is", "primarily", "based", "on", "improved", "diagnostics", "such", "as", "modern", "imaging", "techniques", "and", "the", "refinement", "of", "surgical", "techniques", ".", "The", "DOeSAK", "has", "worked", "out", "distinctive", "guidelines", "for", "effective", "ablative", "oncologic", "surgery", ".", "Surgical", "approaches", "offering", "wide", "exposure", "and", "carrying", "low", "morbidity", "play", "a", "decisive", "role", "in", "radical", "resections", ".", "For", "this", "reason", ",", "midfacial", "degloving", "offers", "an", "essential", "improvement", "for", "the", "resection", "of", "midface", "tumors", ",", "especially", "from", "an", "aesthetic", "point", "of", "view", ".", "Tumors", "situated", "deep", "behind", "the", "viscerocranium", "at", "the", "skull", "base", "can", "be", "clearly", "exposed", "either", "through", "a", "lateral", "approach", "following", "a", "temporary", "osteotomy", "of", "the", "mandibular", "ramus", "or", "a", "transmandibular", ",", "transmaxillar", ",", "or", "transfacial", "approach", "with", "minimal", "morbidity", ".", "Concerning", "the", "concept", "of", "neck", "dissection", ",", "radical", "techniques", "are", "more", "and", "more", "abandoned", "in", "favor", "of", "a", "more", "conservative", "procedure", ".", "Actual", "inquiries", "concerning", "present", "surgical", "procedures", "as", "to", "the", "surgical", "strategy", "in", "\"", "No", "-", "neck", "\"", "or", "marginal", "and", "segmental", "resection", "in", "mandibular", "adherent", "carcinomas", "demand", "scientific", "clarification", "." ]

[ "umlsterm" ]

Surgery is an umlsterm, therapeutic is an umlsterm, treatment is an umlsterm, tumors is an umlsterm, head is an umlsterm, neck is an umlsterm, dates is an umlsterm, lymph node dissection is an umlsterm, surgery is an umlsterm, plastic is an umlsterm, reconstructive surgery is an umlsterm, surgical is an umlsterm, patients is an umlsterm, development is an umlsterm, reconstructive surgery is an umlsterm, stages is an umlsterm, secondary is an umlsterm, flaps is an umlsterm, The change is an umlsterm, skin is an umlsterm, flaps is an umlsterm, flaps is an umlsterm, tissue is an umlsterm, transfer is an umlsterm, bone grafting is an umlsterm, bone grafting is an umlsterm, bone is an umlsterm, transfer is an umlsterm, donor is an umlsterm, five - year - survival is an umlsterm, carcinoma is an umlsterm, oral cavity is an umlsterm, tumor is an umlsterm, surgery is an umlsterm, imaging techniques is an umlsterm, surgical is an umlsterm, techniques is an umlsterm, guidelines is an umlsterm, surgery is an umlsterm, Surgical is an umlsterm, morbidity is an umlsterm, role is an umlsterm, tumors is an umlsterm, Tumors is an umlsterm, viscerocranium is an umlsterm, skull base is an umlsterm, osteotomy is an umlsterm, morbidity is an umlsterm, neck is an umlsterm, dissection is an umlsterm, techniques is an umlsterm, procedure is an umlsterm, inquiries is an umlsterm, surgical procedures is an umlsterm, surgical is an umlsterm, carcinomas is an umlsterm

MundKieferGesichtschirurgie.0004s142.eng.abstr_task1

Sentence: Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification . Instructions: please typing these entity words according to sentence: Surgery, therapeutic, treatment, tumors, head, neck, dates, lymph node dissection, surgery, plastic, reconstructive surgery, surgical, patients, development, reconstructive surgery, stages, secondary, flaps, The change, skin, flaps, flaps, tissue, transfer, bone grafting, bone grafting, bone, transfer, donor, five - year - survival, carcinoma, oral cavity, tumor, surgery, imaging techniques, surgical, techniques, guidelines, surgery, Surgical, morbidity, role, tumors, Tumors, viscerocranium, skull base, osteotomy, morbidity, neck, dissection, techniques, procedure, inquiries, surgical procedures, surgical, carcinomas Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification .

[ "Surgery", "is", "still", "the", "primary", "therapeutic", "approach", "in", "treatment", "of", "tumors", "in", "the", "head", "and", "neck", "area", ",", "dating", "back", "to", "the", "early", "nineteenth", "century", ".", "More", "than", "150", "years", "ago", ",", "hemimaxillectomies", "and", "mandibular", "resections", "as", "well", "as", "hemiglossectomies", "were", "already", "performed", "by", "leading", "surgeons", ".", "The", "block", "principle", "we", "are", "now", "following", "dates", "back", "to", "Crile", ",", "who", "also", "established", "the", "principle", "of", "cervical", "lymph", "node", "dissection", ".", "Ablative", "oncologic", "surgery", "has", "always", "been", "closely", "linked", "with", "plastic", "and", "reconstructive", "surgery", ",", "rendering", "radical", "surgical", "interventions", "possible", "without", "disfiguring", "patients", ".", "The", "development", "of", "facial", "reconstructive", "surgery", "proceeded", "in", "stages", ",", "in", "the", "first", "instance", "as", "secondary", "reconstruction", "using", "tube", "pedicled", "flaps", ".", "The", "change", "to", "the", "concept", "of", "primary", "reconstruction", "occurred", "via", "arterialized", "skin", "flaps", "and", "myocutaneous", "flaps", "to", "the", "widely", "accepted", "and", "performed", "free", "tissue", "transfer", ".", "Free", "bone", "grafting", ",", "inaugurated", "earlier", "and", "still", "representing", "the", "majority", "of", "bone", "grafting", ",", "has", "been", "supplemented", "for", "certain", "reconstructive", "purposes", "by", "free", "vascularized", "bone", "transfer", "from", "various", "donor", "sites", ".", "Although", "the", "five", "-", "year", "-", "survival", "rate", "of", "carcinoma", "of", "the", "oral", "cavity", "has", "remained", "unchanged", "in", "the", "past", "30", "years", ",", "distinctive", "improvements", "in", "tumor", "surgery", "can", "be", "recorded", ".", "This", "is", "primarily", "based", "on", "improved", "diagnostics", "such", "as", "modern", "imaging", "techniques", "and", "the", "refinement", "of", "surgical", "techniques", ".", "The", "DOeSAK", "has", "worked", "out", "distinctive", "guidelines", "for", "effective", "ablative", "oncologic", "surgery", ".", "Surgical", "approaches", "offering", "wide", "exposure", "and", "carrying", "low", "morbidity", "play", "a", "decisive", "role", "in", "radical", "resections", ".", "For", "this", "reason", ",", "midfacial", "degloving", "offers", "an", "essential", "improvement", "for", "the", "resection", "of", "midface", "tumors", ",", "especially", "from", "an", "aesthetic", "point", "of", "view", ".", "Tumors", "situated", "deep", "behind", "the", "viscerocranium", "at", "the", "skull", "base", "can", "be", "clearly", "exposed", "either", "through", "a", "lateral", "approach", "following", "a", "temporary", "osteotomy", "of", "the", "mandibular", "ramus", "or", "a", "transmandibular", ",", "transmaxillar", ",", "or", "transfacial", "approach", "with", "minimal", "morbidity", ".", "Concerning", "the", "concept", "of", "neck", "dissection", ",", "radical", "techniques", "are", "more", "and", "more", "abandoned", "in", "favor", "of", "a", "more", "conservative", "procedure", ".", "Actual", "inquiries", "concerning", "present", "surgical", "procedures", "as", "to", "the", "surgical", "strategy", "in", "\"", "No", "-", "neck", "\"", "or", "marginal", "and", "segmental", "resection", "in", "mandibular", "adherent", "carcinomas", "demand", "scientific", "clarification", "." ]

[ "umlsterm" ]

Surgery, therapeutic, treatment, tumors, head, neck, dates, lymph node dissection, surgery, plastic, reconstructive surgery, surgical, patients, development, reconstructive surgery, stages, secondary, flaps, The change, skin, flaps, flaps, tissue, transfer, bone grafting, bone grafting, bone, transfer, donor, five - year - survival, carcinoma, oral cavity, tumor, surgery, imaging techniques, surgical, techniques, guidelines, surgery, Surgical, morbidity, role, tumors, Tumors, viscerocranium, skull base, osteotomy, morbidity, neck, dissection, techniques, procedure, inquiries, surgical procedures, surgical, carcinomas

MundKieferGesichtschirurgie.0004s142.eng.abstr_task2

Sentence: Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Surgery is still the primary therapeutic approach in treatment of tumors in the head and neck area , dating back to the early nineteenth century . More than 150 years ago , hemimaxillectomies and mandibular resections as well as hemiglossectomies were already performed by leading surgeons . The block principle we are now following dates back to Crile , who also established the principle of cervical lymph node dissection . Ablative oncologic surgery has always been closely linked with plastic and reconstructive surgery , rendering radical surgical interventions possible without disfiguring patients . The development of facial reconstructive surgery proceeded in stages , in the first instance as secondary reconstruction using tube pedicled flaps . The change to the concept of primary reconstruction occurred via arterialized skin flaps and myocutaneous flaps to the widely accepted and performed free tissue transfer . Free bone grafting , inaugurated earlier and still representing the majority of bone grafting , has been supplemented for certain reconstructive purposes by free vascularized bone transfer from various donor sites . Although the five-year-survival rate of carcinoma of the oral cavity has remained unchanged in the past 30 years , distinctive improvements in tumor surgery can be recorded . This is primarily based on improved diagnostics such as modern imaging techniques and the refinement of surgical techniques . The DOeSAK has worked out distinctive guidelines for effective ablative oncologic surgery . Surgical approaches offering wide exposure and carrying low morbidity play a decisive role in radical resections . For this reason , midfacial degloving offers an essential improvement for the resection of midface tumors , especially from an aesthetic point of view . Tumors situated deep behind the viscerocranium at the skull base can be clearly exposed either through a lateral approach following a temporary osteotomy of the mandibular ramus or a transmandibular , transmaxillar , or transfacial approach with minimal morbidity . Concerning the concept of neck dissection , radical techniques are more and more abandoned in favor of a more conservative procedure . Actual inquiries concerning present surgical procedures as to the surgical strategy in " No-neck " or marginal and segmental resection in mandibular adherent carcinomas demand scientific clarification .

[ "Surgery", "is", "still", "the", "primary", "therapeutic", "approach", "in", "treatment", "of", "tumors", "in", "the", "head", "and", "neck", "area", ",", "dating", "back", "to", "the", "early", "nineteenth", "century", ".", "More", "than", "150", "years", "ago", ",", "hemimaxillectomies", "and", "mandibular", "resections", "as", "well", "as", "hemiglossectomies", "were", "already", "performed", "by", "leading", "surgeons", ".", "The", "block", "principle", "we", "are", "now", "following", "dates", "back", "to", "Crile", ",", "who", "also", "established", "the", "principle", "of", "cervical", "lymph", "node", "dissection", ".", "Ablative", "oncologic", "surgery", "has", "always", "been", "closely", "linked", "with", "plastic", "and", "reconstructive", "surgery", ",", "rendering", "radical", "surgical", "interventions", "possible", "without", "disfiguring", "patients", ".", "The", "development", "of", "facial", "reconstructive", "surgery", "proceeded", "in", "stages", ",", "in", "the", "first", "instance", "as", "secondary", "reconstruction", "using", "tube", "pedicled", "flaps", ".", "The", "change", "to", "the", "concept", "of", "primary", "reconstruction", "occurred", "via", "arterialized", "skin", "flaps", "and", "myocutaneous", "flaps", "to", "the", "widely", "accepted", "and", "performed", "free", "tissue", "transfer", ".", "Free", "bone", "grafting", ",", "inaugurated", "earlier", "and", "still", "representing", "the", "majority", "of", "bone", "grafting", ",", "has", "been", "supplemented", "for", "certain", "reconstructive", "purposes", "by", "free", "vascularized", "bone", "transfer", "from", "various", "donor", "sites", ".", "Although", "the", "five", "-", "year", "-", "survival", "rate", "of", "carcinoma", "of", "the", "oral", "cavity", "has", "remained", "unchanged", "in", "the", "past", "30", "years", ",", "distinctive", "improvements", "in", "tumor", "surgery", "can", "be", "recorded", ".", "This", "is", "primarily", "based", "on", "improved", "diagnostics", "such", "as", "modern", "imaging", "techniques", "and", "the", "refinement", "of", "surgical", "techniques", ".", "The", "DOeSAK", "has", "worked", "out", "distinctive", "guidelines", "for", "effective", "ablative", "oncologic", "surgery", ".", "Surgical", "approaches", "offering", "wide", "exposure", "and", "carrying", "low", "morbidity", "play", "a", "decisive", "role", "in", "radical", "resections", ".", "For", "this", "reason", ",", "midfacial", "degloving", "offers", "an", "essential", "improvement", "for", "the", "resection", "of", "midface", "tumors", ",", "especially", "from", "an", "aesthetic", "point", "of", "view", ".", "Tumors", "situated", "deep", "behind", "the", "viscerocranium", "at", "the", "skull", "base", "can", "be", "clearly", "exposed", "either", "through", "a", "lateral", "approach", "following", "a", "temporary", "osteotomy", "of", "the", "mandibular", "ramus", "or", "a", "transmandibular", ",", "transmaxillar", ",", "or", "transfacial", "approach", "with", "minimal", "morbidity", ".", "Concerning", "the", "concept", "of", "neck", "dissection", ",", "radical", "techniques", "are", "more", "and", "more", "abandoned", "in", "favor", "of", "a", "more", "conservative", "procedure", ".", "Actual", "inquiries", "concerning", "present", "surgical", "procedures", "as", "to", "the", "surgical", "strategy", "in", "\"", "No", "-", "neck", "\"", "or", "marginal", "and", "segmental", "resection", "in", "mandibular", "adherent", "carcinomas", "demand", "scientific", "clarification", "." ]

[ "umlsterm" ]

CCL3 is a GENE-Y, CCR1 is a GENE-Y

23059626_task0

Sentence: The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.

[ "The", "effect", "of", "CCL3", "and", "CCR1", "in", "bone", "remodeling", "induced", "by", "mechanical", "loading", "during", "orthodontic", "tooth", "movement", "in", "mice", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

CCL3 is a GENE-Y, CCR1 is a GENE-Y

23059626_task1

Sentence: The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice. Instructions: please typing these entity words according to sentence: CCL3, CCR1 Options: GENE-Y

[ "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.

[ "The", "effect", "of", "CCL3", "and", "CCR1", "in", "bone", "remodeling", "induced", "by", "mechanical", "loading", "during", "orthodontic", "tooth", "movement", "in", "mice", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

CCL3, CCR1

23059626_task2

Sentence: The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

The effect of CCL3 and CCR1 in bone remodeling induced by mechanical loading during orthodontic tooth movement in mice.

[ "The", "effect", "of", "CCL3", "and", "CCR1", "in", "bone", "remodeling", "induced", "by", "mechanical", "loading", "during", "orthodontic", "tooth", "movement", "in", "mice", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Ramipril is an intervention, progression is an outcome

512_task0

Sentence: Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome

[ "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) .

[ "Ramipril", "reduced", "the", "risk", "for", "any", "progression", "(", "OR", ",", "0.87", ";", "95", "%", "CI", ",", "0.78", "to", "0.97", ";", "P", "=", "0.0146", ")", "." ]

[ "outcome", "intervention" ]

Ramipril is an intervention, progression is an outcome

512_task1

Sentence: Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) . Instructions: please typing these entity words according to sentence: Ramipril, progression Options: intervention, outcome

[ "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) .

[ "Ramipril", "reduced", "the", "risk", "for", "any", "progression", "(", "OR", ",", "0.87", ";", "95", "%", "CI", ",", "0.78", "to", "0.97", ";", "P", "=", "0.0146", ")", "." ]

[ "outcome", "intervention" ]

Ramipril, progression

512_task2

Sentence: Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) . Instructions: please extract entity words from the input sentence

[ "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Ramipril reduced the risk for any progression ( OR , 0.87 ; 95 % CI , 0.78 to 0.97 ; P = 0.0146 ) .

[ "Ramipril", "reduced", "the", "risk", "for", "any", "progression", "(", "OR", ",", "0.87", ";", "95", "%", "CI", ",", "0.78", "to", "0.97", ";", "P", "=", "0.0146", ")", "." ]

[ "outcome", "intervention" ]

cisplatin is a CHEMICAL

16876126_task0

Sentence: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]

RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.

[ "RNA", "interference", "-", "triggered", "reversal", "of", "ABCC2-dependent", "cisplatin", "resistance", "in", "human", "cancer", "cells", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

cisplatin is a CHEMICAL

16876126_task1

Sentence: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Instructions: please typing these entity words according to sentence: cisplatin Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]

RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.

[ "RNA", "interference", "-", "triggered", "reversal", "of", "ABCC2-dependent", "cisplatin", "resistance", "in", "human", "cancer", "cells", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

cisplatin

16876126_task2

Sentence: RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]

RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells.

[ "RNA", "interference", "-", "triggered", "reversal", "of", "ABCC2-dependent", "cisplatin", "resistance", "in", "human", "cancer", "cells", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Mn SOD is a Protein, Mn superoxide dismutase is a Protein, Cu , Zn SOD is a Protein, catalase is a Protein, Mn SOD is a Protein, human monocyte nuclear factor - kappaB is a Entity, Mn SOD is a Protein, tumor necrosis factor - alpha is a Protein, macrophage inflammatory protein-1alpha is a Protein, Mn SOD is a Protein, Mn SOD is a Protein, tumor necrosis factor - alpha is a Protein

105_task0

Sentence: Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase.

[ "Induction", "of", "Mn", "SOD", "in", "human", "monocytes", "without", "inflammatory", "cytokine", "production", "by", "a", "mutant", "endotoxin", ".", "\n", "Endotoxin", "selectively", "induces", "monocyte", "Mn", "superoxide", "dismutase", "(", "SOD", ")", "without", "affecting", "levels", "of", "Cu", ",", "Zn", "SOD", ",", "catalase", ",", "or", "glutathione", "peroxidase", ".", "However", ",", "little", "is", "known", "about", "the", "structure", "-", "activity", "relationship", "and", "the", "mechanism", "by", "which", "endotoxin", "induces", "Mn", "SOD", ".", "In", "this", "study", "we", "demonstrated", "that", "a", "mutant", "Escherichia", "coli", "endotoxin", "lacking", "myristoyl", "fatty", "acid", "at", "the", "3", "'", "R-3-hydroxymyristate", "position", "of", "the", "lipid", "A", "moiety", "retained", "its", "full", "capacity", "to", "coagulate", "Limulus", "amoebocyte", "lysate", "compared", "with", "the", "wild", "-", "type", "E.", "coli", "endotoxin", "and", "markedly", "stimulated", "the", "activation", "of", "human", "monocyte", "nuclear", "factor", "-", "kappaB", "and", "the", "induction", "of", "Mn", "SOD", "mRNA", "and", "enzyme", "activity", ".", "However", ",", "in", "contrast", "to", "the", "wild", "-", "type", "endotoxin", ",", "it", "failed", "to", "induce", "significant", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", "and", "macrophage", "inflammatory", "protein-1alpha", "by", "monocytes", "and", "did", "not", "induce", "the", "phosphorylation", "and", "nuclear", "translocation", "of", "mitogen", "-", "activated", "protein", "kinase", ".", "These", "results", "suggest", "that", "1", ")", "lipid", "A", "myristoyl", "fatty", "acid", ",", "although", "it", "is", "important", "for", "the", "induction", "of", "inflammatory", "cytokine", "production", "by", "human", "monocytes", ",", "is", "not", "necessary", "for", "the", "induction", "of", "Mn", "SOD", ",", "2", ")", "endotoxin", "-", "mediated", "induction", "of", "Mn", "SOD", "and", "inflammatory", "cytokines", "are", "regulated", ",", "at", "least", "in", "part", ",", "through", "different", "signal", "transduction", "pathways", ",", "and", "3", ")", "failure", "of", "the", "mutant", "endotoxin", "to", "induce", "tumor", "necrosis", "factor", "-", "alpha", "production", "is", ",", "at", "least", "in", "part", ",", "due", "to", "its", "inability", "to", "activate", "mitogen", "-", "activated", "protein", "kinase", ".", "\n" ]

[ "Protein", "Entity" ]

Mn SOD is a Protein, Mn superoxide dismutase is a Protein, Cu , Zn SOD is a Protein, catalase is a Protein, Mn SOD is a Protein, human monocyte nuclear factor - kappaB is a Entity, Mn SOD is a Protein, tumor necrosis factor - alpha is a Protein, macrophage inflammatory protein-1alpha is a Protein, Mn SOD is a Protein, Mn SOD is a Protein, tumor necrosis factor - alpha is a Protein

105_task1

Sentence: Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase. Instructions: please typing these entity words according to sentence: Mn SOD, Mn superoxide dismutase, Cu , Zn SOD, catalase, Mn SOD, human monocyte nuclear factor - kappaB, Mn SOD, tumor necrosis factor - alpha, macrophage inflammatory protein-1alpha, Mn SOD, Mn SOD, tumor necrosis factor - alpha Options: Entity, Protein

[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase.

[ "Induction", "of", "Mn", "SOD", "in", "human", "monocytes", "without", "inflammatory", "cytokine", "production", "by", "a", "mutant", "endotoxin", ".", "\n", "Endotoxin", "selectively", "induces", "monocyte", "Mn", "superoxide", "dismutase", "(", "SOD", ")", "without", "affecting", "levels", "of", "Cu", ",", "Zn", "SOD", ",", "catalase", ",", "or", "glutathione", "peroxidase", ".", "However", ",", "little", "is", "known", "about", "the", "structure", "-", "activity", "relationship", "and", "the", "mechanism", "by", "which", "endotoxin", "induces", "Mn", "SOD", ".", "In", "this", "study", "we", "demonstrated", "that", "a", "mutant", "Escherichia", "coli", "endotoxin", "lacking", "myristoyl", "fatty", "acid", "at", "the", "3", "'", "R-3-hydroxymyristate", "position", "of", "the", "lipid", "A", "moiety", "retained", "its", "full", "capacity", "to", "coagulate", "Limulus", "amoebocyte", "lysate", "compared", "with", "the", "wild", "-", "type", "E.", "coli", "endotoxin", "and", "markedly", "stimulated", "the", "activation", "of", "human", "monocyte", "nuclear", "factor", "-", "kappaB", "and", "the", "induction", "of", "Mn", "SOD", "mRNA", "and", "enzyme", "activity", ".", "However", ",", "in", "contrast", "to", "the", "wild", "-", "type", "endotoxin", ",", "it", "failed", "to", "induce", "significant", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", "and", "macrophage", "inflammatory", "protein-1alpha", "by", "monocytes", "and", "did", "not", "induce", "the", "phosphorylation", "and", "nuclear", "translocation", "of", "mitogen", "-", "activated", "protein", "kinase", ".", "These", "results", "suggest", "that", "1", ")", "lipid", "A", "myristoyl", "fatty", "acid", ",", "although", "it", "is", "important", "for", "the", "induction", "of", "inflammatory", "cytokine", "production", "by", "human", "monocytes", ",", "is", "not", "necessary", "for", "the", "induction", "of", "Mn", "SOD", ",", "2", ")", "endotoxin", "-", "mediated", "induction", "of", "Mn", "SOD", "and", "inflammatory", "cytokines", "are", "regulated", ",", "at", "least", "in", "part", ",", "through", "different", "signal", "transduction", "pathways", ",", "and", "3", ")", "failure", "of", "the", "mutant", "endotoxin", "to", "induce", "tumor", "necrosis", "factor", "-", "alpha", "production", "is", ",", "at", "least", "in", "part", ",", "due", "to", "its", "inability", "to", "activate", "mitogen", "-", "activated", "protein", "kinase", ".", "\n" ]

[ "Protein", "Entity" ]

Mn SOD, Mn superoxide dismutase, Cu , Zn SOD, catalase, Mn SOD, human monocyte nuclear factor - kappaB, Mn SOD, tumor necrosis factor - alpha, macrophage inflammatory protein-1alpha, Mn SOD, Mn SOD, tumor necrosis factor - alpha

105_task2

Sentence: Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Endotoxin selectively induces monocyte Mn superoxide dismutase (SOD) without affecting levels of Cu,Zn SOD, catalase, or glutathione peroxidase. However, little is known about the structure-activity relationship and the mechanism by which endotoxin induces Mn SOD. In this study we demonstrated that a mutant Escherichia coli endotoxin lacking myristoyl fatty acid at the 3' R-3-hydroxymyristate position of the lipid A moiety retained its full capacity to coagulate Limulus amoebocyte lysate compared with the wild-type E. coli endotoxin and markedly stimulated the activation of human monocyte nuclear factor-kappaB and the induction of Mn SOD mRNA and enzyme activity. However, in contrast to the wild-type endotoxin, it failed to induce significant production of tumor necrosis factor-alpha and macrophage inflammatory protein-1alpha by monocytes and did not induce the phosphorylation and nuclear translocation of mitogen-activated protein kinase. These results suggest that 1) lipid A myristoyl fatty acid, although it is important for the induction of inflammatory cytokine production by human monocytes, is not necessary for the induction of Mn SOD, 2) endotoxin-mediated induction of Mn SOD and inflammatory cytokines are regulated, at least in part, through different signal transduction pathways, and 3) failure of the mutant endotoxin to induce tumor necrosis factor-alpha production is, at least in part, due to its inability to activate mitogen-activated protein kinase.

[ "Induction", "of", "Mn", "SOD", "in", "human", "monocytes", "without", "inflammatory", "cytokine", "production", "by", "a", "mutant", "endotoxin", ".", "\n", "Endotoxin", "selectively", "induces", "monocyte", "Mn", "superoxide", "dismutase", "(", "SOD", ")", "without", "affecting", "levels", "of", "Cu", ",", "Zn", "SOD", ",", "catalase", ",", "or", "glutathione", "peroxidase", ".", "However", ",", "little", "is", "known", "about", "the", "structure", "-", "activity", "relationship", "and", "the", "mechanism", "by", "which", "endotoxin", "induces", "Mn", "SOD", ".", "In", "this", "study", "we", "demonstrated", "that", "a", "mutant", "Escherichia", "coli", "endotoxin", "lacking", "myristoyl", "fatty", "acid", "at", "the", "3", "'", "R-3-hydroxymyristate", "position", "of", "the", "lipid", "A", "moiety", "retained", "its", "full", "capacity", "to", "coagulate", "Limulus", "amoebocyte", "lysate", "compared", "with", "the", "wild", "-", "type", "E.", "coli", "endotoxin", "and", "markedly", "stimulated", "the", "activation", "of", "human", "monocyte", "nuclear", "factor", "-", "kappaB", "and", "the", "induction", "of", "Mn", "SOD", "mRNA", "and", "enzyme", "activity", ".", "However", ",", "in", "contrast", "to", "the", "wild", "-", "type", "endotoxin", ",", "it", "failed", "to", "induce", "significant", "production", "of", "tumor", "necrosis", "factor", "-", "alpha", "and", "macrophage", "inflammatory", "protein-1alpha", "by", "monocytes", "and", "did", "not", "induce", "the", "phosphorylation", "and", "nuclear", "translocation", "of", "mitogen", "-", "activated", "protein", "kinase", ".", "These", "results", "suggest", "that", "1", ")", "lipid", "A", "myristoyl", "fatty", "acid", ",", "although", "it", "is", "important", "for", "the", "induction", "of", "inflammatory", "cytokine", "production", "by", "human", "monocytes", ",", "is", "not", "necessary", "for", "the", "induction", "of", "Mn", "SOD", ",", "2", ")", "endotoxin", "-", "mediated", "induction", "of", "Mn", "SOD", "and", "inflammatory", "cytokines", "are", "regulated", ",", "at", "least", "in", "part", ",", "through", "different", "signal", "transduction", "pathways", ",", "and", "3", ")", "failure", "of", "the", "mutant", "endotoxin", "to", "induce", "tumor", "necrosis", "factor", "-", "alpha", "production", "is", ",", "at", "least", "in", "part", ",", "due", "to", "its", "inability", "to", "activate", "mitogen", "-", "activated", "protein", "kinase", ".", "\n" ]

[ "Protein", "Entity" ]

Surgery is an umlsterm, hyperparathyroidism is an umlsterm, standard is an umlsterm, therapy is an umlsterm, frequency is an umlsterm, testing is an umlsterm, surgery is an umlsterm, evaluation is an umlsterm, surgical is an umlsterm, safety is an umlsterm, retrospective is an umlsterm, analysis is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, female is an umlsterm, age is an umlsterm, patients is an umlsterm, sonography is an umlsterm, adenoma is an umlsterm, catheterization is an umlsterm, analysis is an umlsterm, patients is an umlsterm, patients is an umlsterm, procedures is an umlsterm, ultrasound is an umlsterm, catheterization is an umlsterm, Postoperative is an umlsterm, morbidity is an umlsterm, recurrent laryngeal nerve is an umlsterm, palsy is an umlsterm, patients is an umlsterm, hemorrhage is an umlsterm, reoperation is an umlsterm, hypoparathyroidism is an umlsterm, supplementation is an umlsterm, patients is an umlsterm, hypoparathyroidism is an umlsterm, postoperative is an umlsterm, mortality is an umlsterm, Risk is an umlsterm, factor analysis is an umlsterm, morbidity is an umlsterm, Surgery is an umlsterm, safety is an umlsterm, patients is an umlsterm, patients is an umlsterm, surgery is an umlsterm

DerChirurg.70680141.eng.abstr_task0

Sentence: Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery .

[ "Surgery", "for", "symptomatic", "hyperparathyroidism", "remains", "the", "standard", "therapy", ".", "Asymptomatic", "primary", "hyperparathyroidsm", "(", "pHPT", ")", "is", "being", "diagnosed", "with", "increasing", "frequency", "owing", "to", "broad", "serum", "testing", ".", "Indications", "for", "surgery", "in", "this", "setting", "are", "controversial", ".", "For", "evaluation", "of", "surgical", "safety", "we", "performed", "a", "retrospective", "analysis", "of", "our", "patients", "who", "were", "being", "operated", "on", "for", "asymptomatic", "pHPT", ".", "From", "January", "1988", "until", "August", "1995", ",", "243", "patients", "were", "treated", "for", "pHPT", "and", "registered", "prospectively", "at", "our", "unit", ".", "Seventy", "-", "six", "patients", "were", "classified", "as", "asymptomatic", ".", "In", "all", ",", "75", "%", "of", "the", "patients", "were", "female", ";", "the", "mean", "age", "was", "62", "years", ".", "In", "this", "group", ",", "87", "%", "of", "the", "patients", "had", "cervical", "sonography", "in", "order", "to", "localize", "the", "adenoma", ".", "Highly", "selective", "venous", "catheterization", "was", "required", "in", "cervical", "reexplorations", ".", "Statistical", "analysis", "for", "potential", "prognostic", "factors", "for", "the", "clinical", "outcome", "was", "performed", ".", "Successful", "cervical", "exploration", "was", "possible", "in", "71", "patients", "(", "94.7", "%", ")", ".", "With", "4", "patients", "remaining", "hypercalcemic", ",", "the", "rate", "of", "persistency", "was", "5.2", "%", ".", "Localization", "procedures", "were", "correct", "in", "58", "%", "for", "cervical", "ultrasound", "and", "77", "%", "for", "selective", "venous", "catheterization", ".", "Postoperative", "morbidity", "included", "one", "permanent", "recurrent", "laryngeal", "nerve", "palsy", "and", "2", "patients", "with", "hemorrhage", "who", "were", "treated", "by", "reoperation", ".", "While", "one", "case", "of", "permanent", "hypoparathyroidism", "was", "well", "controlled", "by", "oral", "supplementation", ",", "18", "patients", "recovered", "from", "temporary", "hypoparathyroidism", ".", "No", "postoperative", "mortality", "occurred", ".", "Risk", "factor", "analysis", "revealed", "only", "cervical", "reexplorations", "for", "HPT", "to", "be", "associated", "with", "a", "higher", "morbidity", "(", "P", "=", "0.02", ")", ".", "Surgery", "for", "asymptomatic", "pHPT", "can", "be", "performed", "with", "reasonable", "safety", ".", "Cervical", "reexplorations", "in", "asymptomatic", "patients", "should", "be", "reserved", "for", "special", "indications", ".", "Apart", "from", "this", "small", "group", ",", "all", "patients", "should", "be", "evaluated", "for", "surgery", "." ]

[ "umlsterm" ]

Surgery is an umlsterm, hyperparathyroidism is an umlsterm, standard is an umlsterm, therapy is an umlsterm, frequency is an umlsterm, testing is an umlsterm, surgery is an umlsterm, evaluation is an umlsterm, surgical is an umlsterm, safety is an umlsterm, retrospective is an umlsterm, analysis is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, patients is an umlsterm, female is an umlsterm, age is an umlsterm, patients is an umlsterm, sonography is an umlsterm, adenoma is an umlsterm, catheterization is an umlsterm, analysis is an umlsterm, patients is an umlsterm, patients is an umlsterm, procedures is an umlsterm, ultrasound is an umlsterm, catheterization is an umlsterm, Postoperative is an umlsterm, morbidity is an umlsterm, recurrent laryngeal nerve is an umlsterm, palsy is an umlsterm, patients is an umlsterm, hemorrhage is an umlsterm, reoperation is an umlsterm, hypoparathyroidism is an umlsterm, supplementation is an umlsterm, patients is an umlsterm, hypoparathyroidism is an umlsterm, postoperative is an umlsterm, mortality is an umlsterm, Risk is an umlsterm, factor analysis is an umlsterm, morbidity is an umlsterm, Surgery is an umlsterm, safety is an umlsterm, patients is an umlsterm, patients is an umlsterm, surgery is an umlsterm

DerChirurg.70680141.eng.abstr_task1

Sentence: Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery . Instructions: please typing these entity words according to sentence: Surgery, hyperparathyroidism, standard, therapy, frequency, testing, surgery, evaluation, surgical, safety, retrospective, analysis, patients, patients, patients, patients, female, age, patients, sonography, adenoma, catheterization, analysis, patients, patients, procedures, ultrasound, catheterization, Postoperative, morbidity, recurrent laryngeal nerve, palsy, patients, hemorrhage, reoperation, hypoparathyroidism, supplementation, patients, hypoparathyroidism, postoperative, mortality, Risk, factor analysis, morbidity, Surgery, safety, patients, patients, surgery Options: umlsterm

[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery .

[ "Surgery", "for", "symptomatic", "hyperparathyroidism", "remains", "the", "standard", "therapy", ".", "Asymptomatic", "primary", "hyperparathyroidsm", "(", "pHPT", ")", "is", "being", "diagnosed", "with", "increasing", "frequency", "owing", "to", "broad", "serum", "testing", ".", "Indications", "for", "surgery", "in", "this", "setting", "are", "controversial", ".", "For", "evaluation", "of", "surgical", "safety", "we", "performed", "a", "retrospective", "analysis", "of", "our", "patients", "who", "were", "being", "operated", "on", "for", "asymptomatic", "pHPT", ".", "From", "January", "1988", "until", "August", "1995", ",", "243", "patients", "were", "treated", "for", "pHPT", "and", "registered", "prospectively", "at", "our", "unit", ".", "Seventy", "-", "six", "patients", "were", "classified", "as", "asymptomatic", ".", "In", "all", ",", "75", "%", "of", "the", "patients", "were", "female", ";", "the", "mean", "age", "was", "62", "years", ".", "In", "this", "group", ",", "87", "%", "of", "the", "patients", "had", "cervical", "sonography", "in", "order", "to", "localize", "the", "adenoma", ".", "Highly", "selective", "venous", "catheterization", "was", "required", "in", "cervical", "reexplorations", ".", "Statistical", "analysis", "for", "potential", "prognostic", "factors", "for", "the", "clinical", "outcome", "was", "performed", ".", "Successful", "cervical", "exploration", "was", "possible", "in", "71", "patients", "(", "94.7", "%", ")", ".", "With", "4", "patients", "remaining", "hypercalcemic", ",", "the", "rate", "of", "persistency", "was", "5.2", "%", ".", "Localization", "procedures", "were", "correct", "in", "58", "%", "for", "cervical", "ultrasound", "and", "77", "%", "for", "selective", "venous", "catheterization", ".", "Postoperative", "morbidity", "included", "one", "permanent", "recurrent", "laryngeal", "nerve", "palsy", "and", "2", "patients", "with", "hemorrhage", "who", "were", "treated", "by", "reoperation", ".", "While", "one", "case", "of", "permanent", "hypoparathyroidism", "was", "well", "controlled", "by", "oral", "supplementation", ",", "18", "patients", "recovered", "from", "temporary", "hypoparathyroidism", ".", "No", "postoperative", "mortality", "occurred", ".", "Risk", "factor", "analysis", "revealed", "only", "cervical", "reexplorations", "for", "HPT", "to", "be", "associated", "with", "a", "higher", "morbidity", "(", "P", "=", "0.02", ")", ".", "Surgery", "for", "asymptomatic", "pHPT", "can", "be", "performed", "with", "reasonable", "safety", ".", "Cervical", "reexplorations", "in", "asymptomatic", "patients", "should", "be", "reserved", "for", "special", "indications", ".", "Apart", "from", "this", "small", "group", ",", "all", "patients", "should", "be", "evaluated", "for", "surgery", "." ]

[ "umlsterm" ]

Surgery, hyperparathyroidism, standard, therapy, frequency, testing, surgery, evaluation, surgical, safety, retrospective, analysis, patients, patients, patients, patients, female, age, patients, sonography, adenoma, catheterization, analysis, patients, patients, procedures, ultrasound, catheterization, Postoperative, morbidity, recurrent laryngeal nerve, palsy, patients, hemorrhage, reoperation, hypoparathyroidism, supplementation, patients, hypoparathyroidism, postoperative, mortality, Risk, factor analysis, morbidity, Surgery, safety, patients, patients, surgery

DerChirurg.70680141.eng.abstr_task2

Sentence: Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Surgery for symptomatic hyperparathyroidism remains the standard therapy . Asymptomatic primary hyperparathyroidsm ( pHPT ) is being diagnosed with increasing frequency owing to broad serum testing . Indications for surgery in this setting are controversial . For evaluation of surgical safety we performed a retrospective analysis of our patients who were being operated on for asymptomatic pHPT . From January 1988 until August 1995 , 243 patients were treated for pHPT and registered prospectively at our unit . Seventy-six patients were classified as asymptomatic . In all , 75 % of the patients were female ; the mean age was 62 years . In this group , 87 % of the patients had cervical sonography in order to localize the adenoma . Highly selective venous catheterization was required in cervical reexplorations . Statistical analysis for potential prognostic factors for the clinical outcome was performed . Successful cervical exploration was possible in 71 patients ( 94.7 % ) . With 4 patients remaining hypercalcemic , the rate of persistency was 5.2 % . Localization procedures were correct in 58 % for cervical ultrasound and 77 % for selective venous catheterization . Postoperative morbidity included one permanent recurrent laryngeal nerve palsy and 2 patients with hemorrhage who were treated by reoperation . While one case of permanent hypoparathyroidism was well controlled by oral supplementation , 18 patients recovered from temporary hypoparathyroidism . No postoperative mortality occurred . Risk factor analysis revealed only cervical reexplorations for HPT to be associated with a higher morbidity ( P = 0.02 ) . Surgery for asymptomatic pHPT can be performed with reasonable safety . Cervical reexplorations in asymptomatic patients should be reserved for special indications . Apart from this small group , all patients should be evaluated for surgery .

[ "Surgery", "for", "symptomatic", "hyperparathyroidism", "remains", "the", "standard", "therapy", ".", "Asymptomatic", "primary", "hyperparathyroidsm", "(", "pHPT", ")", "is", "being", "diagnosed", "with", "increasing", "frequency", "owing", "to", "broad", "serum", "testing", ".", "Indications", "for", "surgery", "in", "this", "setting", "are", "controversial", ".", "For", "evaluation", "of", "surgical", "safety", "we", "performed", "a", "retrospective", "analysis", "of", "our", "patients", "who", "were", "being", "operated", "on", "for", "asymptomatic", "pHPT", ".", "From", "January", "1988", "until", "August", "1995", ",", "243", "patients", "were", "treated", "for", "pHPT", "and", "registered", "prospectively", "at", "our", "unit", ".", "Seventy", "-", "six", "patients", "were", "classified", "as", "asymptomatic", ".", "In", "all", ",", "75", "%", "of", "the", "patients", "were", "female", ";", "the", "mean", "age", "was", "62", "years", ".", "In", "this", "group", ",", "87", "%", "of", "the", "patients", "had", "cervical", "sonography", "in", "order", "to", "localize", "the", "adenoma", ".", "Highly", "selective", "venous", "catheterization", "was", "required", "in", "cervical", "reexplorations", ".", "Statistical", "analysis", "for", "potential", "prognostic", "factors", "for", "the", "clinical", "outcome", "was", "performed", ".", "Successful", "cervical", "exploration", "was", "possible", "in", "71", "patients", "(", "94.7", "%", ")", ".", "With", "4", "patients", "remaining", "hypercalcemic", ",", "the", "rate", "of", "persistency", "was", "5.2", "%", ".", "Localization", "procedures", "were", "correct", "in", "58", "%", "for", "cervical", "ultrasound", "and", "77", "%", "for", "selective", "venous", "catheterization", ".", "Postoperative", "morbidity", "included", "one", "permanent", "recurrent", "laryngeal", "nerve", "palsy", "and", "2", "patients", "with", "hemorrhage", "who", "were", "treated", "by", "reoperation", ".", "While", "one", "case", "of", "permanent", "hypoparathyroidism", "was", "well", "controlled", "by", "oral", "supplementation", ",", "18", "patients", "recovered", "from", "temporary", "hypoparathyroidism", ".", "No", "postoperative", "mortality", "occurred", ".", "Risk", "factor", "analysis", "revealed", "only", "cervical", "reexplorations", "for", "HPT", "to", "be", "associated", "with", "a", "higher", "morbidity", "(", "P", "=", "0.02", ")", ".", "Surgery", "for", "asymptomatic", "pHPT", "can", "be", "performed", "with", "reasonable", "safety", ".", "Cervical", "reexplorations", "in", "asymptomatic", "patients", "should", "be", "reserved", "for", "special", "indications", ".", "Apart", "from", "this", "small", "group", ",", "all", "patients", "should", "be", "evaluated", "for", "surgery", "." ]

[ "umlsterm" ]

Wachstum is an umlsterm, Schaedelkorrekturen is an umlsterm, Kraniosynostosen is an umlsterm, Schaedelkonfiguration is an umlsterm, Krankengut is an umlsterm, Kindern is an umlsterm, maennliche is an umlsterm, weibliche is an umlsterm, syndromale is an umlsterm, Kraniosynostosen is an umlsterm, Kraniosynostose is an umlsterm, Kopfumfang is an umlsterm, Kraniotomie is an umlsterm, Bandes is an umlsterm, Kraniosynostosen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kraniosynostosen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kraniosynostosen is an umlsterm, Wachstum is an umlsterm, gegebenen is an umlsterm, Kopfform is an umlsterm, Wachstumsverhalten is an umlsterm, Kraniosynostosen is an umlsterm

MundKieferGesichtschirurgie.8002s049.ger.abstr_task0

Sentence: Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht .

[ "Ziel", "der", "prospektiven", "Studie", "war", "es", "zu", "untersuchen", ",", "ob", "das", "postoperative", "Wachstum", "nach", "Schaedelkorrekturen", "bei", "Kraniosynostosen", "perzentilengerecht", "im", "Verhaeltnis", "zu", "einem", "Normalkollektiv", "weiterverlaeuft", ",", "da", "durch", "die", "Operation", "eine", "normale", "\"", "Schaedelkonfiguration", "\"", "erreicht", "wird", ".", "Das", "Krankengut", "setzte", "sich", "aus", "71", "Kindern", "zusammen", ",", "von", "denen", "57", "(", "36", "maennliche", "und", "21", "weibliche", ")", "mehr", "als", "12", "Monate", "postoperativ", "nachkontrolliert", "werden", "konnten", ";", "36", "betrafen", "unbehandelte", ",", "nicht", "syndromale", "und", "21", "syndromale", "Kraniosynostosen", ".", "In", "11", "Faellen", "erfolgte", "die", "Korrektur", "einer", "okzipitalen", "Kraniosynostose", ".", "Das", "Alter", "bei", "der", "Operation", "lag", "zwischen", "16", "und", "27", "Monaten", ".", "Der", "frontookzipitale", "Kopfumfang", "wurde", "auf", "der", "Perzentilentabelle", "nach", "Prader", "et", "al", ".", "[", "2", "]", "eingetragen", ".", "Die", "einheitliche", "Operation", "bestand", "aus", "einer", "frontoparietalen", "Kraniotomie", ",", "der", "Entfernung", "und", "Neuformung", "des", "frontoorbitalen", "Bandes", "sowie", "der", "Kranioplastik", ".", "Nach", "frontoorbitalem", "Advancement", "isolierter", "Kraniosynostosen", "blieben", "13", "Patienten", "im", "Verlauf", "auf", "der", "postoperativ", "eingenommenen", "Perzentilenkurve", ".", "13", "Patienten", "zeigten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", ".", "Bei", "den", "syndromalen", "Kraniosynostosen", "blieben", "10", "Patienten", "auf", "der", "postoperativ", "eingenommen", "Perzentilenkurve", ",", "waehrend", "8", "Patienten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", "zeigten", ".", "Nach", "der", "Korrektur", "von", "Kraniosynostosen", "kommt", "es", "damit", "zu", "einem", "weiteren", "Wachstum", "in", "der", "durch", "die", "Operation", "gegebenen", "Kopfform", ",", "wobei", "kein", "signifikanter", "Unterschied", "im", "Wachstumsverhalten", "zwischen", "syndromalen", "und", "isolierten", "Kraniosynostosen", "besteht", "." ]

[ "umlsterm" ]

Wachstum is an umlsterm, Schaedelkorrekturen is an umlsterm, Kraniosynostosen is an umlsterm, Schaedelkonfiguration is an umlsterm, Krankengut is an umlsterm, Kindern is an umlsterm, maennliche is an umlsterm, weibliche is an umlsterm, syndromale is an umlsterm, Kraniosynostosen is an umlsterm, Kraniosynostose is an umlsterm, Kopfumfang is an umlsterm, Kraniotomie is an umlsterm, Bandes is an umlsterm, Kraniosynostosen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kraniosynostosen is an umlsterm, Patienten is an umlsterm, Patienten is an umlsterm, Patient is an umlsterm, Kraniosynostosen is an umlsterm, Wachstum is an umlsterm, gegebenen is an umlsterm, Kopfform is an umlsterm, Wachstumsverhalten is an umlsterm, Kraniosynostosen is an umlsterm

MundKieferGesichtschirurgie.8002s049.ger.abstr_task1

Sentence: Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht . Instructions: please typing these entity words according to sentence: Wachstum, Schaedelkorrekturen, Kraniosynostosen, Schaedelkonfiguration, Krankengut, Kindern, maennliche, weibliche, syndromale, Kraniosynostosen, Kraniosynostose, Kopfumfang, Kraniotomie, Bandes, Kraniosynostosen, Patienten, Patienten, Patient, Kraniosynostosen, Patienten, Patienten, Patient, Kraniosynostosen, Wachstum, gegebenen, Kopfform, Wachstumsverhalten, Kraniosynostosen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht .

[ "Ziel", "der", "prospektiven", "Studie", "war", "es", "zu", "untersuchen", ",", "ob", "das", "postoperative", "Wachstum", "nach", "Schaedelkorrekturen", "bei", "Kraniosynostosen", "perzentilengerecht", "im", "Verhaeltnis", "zu", "einem", "Normalkollektiv", "weiterverlaeuft", ",", "da", "durch", "die", "Operation", "eine", "normale", "\"", "Schaedelkonfiguration", "\"", "erreicht", "wird", ".", "Das", "Krankengut", "setzte", "sich", "aus", "71", "Kindern", "zusammen", ",", "von", "denen", "57", "(", "36", "maennliche", "und", "21", "weibliche", ")", "mehr", "als", "12", "Monate", "postoperativ", "nachkontrolliert", "werden", "konnten", ";", "36", "betrafen", "unbehandelte", ",", "nicht", "syndromale", "und", "21", "syndromale", "Kraniosynostosen", ".", "In", "11", "Faellen", "erfolgte", "die", "Korrektur", "einer", "okzipitalen", "Kraniosynostose", ".", "Das", "Alter", "bei", "der", "Operation", "lag", "zwischen", "16", "und", "27", "Monaten", ".", "Der", "frontookzipitale", "Kopfumfang", "wurde", "auf", "der", "Perzentilentabelle", "nach", "Prader", "et", "al", ".", "[", "2", "]", "eingetragen", ".", "Die", "einheitliche", "Operation", "bestand", "aus", "einer", "frontoparietalen", "Kraniotomie", ",", "der", "Entfernung", "und", "Neuformung", "des", "frontoorbitalen", "Bandes", "sowie", "der", "Kranioplastik", ".", "Nach", "frontoorbitalem", "Advancement", "isolierter", "Kraniosynostosen", "blieben", "13", "Patienten", "im", "Verlauf", "auf", "der", "postoperativ", "eingenommenen", "Perzentilenkurve", ".", "13", "Patienten", "zeigten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", ".", "Bei", "den", "syndromalen", "Kraniosynostosen", "blieben", "10", "Patienten", "auf", "der", "postoperativ", "eingenommen", "Perzentilenkurve", ",", "waehrend", "8", "Patienten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", "zeigten", ".", "Nach", "der", "Korrektur", "von", "Kraniosynostosen", "kommt", "es", "damit", "zu", "einem", "weiteren", "Wachstum", "in", "der", "durch", "die", "Operation", "gegebenen", "Kopfform", ",", "wobei", "kein", "signifikanter", "Unterschied", "im", "Wachstumsverhalten", "zwischen", "syndromalen", "und", "isolierten", "Kraniosynostosen", "besteht", "." ]

[ "umlsterm" ]

Wachstum, Schaedelkorrekturen, Kraniosynostosen, Schaedelkonfiguration, Krankengut, Kindern, maennliche, weibliche, syndromale, Kraniosynostosen, Kraniosynostose, Kopfumfang, Kraniotomie, Bandes, Kraniosynostosen, Patienten, Patienten, Patient, Kraniosynostosen, Patienten, Patienten, Patient, Kraniosynostosen, Wachstum, gegebenen, Kopfform, Wachstumsverhalten, Kraniosynostosen

MundKieferGesichtschirurgie.8002s049.ger.abstr_task2

Sentence: Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]

Ziel der prospektiven Studie war es zu untersuchen , ob das postoperative Wachstum nach Schaedelkorrekturen bei Kraniosynostosen perzentilengerecht im Verhaeltnis zu einem Normalkollektiv weiterverlaeuft , da durch die Operation eine normale " Schaedelkonfiguration " erreicht wird . Das Krankengut setzte sich aus 71 Kindern zusammen , von denen 57 ( 36 maennliche und 21 weibliche ) mehr als 12 Monate postoperativ nachkontrolliert werden konnten ; 36 betrafen unbehandelte , nicht syndromale und 21 syndromale Kraniosynostosen . In 11 Faellen erfolgte die Korrektur einer okzipitalen Kraniosynostose . Das Alter bei der Operation lag zwischen 16 und 27 Monaten . Der frontookzipitale Kopfumfang wurde auf der Perzentilentabelle nach Prader et al. [ 2 ] eingetragen . Die einheitliche Operation bestand aus einer frontoparietalen Kraniotomie , der Entfernung und Neuformung des frontoorbitalen Bandes sowie der Kranioplastik . Nach frontoorbitalem Advancement isolierter Kraniosynostosen blieben 13 Patienten im Verlauf auf der postoperativ eingenommenen Perzentilenkurve . 13 Patienten zeigten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve . Bei den syndromalen Kraniosynostosen blieben 10 Patienten auf der postoperativ eingenommen Perzentilenkurve , waehrend 8 Patienten einen Wechsel auf eine niedrigere und 1 Patient auf eine hoehere Perzentilenkurve zeigten . Nach der Korrektur von Kraniosynostosen kommt es damit zu einem weiteren Wachstum in der durch die Operation gegebenen Kopfform , wobei kein signifikanter Unterschied im Wachstumsverhalten zwischen syndromalen und isolierten Kraniosynostosen besteht .

[ "Ziel", "der", "prospektiven", "Studie", "war", "es", "zu", "untersuchen", ",", "ob", "das", "postoperative", "Wachstum", "nach", "Schaedelkorrekturen", "bei", "Kraniosynostosen", "perzentilengerecht", "im", "Verhaeltnis", "zu", "einem", "Normalkollektiv", "weiterverlaeuft", ",", "da", "durch", "die", "Operation", "eine", "normale", "\"", "Schaedelkonfiguration", "\"", "erreicht", "wird", ".", "Das", "Krankengut", "setzte", "sich", "aus", "71", "Kindern", "zusammen", ",", "von", "denen", "57", "(", "36", "maennliche", "und", "21", "weibliche", ")", "mehr", "als", "12", "Monate", "postoperativ", "nachkontrolliert", "werden", "konnten", ";", "36", "betrafen", "unbehandelte", ",", "nicht", "syndromale", "und", "21", "syndromale", "Kraniosynostosen", ".", "In", "11", "Faellen", "erfolgte", "die", "Korrektur", "einer", "okzipitalen", "Kraniosynostose", ".", "Das", "Alter", "bei", "der", "Operation", "lag", "zwischen", "16", "und", "27", "Monaten", ".", "Der", "frontookzipitale", "Kopfumfang", "wurde", "auf", "der", "Perzentilentabelle", "nach", "Prader", "et", "al", ".", "[", "2", "]", "eingetragen", ".", "Die", "einheitliche", "Operation", "bestand", "aus", "einer", "frontoparietalen", "Kraniotomie", ",", "der", "Entfernung", "und", "Neuformung", "des", "frontoorbitalen", "Bandes", "sowie", "der", "Kranioplastik", ".", "Nach", "frontoorbitalem", "Advancement", "isolierter", "Kraniosynostosen", "blieben", "13", "Patienten", "im", "Verlauf", "auf", "der", "postoperativ", "eingenommenen", "Perzentilenkurve", ".", "13", "Patienten", "zeigten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", ".", "Bei", "den", "syndromalen", "Kraniosynostosen", "blieben", "10", "Patienten", "auf", "der", "postoperativ", "eingenommen", "Perzentilenkurve", ",", "waehrend", "8", "Patienten", "einen", "Wechsel", "auf", "eine", "niedrigere", "und", "1", "Patient", "auf", "eine", "hoehere", "Perzentilenkurve", "zeigten", ".", "Nach", "der", "Korrektur", "von", "Kraniosynostosen", "kommt", "es", "damit", "zu", "einem", "weiteren", "Wachstum", "in", "der", "durch", "die", "Operation", "gegebenen", "Kopfform", ",", "wobei", "kein", "signifikanter", "Unterschied", "im", "Wachstumsverhalten", "zwischen", "syndromalen", "und", "isolierten", "Kraniosynostosen", "besteht", "." ]

[ "umlsterm" ]

actin is a protein-family

1.0alpha7.train.98_task0

Sentence: This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O" ]

This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin.

[ "This", "is", "contrary", "to", "what", "one", "would", "expect", "if", "high", "ionic", "strength", "decreases", "the", "effect", "of", "the", "mutation", "on", "the", "binding", "of", "the", "regulatory", "complex", "to", "actin", "." ]

[ "protein-family" ]

actin is a protein-family

1.0alpha7.train.98_task1

Sentence: This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin. Instructions: please typing these entity words according to sentence: actin Options: protein-family

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O" ]

This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin.

[ "This", "is", "contrary", "to", "what", "one", "would", "expect", "if", "high", "ionic", "strength", "decreases", "the", "effect", "of", "the", "mutation", "on", "the", "binding", "of", "the", "regulatory", "complex", "to", "actin", "." ]

[ "protein-family" ]

actin

1.0alpha7.train.98_task2

Sentence: This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O" ]

This is contrary to what one would expect if high ionic strength decreases the effect of the mutation on the binding of the regulatory complex to actin.

[ "This", "is", "contrary", "to", "what", "one", "would", "expect", "if", "high", "ionic", "strength", "decreases", "the", "effect", "of", "the", "mutation", "on", "the", "binding", "of", "the", "regulatory", "complex", "to", "actin", "." ]

[ "protein-family" ]

AT1 receptor is a GENE-Y, BDNF is a GENE-Y

23211364_task0

Sentence: AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O" ]

AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.

[ "AT1", "receptor", "antagonism", "is", "proangiogenic", "in", "the", "brain", ":", "BDNF", "a", "novel", "mediator", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

AT1 receptor is a GENE-Y, BDNF is a GENE-Y

23211364_task1

Sentence: AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. Instructions: please typing these entity words according to sentence: AT1 receptor, BDNF Options: GENE-Y

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O" ]

AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.

[ "AT1", "receptor", "antagonism", "is", "proangiogenic", "in", "the", "brain", ":", "BDNF", "a", "novel", "mediator", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

AT1 receptor, BDNF

23211364_task2

Sentence: AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. Instructions: please extract entity words from the input sentence

[ "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O" ]

AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.

[ "AT1", "receptor", "antagonism", "is", "proangiogenic", "in", "the", "brain", ":", "BDNF", "a", "novel", "mediator", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Paola is a NOMBRE_SUJETO_ASISTENCIA, Barba Vega is a NOMBRE_SUJETO_ASISTENCIA, 4387459 is a ID_SUJETO_ASISTENCIA, 83 56740786 47 is a ID_ASEGURAMIENTO, Calle Puchaicela , 34 is a CALLE, Madrid is a TERRITORIO, 31250 is a TERRITORIO, 21/07/1981 is a FECHAS, España is a PAIS, 34 años is a EDAD_SUJETO_ASISTENCIA, 10/11/2015 is a FECHAS, Ana M. Calvo Benito is a NOMBRE_PERSONAL_SANITARIO, 31 31 20250 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 34 años is a EDAD_SUJETO_ASISTENCIA, Ana M. Calvo Benito is a NOMBRE_PERSONAL_SANITARIO, Hospital de Navarra is a HOSPITAL, C/ Irunlarrea , 3 is a CALLE, 31008 is a TERRITORIO, Pamplona is a TERRITORIO, 848 422179 is a NUMERO_TELEFONO

359_task0

Sentence: Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179 Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, HOSPITAL, CALLE, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O" ]

Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Paola", ".", "\n", "Apellidos", ":", "Barba", "Vega", ".", "\n", "NHC", ":", "4387459", ".", "\n", "NASS", ":", "83", "56740786", "47", ".", "\n", "Domicilio", ":", "Calle", "Puchaicela", ",", "34", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "31250", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1981", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "34", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "10/11/2015", ".", "\n", "Médico", ":", "Ana", "M.", "Calvo", "Benito", "NºCol", ":", "31", "31", "20250", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "34", "años", ",", "embarazada", "de", "18", "semanas", ",", "que", "acudió", "a", "urgencias", "porque", "durante", "un", "episodio", "de", "hiperémesis", "gravídica", "con", "vómitos", "proyectivos", "presentó", "de", "forma", "súbita", "tumefacción", "supraorbitaria", "derecha", "con", "proptosis", "ocular", "y", "alteraciones", "visuales", "del", "ojo", "derecho", ".", "La", "paciente", "no", "presentaba", "antecedentes", "personales", "de", "interés", ",", "no", "tomaba", "ninguna", "medicación", "habitual", "ni", "había", "sufrido", "ningún", "traumatismo", "previamente", ".", "\n", "A", "la", "exploración", "oftalmológica", "destacaba", "la", "presencia", "de", "exoftalmos", "con", "hipoftalmos", "del", "ojo", "derecho", ",", "midriasis", "derecha", "de", "7", "mm", "con", "disminución", "de", "la", "reactividad", "pupilar", ",", "limitación", "de", "la", "supraducción", "y", "supraversión", "con", "diplopia", ",", "miodesopsias", "y", "edema", "palpebral", "superior", "doloroso", "a", "la", "palpación", ".", "La", "exploración", "del", "fondo", "de", "ojo", "fue", "normal", "con", "presión", "intraocular", "de", "24", "mmHg", ".", "No", "se", "observó", "edema", "ni", "anomalías", "vasculares", "en", "la", "conjuntiva", ".", "\n", "Debido", "a", "que", "la", "paciente", "estaba", "embarazada", ",", "se", "solicitó", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "orbitaria", "urgente", "cuyos", "hallazgos", "fueron", "compatibles", "con", "el", "diagnóstico", "de", "hematoma", "intraorbitario", "extraconal", "derecho", ".", "Un", "análisis", "sanguíneo", "basado", "en", "hemograma", ",", "bioquímica", "y", "coagulación", "de", "rutina", "no", "mostró", "ninguna", "alteración", "que", "pudiese", "haber", "precipitado", "el", "cuadro", ".", "\n", "Dada", "la", "repercusión", "clínica", "y", "las", "alteraciones", ",", "cada", "vez", "más", "evidentes", "en", "la", "visión", "de", "la", "paciente", ",", "se", "decidió", "intervenir", "quirúrgicamente", "de", "forma", "urgente", "para", "evacuar", "el", "hematoma", "y", "descomprimir", "la", "órbita", "bajo", "anestesia", "general", ".", "Se", "realizó", "una", "abordaje", "de", "blefaroplastia", "superior", "derecho", ",", "disecando", "el", "músculo", "orbicular", "del", "ojo", "y", "el", "periostio", ",", "hasta", "alcanzar", "el", "reborde", "óseo", "súpero", "-", "externo", "orbitario", ".", "Al", "incidir", "el", "periostio", "a", "nivel", "de", "la", "cara", "orbitaria", "del", "hueso", "frontal", ",", "se", "produjo", "la", "salida", "a", "presión", "de", "coágulos", "y", "sangre", "procedentes", "del", "hematoma", "extraconal", ".", "Tras", "la", "evacuación", "del", "hematoma", "no", "se", "objetivaron", "puntos", "sangrantes", "de", "ningún", "vaso", "de", "la", "región", ".", "Se", "colocó", "un", "drenaje", "fino", "tipo", "Penrose", "y", "se", "instauró", "tratamiento", "para", "la", "hiperémesis", "gravídica", "con", "piridoxina", "10", "mg/8", "h", "iv+tiamina", "100", "mg/24", "h", "iv", "+", "metoclopramida", "10", "mg/8", "h", "iv", ".", "\n", "La", "paciente", "evolucionó", "favorablemente", "tras", "la", "cirugía", ",", "desapareciendo", "la", "midriasis", "y", "las", "alteraciones", "visuales", "en", "las", "primeras", "horas", "postoperatorias", ",", "retirándose", "el", "drenaje", "a", "las", "48", "h", ",", "actualmente", ",", "3", "meses", "después", "de", "la", "cirugía", ",", "la", "paciente", "se", "encuentra", "asintomática", "y", "sin", "secuelas", ".", "\n", "Responsable", "clínico", ":", "Ana", "M.", "Calvo", "Benito", "Servicio", "Cirugía", "General", "y", "Aparato", "Digestivo", "Hospital", "de", "Navarra", "C/", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848", "422179", "\n" ]

[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NUMERO_TELEFONO", "FECHAS", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Paola is a NOMBRE_SUJETO_ASISTENCIA, Barba Vega is a NOMBRE_SUJETO_ASISTENCIA, 4387459 is a ID_SUJETO_ASISTENCIA, 83 56740786 47 is a ID_ASEGURAMIENTO, Calle Puchaicela , 34 is a CALLE, Madrid is a TERRITORIO, 31250 is a TERRITORIO, 21/07/1981 is a FECHAS, España is a PAIS, 34 años is a EDAD_SUJETO_ASISTENCIA, 10/11/2015 is a FECHAS, Ana M. Calvo Benito is a NOMBRE_PERSONAL_SANITARIO, 31 31 20250 is a ID_TITULACION_PERSONAL_SANITARIO, Mujer is a SEXO_SUJETO_ASISTENCIA, 34 años is a EDAD_SUJETO_ASISTENCIA, Ana M. Calvo Benito is a NOMBRE_PERSONAL_SANITARIO, Hospital de Navarra is a HOSPITAL, C/ Irunlarrea , 3 is a CALLE, 31008 is a TERRITORIO, Pamplona is a TERRITORIO, 848 422179 is a NUMERO_TELEFONO

359_task1

Sentence: Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179 Instructions: please typing these entity words according to sentence: Paola, Barba Vega, 4387459, 83 56740786 47, Calle Puchaicela , 34, Madrid, 31250, 21/07/1981, España, 34 años, 10/11/2015, Ana M. Calvo Benito, 31 31 20250, Mujer, 34 años, Ana M. Calvo Benito, Hospital de Navarra, C/ Irunlarrea , 3, 31008, Pamplona, 848 422179 Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, NUMERO_TELEFONO, HOSPITAL, CALLE, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O" ]

Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Paola", ".", "\n", "Apellidos", ":", "Barba", "Vega", ".", "\n", "NHC", ":", "4387459", ".", "\n", "NASS", ":", "83", "56740786", "47", ".", "\n", "Domicilio", ":", "Calle", "Puchaicela", ",", "34", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "31250", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1981", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "34", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "10/11/2015", ".", "\n", "Médico", ":", "Ana", "M.", "Calvo", "Benito", "NºCol", ":", "31", "31", "20250", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "34", "años", ",", "embarazada", "de", "18", "semanas", ",", "que", "acudió", "a", "urgencias", "porque", "durante", "un", "episodio", "de", "hiperémesis", "gravídica", "con", "vómitos", "proyectivos", "presentó", "de", "forma", "súbita", "tumefacción", "supraorbitaria", "derecha", "con", "proptosis", "ocular", "y", "alteraciones", "visuales", "del", "ojo", "derecho", ".", "La", "paciente", "no", "presentaba", "antecedentes", "personales", "de", "interés", ",", "no", "tomaba", "ninguna", "medicación", "habitual", "ni", "había", "sufrido", "ningún", "traumatismo", "previamente", ".", "\n", "A", "la", "exploración", "oftalmológica", "destacaba", "la", "presencia", "de", "exoftalmos", "con", "hipoftalmos", "del", "ojo", "derecho", ",", "midriasis", "derecha", "de", "7", "mm", "con", "disminución", "de", "la", "reactividad", "pupilar", ",", "limitación", "de", "la", "supraducción", "y", "supraversión", "con", "diplopia", ",", "miodesopsias", "y", "edema", "palpebral", "superior", "doloroso", "a", "la", "palpación", ".", "La", "exploración", "del", "fondo", "de", "ojo", "fue", "normal", "con", "presión", "intraocular", "de", "24", "mmHg", ".", "No", "se", "observó", "edema", "ni", "anomalías", "vasculares", "en", "la", "conjuntiva", ".", "\n", "Debido", "a", "que", "la", "paciente", "estaba", "embarazada", ",", "se", "solicitó", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "orbitaria", "urgente", "cuyos", "hallazgos", "fueron", "compatibles", "con", "el", "diagnóstico", "de", "hematoma", "intraorbitario", "extraconal", "derecho", ".", "Un", "análisis", "sanguíneo", "basado", "en", "hemograma", ",", "bioquímica", "y", "coagulación", "de", "rutina", "no", "mostró", "ninguna", "alteración", "que", "pudiese", "haber", "precipitado", "el", "cuadro", ".", "\n", "Dada", "la", "repercusión", "clínica", "y", "las", "alteraciones", ",", "cada", "vez", "más", "evidentes", "en", "la", "visión", "de", "la", "paciente", ",", "se", "decidió", "intervenir", "quirúrgicamente", "de", "forma", "urgente", "para", "evacuar", "el", "hematoma", "y", "descomprimir", "la", "órbita", "bajo", "anestesia", "general", ".", "Se", "realizó", "una", "abordaje", "de", "blefaroplastia", "superior", "derecho", ",", "disecando", "el", "músculo", "orbicular", "del", "ojo", "y", "el", "periostio", ",", "hasta", "alcanzar", "el", "reborde", "óseo", "súpero", "-", "externo", "orbitario", ".", "Al", "incidir", "el", "periostio", "a", "nivel", "de", "la", "cara", "orbitaria", "del", "hueso", "frontal", ",", "se", "produjo", "la", "salida", "a", "presión", "de", "coágulos", "y", "sangre", "procedentes", "del", "hematoma", "extraconal", ".", "Tras", "la", "evacuación", "del", "hematoma", "no", "se", "objetivaron", "puntos", "sangrantes", "de", "ningún", "vaso", "de", "la", "región", ".", "Se", "colocó", "un", "drenaje", "fino", "tipo", "Penrose", "y", "se", "instauró", "tratamiento", "para", "la", "hiperémesis", "gravídica", "con", "piridoxina", "10", "mg/8", "h", "iv+tiamina", "100", "mg/24", "h", "iv", "+", "metoclopramida", "10", "mg/8", "h", "iv", ".", "\n", "La", "paciente", "evolucionó", "favorablemente", "tras", "la", "cirugía", ",", "desapareciendo", "la", "midriasis", "y", "las", "alteraciones", "visuales", "en", "las", "primeras", "horas", "postoperatorias", ",", "retirándose", "el", "drenaje", "a", "las", "48", "h", ",", "actualmente", ",", "3", "meses", "después", "de", "la", "cirugía", ",", "la", "paciente", "se", "encuentra", "asintomática", "y", "sin", "secuelas", ".", "\n", "Responsable", "clínico", ":", "Ana", "M.", "Calvo", "Benito", "Servicio", "Cirugía", "General", "y", "Aparato", "Digestivo", "Hospital", "de", "Navarra", "C/", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848", "422179", "\n" ]

[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NUMERO_TELEFONO", "FECHAS", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Paola, Barba Vega, 4387459, 83 56740786 47, Calle Puchaicela , 34, Madrid, 31250, 21/07/1981, España, 34 años, 10/11/2015, Ana M. Calvo Benito, 31 31 20250, Mujer, 34 años, Ana M. Calvo Benito, Hospital de Navarra, C/ Irunlarrea , 3, 31008, Pamplona, 848 422179

359_task2

Sentence: Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179 Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "B-HOSPITAL", "I-HOSPITAL", "I-HOSPITAL", "B-CALLE", "I-CALLE", "I-CALLE", "I-CALLE", "B-TERRITORIO", "B-TERRITORIO", "O", "O", "B-NUMERO_TELEFONO", "I-NUMERO_TELEFONO", "O" ]

Datos del paciente. Nombre: Paola. Apellidos: Barba Vega. NHC: 4387459. NASS: 83 56740786 47. Domicilio: Calle Puchaicela, 34 . Localidad/ Provincia: Madrid. CP: 31250. Datos asistenciales. Fecha de nacimiento: 21/07/1981. País de nacimiento: España. Edad: 34 años Sexo: M. Fecha de Ingreso: 10/11/2015. Médico: Ana M. Calvo Benito NºCol: 31 31 20250. Informe clínico del paciente: Mujer de 34 años, embarazada de 18 semanas, que acudió a urgencias porque durante un episodio de hiperémesis gravídica con vómitos proyectivos presentó de forma súbita tumefacción supraorbitaria derecha con proptosis ocular y alteraciones visuales del ojo derecho. La paciente no presentaba antecedentes personales de interés, no tomaba ninguna medicación habitual ni había sufrido ningún traumatismo previamente. A la exploración oftalmológica destacaba la presencia de exoftalmos con hipoftalmos del ojo derecho, midriasis derecha de 7 mm con disminución de la reactividad pupilar, limitación de la supraducción y supraversión con diplopia, miodesopsias y edema palpebral superior doloroso a la palpación. La exploración del fondo de ojo fue normal con presión intraocular de 24 mmHg. No se observó edema ni anomalías vasculares en la conjuntiva. Debido a que la paciente estaba embarazada, se solicitó una resonancia magnética nuclear (RMN) orbitaria urgente cuyos hallazgos fueron compatibles con el diagnóstico de hematoma intraorbitario extraconal derecho. Un análisis sanguíneo basado en hemograma, bioquímica y coagulación de rutina no mostró ninguna alteración que pudiese haber precipitado el cuadro. Dada la repercusión clínica y las alteraciones, cada vez más evidentes en la visión de la paciente, se decidió intervenir quirúrgicamente de forma urgente para evacuar el hematoma y descomprimir la órbita bajo anestesia general. Se realizó una abordaje de blefaroplastia superior derecho, disecando el músculo orbicular del ojo y el periostio, hasta alcanzar el reborde óseo súpero-externo orbitario. Al incidir el periostio a nivel de la cara orbitaria del hueso frontal, se produjo la salida a presión de coágulos y sangre procedentes del hematoma extraconal. Tras la evacuación del hematoma no se objetivaron puntos sangrantes de ningún vaso de la región. Se colocó un drenaje fino tipo Penrose y se instauró tratamiento para la hiperémesis gravídica con piridoxina 10 mg/8 h iv+tiamina 100 mg/24 h iv + metoclopramida 10 mg/8 h iv. La paciente evolucionó favorablemente tras la cirugía, desapareciendo la midriasis y las alteraciones visuales en las primeras horas postoperatorias, retirándose el drenaje a las 48 h, actualmente, 3 meses después de la cirugía, la paciente se encuentra asintomática y sin secuelas. Responsable clínico: Ana M. Calvo Benito Servicio Cirugía General y Aparato Digestivo Hospital de Navarra C/ Irunlarrea, 3 31008 Pamplona Tfno. 848 422179

[ "Datos", "del", "paciente", ".", "\n", "Nombre", ":", "Paola", ".", "\n", "Apellidos", ":", "Barba", "Vega", ".", "\n", "NHC", ":", "4387459", ".", "\n", "NASS", ":", "83", "56740786", "47", ".", "\n", "Domicilio", ":", "Calle", "Puchaicela", ",", "34", ".", "\n", "Localidad/", "Provincia", ":", "Madrid", ".", "\n", "CP", ":", "31250", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "21/07/1981", ".", "\n", "País", "de", "nacimiento", ":", "España", ".", "\n", "Edad", ":", "34", "años", "Sexo", ":", "M.", "\n", "Fecha", "de", "Ingreso", ":", "10/11/2015", ".", "\n", "Médico", ":", "Ana", "M.", "Calvo", "Benito", "NºCol", ":", "31", "31", "20250", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Mujer", "de", "34", "años", ",", "embarazada", "de", "18", "semanas", ",", "que", "acudió", "a", "urgencias", "porque", "durante", "un", "episodio", "de", "hiperémesis", "gravídica", "con", "vómitos", "proyectivos", "presentó", "de", "forma", "súbita", "tumefacción", "supraorbitaria", "derecha", "con", "proptosis", "ocular", "y", "alteraciones", "visuales", "del", "ojo", "derecho", ".", "La", "paciente", "no", "presentaba", "antecedentes", "personales", "de", "interés", ",", "no", "tomaba", "ninguna", "medicación", "habitual", "ni", "había", "sufrido", "ningún", "traumatismo", "previamente", ".", "\n", "A", "la", "exploración", "oftalmológica", "destacaba", "la", "presencia", "de", "exoftalmos", "con", "hipoftalmos", "del", "ojo", "derecho", ",", "midriasis", "derecha", "de", "7", "mm", "con", "disminución", "de", "la", "reactividad", "pupilar", ",", "limitación", "de", "la", "supraducción", "y", "supraversión", "con", "diplopia", ",", "miodesopsias", "y", "edema", "palpebral", "superior", "doloroso", "a", "la", "palpación", ".", "La", "exploración", "del", "fondo", "de", "ojo", "fue", "normal", "con", "presión", "intraocular", "de", "24", "mmHg", ".", "No", "se", "observó", "edema", "ni", "anomalías", "vasculares", "en", "la", "conjuntiva", ".", "\n", "Debido", "a", "que", "la", "paciente", "estaba", "embarazada", ",", "se", "solicitó", "una", "resonancia", "magnética", "nuclear", "(", "RMN", ")", "orbitaria", "urgente", "cuyos", "hallazgos", "fueron", "compatibles", "con", "el", "diagnóstico", "de", "hematoma", "intraorbitario", "extraconal", "derecho", ".", "Un", "análisis", "sanguíneo", "basado", "en", "hemograma", ",", "bioquímica", "y", "coagulación", "de", "rutina", "no", "mostró", "ninguna", "alteración", "que", "pudiese", "haber", "precipitado", "el", "cuadro", ".", "\n", "Dada", "la", "repercusión", "clínica", "y", "las", "alteraciones", ",", "cada", "vez", "más", "evidentes", "en", "la", "visión", "de", "la", "paciente", ",", "se", "decidió", "intervenir", "quirúrgicamente", "de", "forma", "urgente", "para", "evacuar", "el", "hematoma", "y", "descomprimir", "la", "órbita", "bajo", "anestesia", "general", ".", "Se", "realizó", "una", "abordaje", "de", "blefaroplastia", "superior", "derecho", ",", "disecando", "el", "músculo", "orbicular", "del", "ojo", "y", "el", "periostio", ",", "hasta", "alcanzar", "el", "reborde", "óseo", "súpero", "-", "externo", "orbitario", ".", "Al", "incidir", "el", "periostio", "a", "nivel", "de", "la", "cara", "orbitaria", "del", "hueso", "frontal", ",", "se", "produjo", "la", "salida", "a", "presión", "de", "coágulos", "y", "sangre", "procedentes", "del", "hematoma", "extraconal", ".", "Tras", "la", "evacuación", "del", "hematoma", "no", "se", "objetivaron", "puntos", "sangrantes", "de", "ningún", "vaso", "de", "la", "región", ".", "Se", "colocó", "un", "drenaje", "fino", "tipo", "Penrose", "y", "se", "instauró", "tratamiento", "para", "la", "hiperémesis", "gravídica", "con", "piridoxina", "10", "mg/8", "h", "iv+tiamina", "100", "mg/24", "h", "iv", "+", "metoclopramida", "10", "mg/8", "h", "iv", ".", "\n", "La", "paciente", "evolucionó", "favorablemente", "tras", "la", "cirugía", ",", "desapareciendo", "la", "midriasis", "y", "las", "alteraciones", "visuales", "en", "las", "primeras", "horas", "postoperatorias", ",", "retirándose", "el", "drenaje", "a", "las", "48", "h", ",", "actualmente", ",", "3", "meses", "después", "de", "la", "cirugía", ",", "la", "paciente", "se", "encuentra", "asintomática", "y", "sin", "secuelas", ".", "\n", "Responsable", "clínico", ":", "Ana", "M.", "Calvo", "Benito", "Servicio", "Cirugía", "General", "y", "Aparato", "Digestivo", "Hospital", "de", "Navarra", "C/", "Irunlarrea", ",", "3", "31008", "Pamplona", "Tfno", ".", "848", "422179", "\n" ]

[ "CALLE", "HOSPITAL", "NOMBRE_PERSONAL_SANITARIO", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "NUMERO_TELEFONO", "FECHAS", "NOMBRE_SUJETO_ASISTENCIA", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Stammzellen is an umlsterm, Wiederherstellung is an umlsterm, Haematopoese is an umlsterm, Therapie is an umlsterm, Behandlung is an umlsterm, Mangelsyndrome is an umlsterm, Stoffwechselkrankheiten is an umlsterm, Transportvehikel is an umlsterm, Gentherapie is an umlsterm, Stammzellen is an umlsterm, Knochenmark is an umlsterm, Blut is an umlsterm, Nabelschnurblut is an umlsterm, Biologie is an umlsterm, Stammzellen is an umlsterm, Zulassung is an umlsterm, Stammzellen is an umlsterm, Arzneimittel is an umlsterm, Person is an umlsterm, Gebrauch is an umlsterm

Bundesgesundheitsblatt.90420105.ger.abstr_task0

Sentence: Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden .

[ "Praeparationen", "haematopoetischer", "Stammzellen", "bieten", "prinzipiell", "eine", "unendliche", "Vielfalt", "klinischer", "Anwendungsmoeglichkeiten", "und", "Zukunftsperspektiven", ".", "Sie", "sind", "die", "Basis", "fuer", "Stammzelltransplantationen", ",", "d.h", ".", "fuer", "die", "Wiederherstellung", "der", "Haematopoese", "nach", "hochdosierter", "zytotoxischer", "Therapie", "und", "bilden", "die", "Grundlage", "der", "Behandlung", "immunologischer", "Mangelsyndrome", "sowie", "erblicher", "Stoffwechselkrankheiten", ".", "Weiterhin", "koennten", "sie", "in", "der", "Zukunft", "ein", "Transportvehikel", "fuer", "die", "Gentherapie", "darstellen", ".", "Stammzellen", "koennen", "vom", "Knochenmark", ",", "vom", "peripheren", "Blut", "oder", "aus", "Nabelschnurblut", "gewonnen", "werden", ".", "Der", "vorliegende", "Artikel", "vermittelt", "einen", "Ueberblick", "ueber", "die", "Biologie", "der", "Stammzellen", "ueber", "Verfahren", ",", "ihrer", "Gewinnung", ",", "die", "gesetzliche", "Grundlage", "fuer", "die", "Herstellung", "von", "Stammzellpraeparationen", "sowie", "ueber", "die", "Grundzuege", "der", "Anforderungen", "fuer", "deren", "Zulassung", ".", "Nach", "der", "deutschen", "Rechtslage", "sind", "Stammzellen", "dann", "zulassungspflichtige", "Arzneimittel", ",", "wenn", "sie", "nicht", "fuer", "eine", "bestimmte", "erkrankte", "Person", "hergestellt", "werden", ",", "sondern", "im", "voraus", "produziert", "und", "-", "bis", "zu", "ihrem", "Gebrauch", "-", "in", "sogenannten", "Zellbanken", "gelagert", "werden", "." ]

[ "umlsterm" ]

Stammzellen is an umlsterm, Wiederherstellung is an umlsterm, Haematopoese is an umlsterm, Therapie is an umlsterm, Behandlung is an umlsterm, Mangelsyndrome is an umlsterm, Stoffwechselkrankheiten is an umlsterm, Transportvehikel is an umlsterm, Gentherapie is an umlsterm, Stammzellen is an umlsterm, Knochenmark is an umlsterm, Blut is an umlsterm, Nabelschnurblut is an umlsterm, Biologie is an umlsterm, Stammzellen is an umlsterm, Zulassung is an umlsterm, Stammzellen is an umlsterm, Arzneimittel is an umlsterm, Person is an umlsterm, Gebrauch is an umlsterm

Bundesgesundheitsblatt.90420105.ger.abstr_task1

Sentence: Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden . Instructions: please typing these entity words according to sentence: Stammzellen, Wiederherstellung, Haematopoese, Therapie, Behandlung, Mangelsyndrome, Stoffwechselkrankheiten, Transportvehikel, Gentherapie, Stammzellen, Knochenmark, Blut, Nabelschnurblut, Biologie, Stammzellen, Zulassung, Stammzellen, Arzneimittel, Person, Gebrauch Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden .

[ "Praeparationen", "haematopoetischer", "Stammzellen", "bieten", "prinzipiell", "eine", "unendliche", "Vielfalt", "klinischer", "Anwendungsmoeglichkeiten", "und", "Zukunftsperspektiven", ".", "Sie", "sind", "die", "Basis", "fuer", "Stammzelltransplantationen", ",", "d.h", ".", "fuer", "die", "Wiederherstellung", "der", "Haematopoese", "nach", "hochdosierter", "zytotoxischer", "Therapie", "und", "bilden", "die", "Grundlage", "der", "Behandlung", "immunologischer", "Mangelsyndrome", "sowie", "erblicher", "Stoffwechselkrankheiten", ".", "Weiterhin", "koennten", "sie", "in", "der", "Zukunft", "ein", "Transportvehikel", "fuer", "die", "Gentherapie", "darstellen", ".", "Stammzellen", "koennen", "vom", "Knochenmark", ",", "vom", "peripheren", "Blut", "oder", "aus", "Nabelschnurblut", "gewonnen", "werden", ".", "Der", "vorliegende", "Artikel", "vermittelt", "einen", "Ueberblick", "ueber", "die", "Biologie", "der", "Stammzellen", "ueber", "Verfahren", ",", "ihrer", "Gewinnung", ",", "die", "gesetzliche", "Grundlage", "fuer", "die", "Herstellung", "von", "Stammzellpraeparationen", "sowie", "ueber", "die", "Grundzuege", "der", "Anforderungen", "fuer", "deren", "Zulassung", ".", "Nach", "der", "deutschen", "Rechtslage", "sind", "Stammzellen", "dann", "zulassungspflichtige", "Arzneimittel", ",", "wenn", "sie", "nicht", "fuer", "eine", "bestimmte", "erkrankte", "Person", "hergestellt", "werden", ",", "sondern", "im", "voraus", "produziert", "und", "-", "bis", "zu", "ihrem", "Gebrauch", "-", "in", "sogenannten", "Zellbanken", "gelagert", "werden", "." ]

[ "umlsterm" ]

Stammzellen, Wiederherstellung, Haematopoese, Therapie, Behandlung, Mangelsyndrome, Stoffwechselkrankheiten, Transportvehikel, Gentherapie, Stammzellen, Knochenmark, Blut, Nabelschnurblut, Biologie, Stammzellen, Zulassung, Stammzellen, Arzneimittel, Person, Gebrauch

Bundesgesundheitsblatt.90420105.ger.abstr_task2

Sentence: Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Praeparationen haematopoetischer Stammzellen bieten prinzipiell eine unendliche Vielfalt klinischer Anwendungsmoeglichkeiten und Zukunftsperspektiven . Sie sind die Basis fuer Stammzelltransplantationen , d.h. fuer die Wiederherstellung der Haematopoese nach hochdosierter zytotoxischer Therapie und bilden die Grundlage der Behandlung immunologischer Mangelsyndrome sowie erblicher Stoffwechselkrankheiten . Weiterhin koennten sie in der Zukunft ein Transportvehikel fuer die Gentherapie darstellen . Stammzellen koennen vom Knochenmark , vom peripheren Blut oder aus Nabelschnurblut gewonnen werden . Der vorliegende Artikel vermittelt einen Ueberblick ueber die Biologie der Stammzellen ueber Verfahren , ihrer Gewinnung , die gesetzliche Grundlage fuer die Herstellung von Stammzellpraeparationen sowie ueber die Grundzuege der Anforderungen fuer deren Zulassung . Nach der deutschen Rechtslage sind Stammzellen dann zulassungspflichtige Arzneimittel , wenn sie nicht fuer eine bestimmte erkrankte Person hergestellt werden , sondern im voraus produziert und - bis zu ihrem Gebrauch - in sogenannten Zellbanken gelagert werden .

[ "Praeparationen", "haematopoetischer", "Stammzellen", "bieten", "prinzipiell", "eine", "unendliche", "Vielfalt", "klinischer", "Anwendungsmoeglichkeiten", "und", "Zukunftsperspektiven", ".", "Sie", "sind", "die", "Basis", "fuer", "Stammzelltransplantationen", ",", "d.h", ".", "fuer", "die", "Wiederherstellung", "der", "Haematopoese", "nach", "hochdosierter", "zytotoxischer", "Therapie", "und", "bilden", "die", "Grundlage", "der", "Behandlung", "immunologischer", "Mangelsyndrome", "sowie", "erblicher", "Stoffwechselkrankheiten", ".", "Weiterhin", "koennten", "sie", "in", "der", "Zukunft", "ein", "Transportvehikel", "fuer", "die", "Gentherapie", "darstellen", ".", "Stammzellen", "koennen", "vom", "Knochenmark", ",", "vom", "peripheren", "Blut", "oder", "aus", "Nabelschnurblut", "gewonnen", "werden", ".", "Der", "vorliegende", "Artikel", "vermittelt", "einen", "Ueberblick", "ueber", "die", "Biologie", "der", "Stammzellen", "ueber", "Verfahren", ",", "ihrer", "Gewinnung", ",", "die", "gesetzliche", "Grundlage", "fuer", "die", "Herstellung", "von", "Stammzellpraeparationen", "sowie", "ueber", "die", "Grundzuege", "der", "Anforderungen", "fuer", "deren", "Zulassung", ".", "Nach", "der", "deutschen", "Rechtslage", "sind", "Stammzellen", "dann", "zulassungspflichtige", "Arzneimittel", ",", "wenn", "sie", "nicht", "fuer", "eine", "bestimmte", "erkrankte", "Person", "hergestellt", "werden", ",", "sondern", "im", "voraus", "produziert", "und", "-", "bis", "zu", "ihrem", "Gebrauch", "-", "in", "sogenannten", "Zellbanken", "gelagert", "werden", "." ]

[ "umlsterm" ]

Ifenprodil is a CHEMICAL, Fluorescein is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - Methyl - D - aspartate Receptor is a GENE-N

23532918_task0

Sentence: Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]

Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists.

[ "Synthesis", "and", "in", "Vitro", "Characterisation", "of", "Ifenprodil", "-", "Based", "Fluorescein", "Conjugates", "as", "GluN1", "/", "GluN2B", "N", "-", "Methyl", "-", "D", "-", "aspartate", "Receptor", "Antagonists", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Ifenprodil is a CHEMICAL, Fluorescein is a CHEMICAL, GluN1 is a GENE-Y, GluN2B is a GENE-Y, N - Methyl - D - aspartate Receptor is a GENE-N

23532918_task1

Sentence: Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists. Instructions: please typing these entity words according to sentence: Ifenprodil, Fluorescein, GluN1, GluN2B, N - Methyl - D - aspartate Receptor Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]

Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists.

[ "Synthesis", "and", "in", "Vitro", "Characterisation", "of", "Ifenprodil", "-", "Based", "Fluorescein", "Conjugates", "as", "GluN1", "/", "GluN2B", "N", "-", "Methyl", "-", "D", "-", "aspartate", "Receptor", "Antagonists", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Ifenprodil, Fluorescein, GluN1, GluN2B, N - Methyl - D - aspartate Receptor

23532918_task2

Sentence: Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O" ]

Synthesis and in Vitro Characterisation of Ifenprodil-Based Fluorescein Conjugates as GluN1/GluN2B N-Methyl-D-aspartate Receptor Antagonists.

[ "Synthesis", "and", "in", "Vitro", "Characterisation", "of", "Ifenprodil", "-", "Based", "Fluorescein", "Conjugates", "as", "GluN1", "/", "GluN2B", "N", "-", "Methyl", "-", "D", "-", "aspartate", "Receptor", "Antagonists", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

Fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, 4-hydroxytolbutamide is a DRUG_N, carboxytolbutamide is a DRUG_N, fluvoxamine is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, 4-hydroxytolbutamide is a DRUG_N, carboxytolbutamide is a DRUG_N, tolbutamide is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, Fluvoxamine is a DRUG

11180037_task0

Sentence: Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG_N, DRUG

[ "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo.

[ "Fluvoxamine", "inhibits", "the", "CYP2C9", "catalyzed", "biotransformation", "of", "tolbutamide", ".", "OBJECTIVE", ":", "Our", "objective", "was", "to", "examine", "the", "interaction", "between", "fluvoxamine", "and", "tolbutamide", "to", "confirm", "that", "fluvoxamine", "inhibits", "CYP2C9", ".", "METHODS", ":", "The", "study", "was", "carried", "out", "as", "an", "open", ",", "randomized", ",", "crossover", "design", "with", "14", "healthy", "participants", ".", "In", "period", "A", ",", "all", "volunteers", "took", "500", "mg", "of", "tolbutamide", "orally", ".", "In", "period", "B", ",", "the", "volunteers", "were", "randomly", "assigned", "to", "one", "of", "two", "groups", ".", "Each", "group", "took", "either", "150", "mg", "or", "75", "mg", "of", "fluvoxamine", "a", "day", "for", "5", "days", "(", "day", "-3", "to", "day", "2", ")", ".", "The", "groups", "then", "took", "500", "mg", "of", "tolbutamide", "as", "a", "single", "dose", "(", "day", "0", ")", ".", "In", "both", "periods", ",", "blood", "and", "urine", "were", "sampled", "at", "regular", "intervals", ".", "Plasma", "was", "analyzed", "for", "tolbutamide", ",", "and", "urine", "was", "analyzed", "for", "tolbutamide", "and", "its", "two", "metabolites", ",", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "by", "means", "of", "HPLC", ".", "RESULTS", ":", "During", "treatment", "with", "fluvoxamine", ",", "there", "was", "a", "statistically", "significant", "decrease", "in", "the", "median", "of", "the", "total", "clearance", "of", "tolbutamide", ",", "from", "845", "mL", "/", "h", "to", "688", "mL", "/", "h", ",", "among", "the", "volunteers", "who", "received", "75", "mg", "/", "d.", "There", "was", "a", "reduction", "that", "reached", "borderline", "statistical", "significance", "in", "the", "group", "that", "received", "150", "mg", "/", "d", "of", "tolbutamide", ".", "The", "clearance", "by", "means", "of", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "was", "significantly", "reduced", "in", "both", "groups", "(", "ie", ",", "from", "901", "mL", "/", "h", "to", "318", "mL", "/", "h", "in", "the", "group", "that", "received", "150", "mg", "of", "tolbutamide", "per", "day", "and", "from", "723", "mL", "/", "h", "to", "457", "mL", "/", "h", "in", "the", "group", "that", "received", "75", "mg", "of", "tolbutamide", "per", "day", ")", ".", "Thus", "there", "was", "a", "tendency", "toward", "a", "more", "pronounced", "inhibition", "of", "the", "4-hydroxylation", "during", "treatment", "with", "150", "mg", "/", "d", "of", "fluvoxamine", "compared", "with", "75", "mg", "/", "d", ",", "but", "the", "difference", "was", "not", "statistically", "significant", ".", "CONCLUSION", ":", "Fluvoxamine", "is", "a", "moderate", "inhibitor", "of", "CYP2C9", "in", "vivo", "." ]

[ "DRUG_N", "DRUG" ]

Fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, 4-hydroxytolbutamide is a DRUG_N, carboxytolbutamide is a DRUG_N, fluvoxamine is a DRUG, tolbutamide is a DRUG, tolbutamide is a DRUG, 4-hydroxytolbutamide is a DRUG_N, carboxytolbutamide is a DRUG_N, tolbutamide is a DRUG, tolbutamide is a DRUG, fluvoxamine is a DRUG, Fluvoxamine is a DRUG

11180037_task1

Sentence: Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo. Instructions: please typing these entity words according to sentence: Fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, tolbutamide, tolbutamide, 4-hydroxytolbutamide, carboxytolbutamide, fluvoxamine, tolbutamide, tolbutamide, 4-hydroxytolbutamide, carboxytolbutamide, tolbutamide, tolbutamide, fluvoxamine, Fluvoxamine Options: DRUG_N, DRUG

[ "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo.

[ "Fluvoxamine", "inhibits", "the", "CYP2C9", "catalyzed", "biotransformation", "of", "tolbutamide", ".", "OBJECTIVE", ":", "Our", "objective", "was", "to", "examine", "the", "interaction", "between", "fluvoxamine", "and", "tolbutamide", "to", "confirm", "that", "fluvoxamine", "inhibits", "CYP2C9", ".", "METHODS", ":", "The", "study", "was", "carried", "out", "as", "an", "open", ",", "randomized", ",", "crossover", "design", "with", "14", "healthy", "participants", ".", "In", "period", "A", ",", "all", "volunteers", "took", "500", "mg", "of", "tolbutamide", "orally", ".", "In", "period", "B", ",", "the", "volunteers", "were", "randomly", "assigned", "to", "one", "of", "two", "groups", ".", "Each", "group", "took", "either", "150", "mg", "or", "75", "mg", "of", "fluvoxamine", "a", "day", "for", "5", "days", "(", "day", "-3", "to", "day", "2", ")", ".", "The", "groups", "then", "took", "500", "mg", "of", "tolbutamide", "as", "a", "single", "dose", "(", "day", "0", ")", ".", "In", "both", "periods", ",", "blood", "and", "urine", "were", "sampled", "at", "regular", "intervals", ".", "Plasma", "was", "analyzed", "for", "tolbutamide", ",", "and", "urine", "was", "analyzed", "for", "tolbutamide", "and", "its", "two", "metabolites", ",", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "by", "means", "of", "HPLC", ".", "RESULTS", ":", "During", "treatment", "with", "fluvoxamine", ",", "there", "was", "a", "statistically", "significant", "decrease", "in", "the", "median", "of", "the", "total", "clearance", "of", "tolbutamide", ",", "from", "845", "mL", "/", "h", "to", "688", "mL", "/", "h", ",", "among", "the", "volunteers", "who", "received", "75", "mg", "/", "d.", "There", "was", "a", "reduction", "that", "reached", "borderline", "statistical", "significance", "in", "the", "group", "that", "received", "150", "mg", "/", "d", "of", "tolbutamide", ".", "The", "clearance", "by", "means", "of", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "was", "significantly", "reduced", "in", "both", "groups", "(", "ie", ",", "from", "901", "mL", "/", "h", "to", "318", "mL", "/", "h", "in", "the", "group", "that", "received", "150", "mg", "of", "tolbutamide", "per", "day", "and", "from", "723", "mL", "/", "h", "to", "457", "mL", "/", "h", "in", "the", "group", "that", "received", "75", "mg", "of", "tolbutamide", "per", "day", ")", ".", "Thus", "there", "was", "a", "tendency", "toward", "a", "more", "pronounced", "inhibition", "of", "the", "4-hydroxylation", "during", "treatment", "with", "150", "mg", "/", "d", "of", "fluvoxamine", "compared", "with", "75", "mg", "/", "d", ",", "but", "the", "difference", "was", "not", "statistically", "significant", ".", "CONCLUSION", ":", "Fluvoxamine", "is", "a", "moderate", "inhibitor", "of", "CYP2C9", "in", "vivo", "." ]

[ "DRUG_N", "DRUG" ]

Fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, fluvoxamine, tolbutamide, tolbutamide, tolbutamide, 4-hydroxytolbutamide, carboxytolbutamide, fluvoxamine, tolbutamide, tolbutamide, 4-hydroxytolbutamide, carboxytolbutamide, tolbutamide, tolbutamide, fluvoxamine, Fluvoxamine

11180037_task2

Sentence: Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo. Instructions: please extract entity words from the input sentence

[ "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "O", "B-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and tolbutamide to confirm that fluvoxamine inhibits CYP2C9. METHODS: The study was carried out as an open, randomized, crossover design with 14 healthy participants. In period A, all volunteers took 500 mg of tolbutamide orally. In period B, the volunteers were randomly assigned to one of two groups. Each group took either 150 mg or 75 mg of fluvoxamine a day for 5 days (day -3 to day 2). The groups then took 500 mg of tolbutamide as a single dose (day 0). In both periods, blood and urine were sampled at regular intervals. Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. RESULTS: During treatment with fluvoxamine, there was a statistically significant decrease in the median of the total clearance of tolbutamide, from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. There was a reduction that reached borderline statistical significance in the group that received 150 mg/d of tolbutamide. The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). Thus there was a tendency toward a more pronounced inhibition of the 4-hydroxylation during treatment with 150 mg/d of fluvoxamine compared with 75 mg/d, but the difference was not statistically significant. CONCLUSION: Fluvoxamine is a moderate inhibitor of CYP2C9 in vivo.

[ "Fluvoxamine", "inhibits", "the", "CYP2C9", "catalyzed", "biotransformation", "of", "tolbutamide", ".", "OBJECTIVE", ":", "Our", "objective", "was", "to", "examine", "the", "interaction", "between", "fluvoxamine", "and", "tolbutamide", "to", "confirm", "that", "fluvoxamine", "inhibits", "CYP2C9", ".", "METHODS", ":", "The", "study", "was", "carried", "out", "as", "an", "open", ",", "randomized", ",", "crossover", "design", "with", "14", "healthy", "participants", ".", "In", "period", "A", ",", "all", "volunteers", "took", "500", "mg", "of", "tolbutamide", "orally", ".", "In", "period", "B", ",", "the", "volunteers", "were", "randomly", "assigned", "to", "one", "of", "two", "groups", ".", "Each", "group", "took", "either", "150", "mg", "or", "75", "mg", "of", "fluvoxamine", "a", "day", "for", "5", "days", "(", "day", "-3", "to", "day", "2", ")", ".", "The", "groups", "then", "took", "500", "mg", "of", "tolbutamide", "as", "a", "single", "dose", "(", "day", "0", ")", ".", "In", "both", "periods", ",", "blood", "and", "urine", "were", "sampled", "at", "regular", "intervals", ".", "Plasma", "was", "analyzed", "for", "tolbutamide", ",", "and", "urine", "was", "analyzed", "for", "tolbutamide", "and", "its", "two", "metabolites", ",", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "by", "means", "of", "HPLC", ".", "RESULTS", ":", "During", "treatment", "with", "fluvoxamine", ",", "there", "was", "a", "statistically", "significant", "decrease", "in", "the", "median", "of", "the", "total", "clearance", "of", "tolbutamide", ",", "from", "845", "mL", "/", "h", "to", "688", "mL", "/", "h", ",", "among", "the", "volunteers", "who", "received", "75", "mg", "/", "d.", "There", "was", "a", "reduction", "that", "reached", "borderline", "statistical", "significance", "in", "the", "group", "that", "received", "150", "mg", "/", "d", "of", "tolbutamide", ".", "The", "clearance", "by", "means", "of", "4-hydroxytolbutamide", "and", "carboxytolbutamide", "was", "significantly", "reduced", "in", "both", "groups", "(", "ie", ",", "from", "901", "mL", "/", "h", "to", "318", "mL", "/", "h", "in", "the", "group", "that", "received", "150", "mg", "of", "tolbutamide", "per", "day", "and", "from", "723", "mL", "/", "h", "to", "457", "mL", "/", "h", "in", "the", "group", "that", "received", "75", "mg", "of", "tolbutamide", "per", "day", ")", ".", "Thus", "there", "was", "a", "tendency", "toward", "a", "more", "pronounced", "inhibition", "of", "the", "4-hydroxylation", "during", "treatment", "with", "150", "mg", "/", "d", "of", "fluvoxamine", "compared", "with", "75", "mg", "/", "d", ",", "but", "the", "difference", "was", "not", "statistically", "significant", ".", "CONCLUSION", ":", "Fluvoxamine", "is", "a", "moderate", "inhibitor", "of", "CYP2C9", "in", "vivo", "." ]

[ "DRUG_N", "DRUG" ]

GrpL is a Protein, SLP-76 is a Protein, SH2 domain - containing protein 76 is a Protein, SLP-76 is a Protein, Vav is a Protein, Grb2-related protein of the lymphoid system is a Protein, GrpL is a Protein, GrpL is a Protein, Grb2 is a Protein, GrpL is a Protein, SLP-76 is a Protein, Sos1 is a Protein, Sos2 is a Protein, Grb2 is a Protein, Sos1 is a Protein, Sos2 is a Protein, SLP-76 is a Protein, tyrosine is a Entity, LAT is a Protein, pp36/38 is a Protein, Grb2 is a Protein, GrpL is a Protein, Grb2 is a Protein, GrpL is a Protein, SLP-76 is a Protein, GrpL is a Protein, SLP-76 is a Protein

152_task0

Sentence: GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells.

[ "GrpL", ",", "a", "Grb2-related", "adaptor", "protein", ",", "interacts", "with", "SLP-76", "to", "regulate", "nuclear", "factor", "of", "activated", "T", "cell", "activation", ".", "\n", "Propagation", "of", "signals", "from", "the", "T", "cell", "antigen", "receptor", "(", "TCR", ")", "involves", "a", "number", "of", "adaptor", "molecules", ".", "SH2", "domain", "-", "containing", "protein", "76", "(", "SLP-76", ")", "interacts", "with", "the", "guanine", "nucleotide", "exchange", "factor", "Vav", "to", "activate", "the", "nuclear", "factor", "of", "activated", "cells", "(", "NF", "-", "AT", ")", ",", "and", "its", "expression", "is", "required", "for", "normal", "T", "cell", "development", ".", "We", "report", "the", "cloning", "and", "characterization", "of", "a", "novel", "Grb2-like", "adaptor", "molecule", "designated", "as", "Grb2-related", "protein", "of", "the", "lymphoid", "system", "(", "GrpL", ")", ".", "Expression", "of", "GrpL", "is", "restricted", "to", "hematopoietic", "tissues", ",", "and", "it", "is", "distinguished", "from", "Grb2", "by", "having", "a", "proline", "-", "rich", "region", ".", "GrpL", "can", "be", "coimmunoprecipitated", "with", "SLP-76", "but", "not", "with", "Sos1", "or", "Sos2", "from", "Jurkat", "cell", "lysates", ".", "In", "contrast", ",", "Grb2", "can", "be", "coimmunoprecipitated", "with", "Sos1", "and", "Sos2", "but", "not", "with", "SLP-76", ".", "Moreover", ",", "tyrosine", "-", "phosphorylated", "LAT", "/", "pp36/38", "in", "detergent", "lysates", "prepared", "from", "anti", "-", "CD3", "stimulated", "T", "cells", "associated", "with", "Grb2", "but", "not", "GrpL.", "These", "data", "reveal", "the", "presence", "of", "distinct", "complexes", "involving", "GrpL", "and", "Grb2", "in", "T", "cells", ".", "A", "functional", "role", "of", "the", "GrpL", "-", "SLP-76", "complex", "is", "suggested", "by", "the", "ability", "of", "GrpL", "to", "act", "alone", "or", "in", "concert", "with", "SLP-76", "to", "augment", "NF", "-", "AT", "activation", "in", "Jurkat", "T", "cells", "." ]

[ "Protein", "Entity" ]

GrpL is a Protein, SLP-76 is a Protein, SH2 domain - containing protein 76 is a Protein, SLP-76 is a Protein, Vav is a Protein, Grb2-related protein of the lymphoid system is a Protein, GrpL is a Protein, GrpL is a Protein, Grb2 is a Protein, GrpL is a Protein, SLP-76 is a Protein, Sos1 is a Protein, Sos2 is a Protein, Grb2 is a Protein, Sos1 is a Protein, Sos2 is a Protein, SLP-76 is a Protein, tyrosine is a Entity, LAT is a Protein, pp36/38 is a Protein, Grb2 is a Protein, GrpL is a Protein, Grb2 is a Protein, GrpL is a Protein, SLP-76 is a Protein, GrpL is a Protein, SLP-76 is a Protein

152_task1

Sentence: GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells. Instructions: please typing these entity words according to sentence: GrpL, SLP-76, SH2 domain - containing protein 76, SLP-76, Vav, Grb2-related protein of the lymphoid system, GrpL, GrpL, Grb2, GrpL, SLP-76, Sos1, Sos2, Grb2, Sos1, Sos2, SLP-76, tyrosine, LAT, pp36/38, Grb2, GrpL, Grb2, GrpL, SLP-76, GrpL, SLP-76 Options: Entity, Protein

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells.

[ "GrpL", ",", "a", "Grb2-related", "adaptor", "protein", ",", "interacts", "with", "SLP-76", "to", "regulate", "nuclear", "factor", "of", "activated", "T", "cell", "activation", ".", "\n", "Propagation", "of", "signals", "from", "the", "T", "cell", "antigen", "receptor", "(", "TCR", ")", "involves", "a", "number", "of", "adaptor", "molecules", ".", "SH2", "domain", "-", "containing", "protein", "76", "(", "SLP-76", ")", "interacts", "with", "the", "guanine", "nucleotide", "exchange", "factor", "Vav", "to", "activate", "the", "nuclear", "factor", "of", "activated", "cells", "(", "NF", "-", "AT", ")", ",", "and", "its", "expression", "is", "required", "for", "normal", "T", "cell", "development", ".", "We", "report", "the", "cloning", "and", "characterization", "of", "a", "novel", "Grb2-like", "adaptor", "molecule", "designated", "as", "Grb2-related", "protein", "of", "the", "lymphoid", "system", "(", "GrpL", ")", ".", "Expression", "of", "GrpL", "is", "restricted", "to", "hematopoietic", "tissues", ",", "and", "it", "is", "distinguished", "from", "Grb2", "by", "having", "a", "proline", "-", "rich", "region", ".", "GrpL", "can", "be", "coimmunoprecipitated", "with", "SLP-76", "but", "not", "with", "Sos1", "or", "Sos2", "from", "Jurkat", "cell", "lysates", ".", "In", "contrast", ",", "Grb2", "can", "be", "coimmunoprecipitated", "with", "Sos1", "and", "Sos2", "but", "not", "with", "SLP-76", ".", "Moreover", ",", "tyrosine", "-", "phosphorylated", "LAT", "/", "pp36/38", "in", "detergent", "lysates", "prepared", "from", "anti", "-", "CD3", "stimulated", "T", "cells", "associated", "with", "Grb2", "but", "not", "GrpL.", "These", "data", "reveal", "the", "presence", "of", "distinct", "complexes", "involving", "GrpL", "and", "Grb2", "in", "T", "cells", ".", "A", "functional", "role", "of", "the", "GrpL", "-", "SLP-76", "complex", "is", "suggested", "by", "the", "ability", "of", "GrpL", "to", "act", "alone", "or", "in", "concert", "with", "SLP-76", "to", "augment", "NF", "-", "AT", "activation", "in", "Jurkat", "T", "cells", "." ]

[ "Protein", "Entity" ]

GrpL, SLP-76, SH2 domain - containing protein 76, SLP-76, Vav, Grb2-related protein of the lymphoid system, GrpL, GrpL, Grb2, GrpL, SLP-76, Sos1, Sos2, Grb2, Sos1, Sos2, SLP-76, tyrosine, LAT, pp36/38, Grb2, GrpL, Grb2, GrpL, SLP-76, GrpL, SLP-76

152_task2

Sentence: GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells. Instructions: please extract entity words from the input sentence

[ "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

GrpL, a Grb2-related adaptor protein, interacts with SLP-76 to regulate nuclear factor of activated T cell activation. Propagation of signals from the T cell antigen receptor (TCR) involves a number of adaptor molecules. SH2 domain-containing protein 76 (SLP-76) interacts with the guanine nucleotide exchange factor Vav to activate the nuclear factor of activated cells (NF-AT), and its expression is required for normal T cell development. We report the cloning and characterization of a novel Grb2-like adaptor molecule designated as Grb2-related protein of the lymphoid system (GrpL). Expression of GrpL is restricted to hematopoietic tissues, and it is distinguished from Grb2 by having a proline-rich region. GrpL can be coimmunoprecipitated with SLP-76 but not with Sos1 or Sos2 from Jurkat cell lysates. In contrast, Grb2 can be coimmunoprecipitated with Sos1 and Sos2 but not with SLP-76. Moreover, tyrosine-phosphorylated LAT/pp36/38 in detergent lysates prepared from anti-CD3 stimulated T cells associated with Grb2 but not GrpL. These data reveal the presence of distinct complexes involving GrpL and Grb2 in T cells. A functional role of the GrpL-SLP-76 complex is suggested by the ability of GrpL to act alone or in concert with SLP-76 to augment NF-AT activation in Jurkat T cells.

[ "GrpL", ",", "a", "Grb2-related", "adaptor", "protein", ",", "interacts", "with", "SLP-76", "to", "regulate", "nuclear", "factor", "of", "activated", "T", "cell", "activation", ".", "\n", "Propagation", "of", "signals", "from", "the", "T", "cell", "antigen", "receptor", "(", "TCR", ")", "involves", "a", "number", "of", "adaptor", "molecules", ".", "SH2", "domain", "-", "containing", "protein", "76", "(", "SLP-76", ")", "interacts", "with", "the", "guanine", "nucleotide", "exchange", "factor", "Vav", "to", "activate", "the", "nuclear", "factor", "of", "activated", "cells", "(", "NF", "-", "AT", ")", ",", "and", "its", "expression", "is", "required", "for", "normal", "T", "cell", "development", ".", "We", "report", "the", "cloning", "and", "characterization", "of", "a", "novel", "Grb2-like", "adaptor", "molecule", "designated", "as", "Grb2-related", "protein", "of", "the", "lymphoid", "system", "(", "GrpL", ")", ".", "Expression", "of", "GrpL", "is", "restricted", "to", "hematopoietic", "tissues", ",", "and", "it", "is", "distinguished", "from", "Grb2", "by", "having", "a", "proline", "-", "rich", "region", ".", "GrpL", "can", "be", "coimmunoprecipitated", "with", "SLP-76", "but", "not", "with", "Sos1", "or", "Sos2", "from", "Jurkat", "cell", "lysates", ".", "In", "contrast", ",", "Grb2", "can", "be", "coimmunoprecipitated", "with", "Sos1", "and", "Sos2", "but", "not", "with", "SLP-76", ".", "Moreover", ",", "tyrosine", "-", "phosphorylated", "LAT", "/", "pp36/38", "in", "detergent", "lysates", "prepared", "from", "anti", "-", "CD3", "stimulated", "T", "cells", "associated", "with", "Grb2", "but", "not", "GrpL.", "These", "data", "reveal", "the", "presence", "of", "distinct", "complexes", "involving", "GrpL", "and", "Grb2", "in", "T", "cells", ".", "A", "functional", "role", "of", "the", "GrpL", "-", "SLP-76", "complex", "is", "suggested", "by", "the", "ability", "of", "GrpL", "to", "act", "alone", "or", "in", "concert", "with", "SLP-76", "to", "augment", "NF", "-", "AT", "activation", "in", "Jurkat", "T", "cells", "." ]

[ "Protein", "Entity" ]

células tumorales malignas is a MORFOLOGIA_NEOPLASIA

647_task0

Sentence: Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético.

[ "Anamnesis", "\n", "Acude", "a", "Urgencias", "al", "4º", "día", "del", "1er", "ciclo", ",", "por", "cuadro", "de", "24", "horas", "de", "evolución", "consistente", "en", "palpitaciones", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "reposo", ".", "Afebril", "en", "domicilio", ",", "sin", "dolor", "torácico", ",", "ni", "otra", "sintomatología", "acompañante", ".", "\n", "Ante", "hipotensión", "marcada", ",", "precisa", "la", "instauración", "de", "aminas", "en", "Urgencias", "(", "noradrenalina", "y", "dobutamina", ")", "para", "mantener", "la", "tensión", "arterial", ".", "Se", "avisa", "a", "Cardiología", "y", "UCI", "para", "valoración", ",", "realizando", "ecocardiograma", "donde", "se", "evidencia", "disfunción", "biventricular", "grave", ",", "decidiéndose", "ingreso", "en", "UCI", ".", "\n\n", "Exploración", "física", "\n", "Destaca", "mal", "estado", "general", "y", "mala", "perfusión", "periférica", "con", "relleno", "capilar", "lento", ".", "TA", "85/45", "mm", "Hg", ",", "taquicardia", "sinusal", "a", "170", "lpm", ",", "febril", "con", "Tª", "39", "ºC", ",", "SatO2", "94", "%", "con", "gafas", "nasales", "2", "lpm", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "analítica", "realizada", "en", "Urgencias", "existía", "un", "ligero", "aumento", "de", "transaminasas", "(", "GPT", "102", ")", ",", "incremento", "de", "marcadores", "de", "insuficiencia", "cardiaca", "(", "proBNP", "27885", ")", ",", "mínima", "alteración", "de", "enzimas", "cardiacas", "(", "TnTus", "59", ")", ",", "leucocitosis", "con", "neutrofilia", ",", "coagulopatía", "con", "TP", "61", "%", "y", "gasometría", "arterial", "sin", "hallazgos", ".", "En", "el", "electrocardiograma", "se", "muestra", "taquicardia", "sinusal", "a", "180", "lpm", ",", "sin", "signos", "de", "isquemia", "aguda", "ni", "alteraciones", "de", "la", "repolarización", ".", "\n", "En", "cuanto", "a", "los", "estudios", "de", "imagen", ",", "la", "radiografía", "de", "tórax", "mostraba", "derrame", "pleural", "derecho", ".", "Se", "solicita", "una", "angio", "-", "TC", "por", "la", "sospecha", "de", "TEP", "ante", "la", "aparición", "de", "disnea", "súbita", ",", "que", "se", "descarta", ",", "destacando", "en", "dicha", "TC", "derrame", "pleural", "derecho", "junto", "con", "infiltrados", "en", "lóbulo", "superior", "derecho", ",", "medio", "y", "língula", ".", "\n", "Respecto", "al", "ecocardiograma", "de", "Urgencias", ",", "destaca", "FEVI", "estimada", "visualmente", "de", "10", "-", "15", "%", "con", "hipocinesia", "-", "aquinesia", "difusa", ",", "presentando", "cierta", "contractilidad", "únicamente", "en", "segmentos", "basales", ".", "Se", "extrajeron", "hemocultivos", "y", "se", "realizó", "toracocentesis", "derecha", "diagnóstica", "con", "resultado", "de", "líquido", "trasudativo", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", "de", "un", "shock", "cardiogénico", "asociado", "a", "disfunción", "biventricular", "grave", "secundaria", "a", "cardiotoxicidad", "aguda", "en", "probable", "relación", "a", "infusión", "de", "fluorouracilo", ";", "además", "de", "disfunción", "hepática", "secundaria", "a", "congestión", "hepática", "por", "fallo", "de", "ventrículo", "derecho", "más", "bajo", "gasto", "cardiaco", ".", "\n\n", "Tratamiento", "\n", "A", "su", "llegada", "a", "UCI", "se", "procede", "a", "monitorización", ",", "vitamina", "K", "y", "canalización", "ecoguiada", "para", "monitorización", "con", "catéter", "de", "arteria", "pulmonar", ".", "Se", "realiza", "ajuste", "de", "aminas", "vasoactivas", ",", "diuréticos", ",", "sueroterapia", "con", "ajuste", "de", "iones", "y", "antibioterapia", "empírica", "con", "meropenem", "y", "linezolid", ".", "\n\n", "Evolución", "\n", "Mejoría", "hemodinámica", "en", "las", "primeras", "24", "horas", "de", "evolución", "en", "UCI", ",", "con", "soporte", "con", "dobutamina", "y", "noradrenalina", ",", "manteniendo", "buenos", "niveles", "tensionales", "y", "diuresis", "conservada", "con", "balance", "negativo", "diario", ".", "\n", "En", "primera", "eco", "-", "cardio", "de", "control", ",", "función", "sistólica", "global", "ligera", "-", "moderadamente", "deprimida", "FEVI", "40", "%", "con", "hipoquinesia", "generalizada", ".", "En", "analíticas", "de", "UCI", ",", "destaca", "elevación", "de", "enzimas", "hepáticas", ",", "llegando", "a", "un", "pico", "de", "GPT", "de", "4.282", ",", "LDH", "6.041", ",", "TP", "29", "%", "y", "TTPA30", ".", "\n", "Se", "planteó", "la", "posibilidad", "de", "traslado", "a", "otro", "centro", "con", "disponibilidad", "de", "extracorporeal", "membrane", "oxygenation", "(", "ECMO", ")", "como", "sistema", "de", "asistencia", "mecánica", "circulatoria", "de", "corta", "duración", ",", "pero", "finalmente", "se", "desestimó", ".", "\n", "Se", "colocó", "Pleurocath", "®", ",", "por", "presencia", "de", "derrame", "pleural", "en", "estudios", "de", "imagen", ",", "con", "salida", "de", "1", "l", "de", "líquido", "pleural", "seroso", "retirado", "a", "las", "24", "h", "con", "descenso", "de", "taquipnea", "sin", "llegar", "a", "precisar", "ventilación", "mecánica", ".", "\n", "Los", "resultados", "de", "los", "hemocultivos", "fueron", "negativos", ",", "con", "leucocitosis", "en", "descenso", ",", "por", "lo", "que", ",", "tras", "un", "ciclo", "corto", "de", "cobertura", "empírica", "con", "meropenem", "y", "linezolid", ",", "se", "suspenden", ".", "Mejoría", "progresiva", "de", "enzimas", "hepáticas", "(", "GPT", "302", ")", ",", "ausencia", "de", "leucocitosis", "(", "5.980", "con", "49", "%", "neutrófilos", ")", "y", "coagulopatía", "corregida", "(", "INR", ":", "1,1", ";", "TTPA", "32,5", "s", ")", ".", "La", "citología", "de", "líquido", "pleural", "fue", "negativa", "para", "células", "tumorales", "malignas", ".", "\n", "Dada", "la", "estabilidad", "hemodinámica", ",", "se", "traslada", "a", "planta", "de", "Cardiología", "donde", "se", "ajusta", "tratamiento", "con", "IECA", ",", "beta", "-", "bloqueantes", "y", "espironolactona", "con", "buena", "tolerancia", "clínica", ".", "Ecocardiograma", "con", "recuperación", "de", "FEVI", "(", "60", "%", ")", ",", "por", "lo", "que", "se", "procede", "al", "alta", ".", "\n", "Valorada", "de", "nuevo", "en", "consulta", "de", "Oncología", ",", "se", "muestra", "asintomática", "con", "controles", "y", "ajuste", "de", "tratamiento", "por", "Cardiología", ".", "Dada", "la", "toxicidad", "grave", "desarrollada", ",", "con", "shock", "cardiogénico", "tras", "primera", "infusión", "de", "fluorouracilo", ",", "que", "descarta", "su", "utilización", "posterior", ",", "se", "pide", "TC", "de", "reevaluación", "sin", "adenopatías", "macroscópicas", "ni", "otros", "hallazgos", "de", "enfermedad", "activa", ";", "se", "da", "por", "finalizada", "la", "adyuvancia", ",", "y", "pasa", "a", "control", "estrecho", ".", "Está", "pendiente", "de", "los", "resultados", "del", "Consejo", "Genético", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

células tumorales malignas is a MORFOLOGIA_NEOPLASIA

647_task1

Sentence: Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético. Instructions: please typing these entity words according to sentence: células tumorales malignas Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético.

[ "Anamnesis", "\n", "Acude", "a", "Urgencias", "al", "4º", "día", "del", "1er", "ciclo", ",", "por", "cuadro", "de", "24", "horas", "de", "evolución", "consistente", "en", "palpitaciones", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "reposo", ".", "Afebril", "en", "domicilio", ",", "sin", "dolor", "torácico", ",", "ni", "otra", "sintomatología", "acompañante", ".", "\n", "Ante", "hipotensión", "marcada", ",", "precisa", "la", "instauración", "de", "aminas", "en", "Urgencias", "(", "noradrenalina", "y", "dobutamina", ")", "para", "mantener", "la", "tensión", "arterial", ".", "Se", "avisa", "a", "Cardiología", "y", "UCI", "para", "valoración", ",", "realizando", "ecocardiograma", "donde", "se", "evidencia", "disfunción", "biventricular", "grave", ",", "decidiéndose", "ingreso", "en", "UCI", ".", "\n\n", "Exploración", "física", "\n", "Destaca", "mal", "estado", "general", "y", "mala", "perfusión", "periférica", "con", "relleno", "capilar", "lento", ".", "TA", "85/45", "mm", "Hg", ",", "taquicardia", "sinusal", "a", "170", "lpm", ",", "febril", "con", "Tª", "39", "ºC", ",", "SatO2", "94", "%", "con", "gafas", "nasales", "2", "lpm", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "analítica", "realizada", "en", "Urgencias", "existía", "un", "ligero", "aumento", "de", "transaminasas", "(", "GPT", "102", ")", ",", "incremento", "de", "marcadores", "de", "insuficiencia", "cardiaca", "(", "proBNP", "27885", ")", ",", "mínima", "alteración", "de", "enzimas", "cardiacas", "(", "TnTus", "59", ")", ",", "leucocitosis", "con", "neutrofilia", ",", "coagulopatía", "con", "TP", "61", "%", "y", "gasometría", "arterial", "sin", "hallazgos", ".", "En", "el", "electrocardiograma", "se", "muestra", "taquicardia", "sinusal", "a", "180", "lpm", ",", "sin", "signos", "de", "isquemia", "aguda", "ni", "alteraciones", "de", "la", "repolarización", ".", "\n", "En", "cuanto", "a", "los", "estudios", "de", "imagen", ",", "la", "radiografía", "de", "tórax", "mostraba", "derrame", "pleural", "derecho", ".", "Se", "solicita", "una", "angio", "-", "TC", "por", "la", "sospecha", "de", "TEP", "ante", "la", "aparición", "de", "disnea", "súbita", ",", "que", "se", "descarta", ",", "destacando", "en", "dicha", "TC", "derrame", "pleural", "derecho", "junto", "con", "infiltrados", "en", "lóbulo", "superior", "derecho", ",", "medio", "y", "língula", ".", "\n", "Respecto", "al", "ecocardiograma", "de", "Urgencias", ",", "destaca", "FEVI", "estimada", "visualmente", "de", "10", "-", "15", "%", "con", "hipocinesia", "-", "aquinesia", "difusa", ",", "presentando", "cierta", "contractilidad", "únicamente", "en", "segmentos", "basales", ".", "Se", "extrajeron", "hemocultivos", "y", "se", "realizó", "toracocentesis", "derecha", "diagnóstica", "con", "resultado", "de", "líquido", "trasudativo", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", "de", "un", "shock", "cardiogénico", "asociado", "a", "disfunción", "biventricular", "grave", "secundaria", "a", "cardiotoxicidad", "aguda", "en", "probable", "relación", "a", "infusión", "de", "fluorouracilo", ";", "además", "de", "disfunción", "hepática", "secundaria", "a", "congestión", "hepática", "por", "fallo", "de", "ventrículo", "derecho", "más", "bajo", "gasto", "cardiaco", ".", "\n\n", "Tratamiento", "\n", "A", "su", "llegada", "a", "UCI", "se", "procede", "a", "monitorización", ",", "vitamina", "K", "y", "canalización", "ecoguiada", "para", "monitorización", "con", "catéter", "de", "arteria", "pulmonar", ".", "Se", "realiza", "ajuste", "de", "aminas", "vasoactivas", ",", "diuréticos", ",", "sueroterapia", "con", "ajuste", "de", "iones", "y", "antibioterapia", "empírica", "con", "meropenem", "y", "linezolid", ".", "\n\n", "Evolución", "\n", "Mejoría", "hemodinámica", "en", "las", "primeras", "24", "horas", "de", "evolución", "en", "UCI", ",", "con", "soporte", "con", "dobutamina", "y", "noradrenalina", ",", "manteniendo", "buenos", "niveles", "tensionales", "y", "diuresis", "conservada", "con", "balance", "negativo", "diario", ".", "\n", "En", "primera", "eco", "-", "cardio", "de", "control", ",", "función", "sistólica", "global", "ligera", "-", "moderadamente", "deprimida", "FEVI", "40", "%", "con", "hipoquinesia", "generalizada", ".", "En", "analíticas", "de", "UCI", ",", "destaca", "elevación", "de", "enzimas", "hepáticas", ",", "llegando", "a", "un", "pico", "de", "GPT", "de", "4.282", ",", "LDH", "6.041", ",", "TP", "29", "%", "y", "TTPA30", ".", "\n", "Se", "planteó", "la", "posibilidad", "de", "traslado", "a", "otro", "centro", "con", "disponibilidad", "de", "extracorporeal", "membrane", "oxygenation", "(", "ECMO", ")", "como", "sistema", "de", "asistencia", "mecánica", "circulatoria", "de", "corta", "duración", ",", "pero", "finalmente", "se", "desestimó", ".", "\n", "Se", "colocó", "Pleurocath", "®", ",", "por", "presencia", "de", "derrame", "pleural", "en", "estudios", "de", "imagen", ",", "con", "salida", "de", "1", "l", "de", "líquido", "pleural", "seroso", "retirado", "a", "las", "24", "h", "con", "descenso", "de", "taquipnea", "sin", "llegar", "a", "precisar", "ventilación", "mecánica", ".", "\n", "Los", "resultados", "de", "los", "hemocultivos", "fueron", "negativos", ",", "con", "leucocitosis", "en", "descenso", ",", "por", "lo", "que", ",", "tras", "un", "ciclo", "corto", "de", "cobertura", "empírica", "con", "meropenem", "y", "linezolid", ",", "se", "suspenden", ".", "Mejoría", "progresiva", "de", "enzimas", "hepáticas", "(", "GPT", "302", ")", ",", "ausencia", "de", "leucocitosis", "(", "5.980", "con", "49", "%", "neutrófilos", ")", "y", "coagulopatía", "corregida", "(", "INR", ":", "1,1", ";", "TTPA", "32,5", "s", ")", ".", "La", "citología", "de", "líquido", "pleural", "fue", "negativa", "para", "células", "tumorales", "malignas", ".", "\n", "Dada", "la", "estabilidad", "hemodinámica", ",", "se", "traslada", "a", "planta", "de", "Cardiología", "donde", "se", "ajusta", "tratamiento", "con", "IECA", ",", "beta", "-", "bloqueantes", "y", "espironolactona", "con", "buena", "tolerancia", "clínica", ".", "Ecocardiograma", "con", "recuperación", "de", "FEVI", "(", "60", "%", ")", ",", "por", "lo", "que", "se", "procede", "al", "alta", ".", "\n", "Valorada", "de", "nuevo", "en", "consulta", "de", "Oncología", ",", "se", "muestra", "asintomática", "con", "controles", "y", "ajuste", "de", "tratamiento", "por", "Cardiología", ".", "Dada", "la", "toxicidad", "grave", "desarrollada", ",", "con", "shock", "cardiogénico", "tras", "primera", "infusión", "de", "fluorouracilo", ",", "que", "descarta", "su", "utilización", "posterior", ",", "se", "pide", "TC", "de", "reevaluación", "sin", "adenopatías", "macroscópicas", "ni", "otros", "hallazgos", "de", "enfermedad", "activa", ";", "se", "da", "por", "finalizada", "la", "adyuvancia", ",", "y", "pasa", "a", "control", "estrecho", ".", "Está", "pendiente", "de", "los", "resultados", "del", "Consejo", "Genético", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

células tumorales malignas

647_task2

Sentence: Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Acude a Urgencias al 4º día del 1er ciclo, por cuadro de 24 horas de evolución consistente en palpitaciones y disnea progresiva hasta hacerse de reposo. Afebril en domicilio, sin dolor torácico, ni otra sintomatología acompañante. Ante hipotensión marcada, precisa la instauración de aminas en Urgencias (noradrenalina y dobutamina) para mantener la tensión arterial. Se avisa a Cardiología y UCI para valoración, realizando ecocardiograma donde se evidencia disfunción biventricular grave, decidiéndose ingreso en UCI. Exploración física Destaca mal estado general y mala perfusión periférica con relleno capilar lento. TA 85/45 mm Hg, taquicardia sinusal a 170 lpm, febril con Tª 39 ºC, SatO2 94 % con gafas nasales 2 lpm. Pruebas complementarias En la analítica realizada en Urgencias existía un ligero aumento de transaminasas (GPT 102), incremento de marcadores de insuficiencia cardiaca (proBNP 27885), mínima alteración de enzimas cardiacas (TnTus 59), leucocitosis con neutrofilia, coagulopatía con TP 61 % y gasometría arterial sin hallazgos. En el electrocardiograma se muestra taquicardia sinusal a 180 lpm, sin signos de isquemia aguda ni alteraciones de la repolarización. En cuanto a los estudios de imagen, la radiografía de tórax mostraba derrame pleural derecho. Se solicita una angio-TC por la sospecha de TEP ante la aparición de disnea súbita, que se descarta, destacando en dicha TC derrame pleural derecho junto con infiltrados en lóbulo superior derecho, medio y língula. Respecto al ecocardiograma de Urgencias, destaca FEVI estimada visualmente de 10-15 % con hipocinesia-aquinesia difusa, presentando cierta contractilidad únicamente en segmentos basales. Se extrajeron hemocultivos y se realizó toracocentesis derecha diagnóstica con resultado de líquido trasudativo. Diagnóstico Se trata de un shock cardiogénico asociado a disfunción biventricular grave secundaria a cardiotoxicidad aguda en probable relación a infusión de fluorouracilo; además de disfunción hepática secundaria a congestión hepática por fallo de ventrículo derecho más bajo gasto cardiaco. Tratamiento A su llegada a UCI se procede a monitorización, vitamina K y canalización ecoguiada para monitorización con catéter de arteria pulmonar. Se realiza ajuste de aminas vasoactivas, diuréticos, sueroterapia con ajuste de iones y antibioterapia empírica con meropenem y linezolid. Evolución Mejoría hemodinámica en las primeras 24 horas de evolución en UCI, con soporte con dobutamina y noradrenalina, manteniendo buenos niveles tensionales y diuresis conservada con balance negativo diario. En primera eco-cardio de control, función sistólica global ligera-moderadamente deprimida FEVI 40 % con hipoquinesia generalizada. En analíticas de UCI, destaca elevación de enzimas hepáticas, llegando a un pico de GPT de 4.282, LDH 6.041, TP 29 % y TTPA30. Se planteó la posibilidad de traslado a otro centro con disponibilidad de extracorporeal membrane oxygenation (ECMO) como sistema de asistencia mecánica circulatoria de corta duración, pero finalmente se desestimó. Se colocó Pleurocath®, por presencia de derrame pleural en estudios de imagen, con salida de 1 l de líquido pleural seroso retirado a las 24 h con descenso de taquipnea sin llegar a precisar ventilación mecánica. Los resultados de los hemocultivos fueron negativos, con leucocitosis en descenso, por lo que, tras un ciclo corto de cobertura empírica con meropenem y linezolid, se suspenden. Mejoría progresiva de enzimas hepáticas (GPT 302), ausencia de leucocitosis (5.980 con 49 % neutrófilos) y coagulopatía corregida (INR: 1,1; TTPA 32,5 s). La citología de líquido pleural fue negativa para células tumorales malignas. Dada la estabilidad hemodinámica, se traslada a planta de Cardiología donde se ajusta tratamiento con IECA, beta-bloqueantes y espironolactona con buena tolerancia clínica. Ecocardiograma con recuperación de FEVI (60 %), por lo que se procede al alta. Valorada de nuevo en consulta de Oncología, se muestra asintomática con controles y ajuste de tratamiento por Cardiología. Dada la toxicidad grave desarrollada, con shock cardiogénico tras primera infusión de fluorouracilo, que descarta su utilización posterior, se pide TC de reevaluación sin adenopatías macroscópicas ni otros hallazgos de enfermedad activa; se da por finalizada la adyuvancia, y pasa a control estrecho. Está pendiente de los resultados del Consejo Genético.

[ "Anamnesis", "\n", "Acude", "a", "Urgencias", "al", "4º", "día", "del", "1er", "ciclo", ",", "por", "cuadro", "de", "24", "horas", "de", "evolución", "consistente", "en", "palpitaciones", "y", "disnea", "progresiva", "hasta", "hacerse", "de", "reposo", ".", "Afebril", "en", "domicilio", ",", "sin", "dolor", "torácico", ",", "ni", "otra", "sintomatología", "acompañante", ".", "\n", "Ante", "hipotensión", "marcada", ",", "precisa", "la", "instauración", "de", "aminas", "en", "Urgencias", "(", "noradrenalina", "y", "dobutamina", ")", "para", "mantener", "la", "tensión", "arterial", ".", "Se", "avisa", "a", "Cardiología", "y", "UCI", "para", "valoración", ",", "realizando", "ecocardiograma", "donde", "se", "evidencia", "disfunción", "biventricular", "grave", ",", "decidiéndose", "ingreso", "en", "UCI", ".", "\n\n", "Exploración", "física", "\n", "Destaca", "mal", "estado", "general", "y", "mala", "perfusión", "periférica", "con", "relleno", "capilar", "lento", ".", "TA", "85/45", "mm", "Hg", ",", "taquicardia", "sinusal", "a", "170", "lpm", ",", "febril", "con", "Tª", "39", "ºC", ",", "SatO2", "94", "%", "con", "gafas", "nasales", "2", "lpm", ".", "\n\n", "Pruebas", "complementarias", "\n", "En", "la", "analítica", "realizada", "en", "Urgencias", "existía", "un", "ligero", "aumento", "de", "transaminasas", "(", "GPT", "102", ")", ",", "incremento", "de", "marcadores", "de", "insuficiencia", "cardiaca", "(", "proBNP", "27885", ")", ",", "mínima", "alteración", "de", "enzimas", "cardiacas", "(", "TnTus", "59", ")", ",", "leucocitosis", "con", "neutrofilia", ",", "coagulopatía", "con", "TP", "61", "%", "y", "gasometría", "arterial", "sin", "hallazgos", ".", "En", "el", "electrocardiograma", "se", "muestra", "taquicardia", "sinusal", "a", "180", "lpm", ",", "sin", "signos", "de", "isquemia", "aguda", "ni", "alteraciones", "de", "la", "repolarización", ".", "\n", "En", "cuanto", "a", "los", "estudios", "de", "imagen", ",", "la", "radiografía", "de", "tórax", "mostraba", "derrame", "pleural", "derecho", ".", "Se", "solicita", "una", "angio", "-", "TC", "por", "la", "sospecha", "de", "TEP", "ante", "la", "aparición", "de", "disnea", "súbita", ",", "que", "se", "descarta", ",", "destacando", "en", "dicha", "TC", "derrame", "pleural", "derecho", "junto", "con", "infiltrados", "en", "lóbulo", "superior", "derecho", ",", "medio", "y", "língula", ".", "\n", "Respecto", "al", "ecocardiograma", "de", "Urgencias", ",", "destaca", "FEVI", "estimada", "visualmente", "de", "10", "-", "15", "%", "con", "hipocinesia", "-", "aquinesia", "difusa", ",", "presentando", "cierta", "contractilidad", "únicamente", "en", "segmentos", "basales", ".", "Se", "extrajeron", "hemocultivos", "y", "se", "realizó", "toracocentesis", "derecha", "diagnóstica", "con", "resultado", "de", "líquido", "trasudativo", ".", "\n\n", "Diagnóstico", "\n", "Se", "trata", "de", "un", "shock", "cardiogénico", "asociado", "a", "disfunción", "biventricular", "grave", "secundaria", "a", "cardiotoxicidad", "aguda", "en", "probable", "relación", "a", "infusión", "de", "fluorouracilo", ";", "además", "de", "disfunción", "hepática", "secundaria", "a", "congestión", "hepática", "por", "fallo", "de", "ventrículo", "derecho", "más", "bajo", "gasto", "cardiaco", ".", "\n\n", "Tratamiento", "\n", "A", "su", "llegada", "a", "UCI", "se", "procede", "a", "monitorización", ",", "vitamina", "K", "y", "canalización", "ecoguiada", "para", "monitorización", "con", "catéter", "de", "arteria", "pulmonar", ".", "Se", "realiza", "ajuste", "de", "aminas", "vasoactivas", ",", "diuréticos", ",", "sueroterapia", "con", "ajuste", "de", "iones", "y", "antibioterapia", "empírica", "con", "meropenem", "y", "linezolid", ".", "\n\n", "Evolución", "\n", "Mejoría", "hemodinámica", "en", "las", "primeras", "24", "horas", "de", "evolución", "en", "UCI", ",", "con", "soporte", "con", "dobutamina", "y", "noradrenalina", ",", "manteniendo", "buenos", "niveles", "tensionales", "y", "diuresis", "conservada", "con", "balance", "negativo", "diario", ".", "\n", "En", "primera", "eco", "-", "cardio", "de", "control", ",", "función", "sistólica", "global", "ligera", "-", "moderadamente", "deprimida", "FEVI", "40", "%", "con", "hipoquinesia", "generalizada", ".", "En", "analíticas", "de", "UCI", ",", "destaca", "elevación", "de", "enzimas", "hepáticas", ",", "llegando", "a", "un", "pico", "de", "GPT", "de", "4.282", ",", "LDH", "6.041", ",", "TP", "29", "%", "y", "TTPA30", ".", "\n", "Se", "planteó", "la", "posibilidad", "de", "traslado", "a", "otro", "centro", "con", "disponibilidad", "de", "extracorporeal", "membrane", "oxygenation", "(", "ECMO", ")", "como", "sistema", "de", "asistencia", "mecánica", "circulatoria", "de", "corta", "duración", ",", "pero", "finalmente", "se", "desestimó", ".", "\n", "Se", "colocó", "Pleurocath", "®", ",", "por", "presencia", "de", "derrame", "pleural", "en", "estudios", "de", "imagen", ",", "con", "salida", "de", "1", "l", "de", "líquido", "pleural", "seroso", "retirado", "a", "las", "24", "h", "con", "descenso", "de", "taquipnea", "sin", "llegar", "a", "precisar", "ventilación", "mecánica", ".", "\n", "Los", "resultados", "de", "los", "hemocultivos", "fueron", "negativos", ",", "con", "leucocitosis", "en", "descenso", ",", "por", "lo", "que", ",", "tras", "un", "ciclo", "corto", "de", "cobertura", "empírica", "con", "meropenem", "y", "linezolid", ",", "se", "suspenden", ".", "Mejoría", "progresiva", "de", "enzimas", "hepáticas", "(", "GPT", "302", ")", ",", "ausencia", "de", "leucocitosis", "(", "5.980", "con", "49", "%", "neutrófilos", ")", "y", "coagulopatía", "corregida", "(", "INR", ":", "1,1", ";", "TTPA", "32,5", "s", ")", ".", "La", "citología", "de", "líquido", "pleural", "fue", "negativa", "para", "células", "tumorales", "malignas", ".", "\n", "Dada", "la", "estabilidad", "hemodinámica", ",", "se", "traslada", "a", "planta", "de", "Cardiología", "donde", "se", "ajusta", "tratamiento", "con", "IECA", ",", "beta", "-", "bloqueantes", "y", "espironolactona", "con", "buena", "tolerancia", "clínica", ".", "Ecocardiograma", "con", "recuperación", "de", "FEVI", "(", "60", "%", ")", ",", "por", "lo", "que", "se", "procede", "al", "alta", ".", "\n", "Valorada", "de", "nuevo", "en", "consulta", "de", "Oncología", ",", "se", "muestra", "asintomática", "con", "controles", "y", "ajuste", "de", "tratamiento", "por", "Cardiología", ".", "Dada", "la", "toxicidad", "grave", "desarrollada", ",", "con", "shock", "cardiogénico", "tras", "primera", "infusión", "de", "fluorouracilo", ",", "que", "descarta", "su", "utilización", "posterior", ",", "se", "pide", "TC", "de", "reevaluación", "sin", "adenopatías", "macroscópicas", "ni", "otros", "hallazgos", "de", "enfermedad", "activa", ";", "se", "da", "por", "finalizada", "la", "adyuvancia", ",", "y", "pasa", "a", "control", "estrecho", ".", "Está", "pendiente", "de", "los", "resultados", "del", "Consejo", "Genético", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

F is a Person, age is a Person, 18 to 70 is a Value, American Society of Anesthesiologists ( ASA ) is a Measurement, I e II is a Value, breast cancer is a Condition, DIN 2 e 3 , o LIN 2 e 3 sec . Tavassoli is a Scope, scheduled for is a Mood, nipple - sparing mastectomy is a Condition, simple mastectomy is a Condition, skin - sparing mastectomy is a Condition, skin - reducing mastectomy is a Condition, lymphnode biopsy is a Condition, axillary dissection is a Condition, immediate is a Qualifier, sub - pectoral prosthetic reconstruction is a Procedure

NCT02035904_inc_task0

Sentence: F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Condition, Qualifier, Value, Person, Procedure, Scope, Measurement, Mood

[ "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O" ]

F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent.

[ "F", ";", "age", "18", "to", "70", "\n", "American", "Society", "of", "Anesthesiologists", "(", "ASA", ")", "I", "e", "II", ";", "\n", "breast", "cancer", "(", "DIN", "2", "e", "3", ",", "o", "LIN", "2", "e", "3", "sec", ".", "Tavassoli", ")", "scheduled", "for", "nipple", "-", "sparing", "mastectomy", ",", "simple", "mastectomy", ",", "skin", "-", "sparing", "mastectomy", ",", "skin", "-", "reducing", "mastectomy", "c", ",", "lymphnode", "biopsy", "and", "axillary", "dissection", ";", "\n", "immediate", "sub", "-", "pectoral", "prosthetic", "reconstruction", ";", "\n", "signed", "informed", "consent", ".", "\n" ]

[ "Measurement", "Procedure", "Scope", "Condition", "Mood", "Value", "Qualifier", "Person" ]

F is a Person, age is a Person, 18 to 70 is a Value, American Society of Anesthesiologists ( ASA ) is a Measurement, I e II is a Value, breast cancer is a Condition, DIN 2 e 3 , o LIN 2 e 3 sec . Tavassoli is a Scope, scheduled for is a Mood, nipple - sparing mastectomy is a Condition, simple mastectomy is a Condition, skin - sparing mastectomy is a Condition, skin - reducing mastectomy is a Condition, lymphnode biopsy is a Condition, axillary dissection is a Condition, immediate is a Qualifier, sub - pectoral prosthetic reconstruction is a Procedure

NCT02035904_inc_task1

Sentence: F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent. Instructions: please typing these entity words according to sentence: F, age, 18 to 70, American Society of Anesthesiologists ( ASA ), I e II, breast cancer, DIN 2 e 3 , o LIN 2 e 3 sec . Tavassoli, scheduled for, nipple - sparing mastectomy, simple mastectomy, skin - sparing mastectomy, skin - reducing mastectomy, lymphnode biopsy, axillary dissection, immediate, sub - pectoral prosthetic reconstruction Options: Condition, Qualifier, Value, Person, Procedure, Scope, Measurement, Mood

[ "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O" ]

F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent.

[ "F", ";", "age", "18", "to", "70", "\n", "American", "Society", "of", "Anesthesiologists", "(", "ASA", ")", "I", "e", "II", ";", "\n", "breast", "cancer", "(", "DIN", "2", "e", "3", ",", "o", "LIN", "2", "e", "3", "sec", ".", "Tavassoli", ")", "scheduled", "for", "nipple", "-", "sparing", "mastectomy", ",", "simple", "mastectomy", ",", "skin", "-", "sparing", "mastectomy", ",", "skin", "-", "reducing", "mastectomy", "c", ",", "lymphnode", "biopsy", "and", "axillary", "dissection", ";", "\n", "immediate", "sub", "-", "pectoral", "prosthetic", "reconstruction", ";", "\n", "signed", "informed", "consent", ".", "\n" ]

[ "Measurement", "Procedure", "Scope", "Condition", "Mood", "Value", "Qualifier", "Person" ]

F, age, 18 to 70, American Society of Anesthesiologists ( ASA ), I e II, breast cancer, DIN 2 e 3 , o LIN 2 e 3 sec . Tavassoli, scheduled for, nipple - sparing mastectomy, simple mastectomy, skin - sparing mastectomy, skin - reducing mastectomy, lymphnode biopsy, axillary dissection, immediate, sub - pectoral prosthetic reconstruction

NCT02035904_inc_task2

Sentence: F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent. Instructions: please extract entity words from the input sentence

[ "B-Person", "O", "B-Person", "B-Value", "I-Value", "I-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "O", "O", "B-Condition", "I-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Mood", "I-Mood", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Qualifier", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O" ]

F; age 18 to 70 American Society of Anesthesiologists (ASA) I e II; breast cancer ( DIN 2 e 3, o LIN 2 e 3 sec. Tavassoli) scheduled for nipple-sparing mastectomy, simple mastectomy, skin-sparing mastectomy, skin-reducing mastectomy c, lymphnode biopsy and axillary dissection; immediate sub-pectoral prosthetic reconstruction; signed informed consent.

[ "F", ";", "age", "18", "to", "70", "\n", "American", "Society", "of", "Anesthesiologists", "(", "ASA", ")", "I", "e", "II", ";", "\n", "breast", "cancer", "(", "DIN", "2", "e", "3", ",", "o", "LIN", "2", "e", "3", "sec", ".", "Tavassoli", ")", "scheduled", "for", "nipple", "-", "sparing", "mastectomy", ",", "simple", "mastectomy", ",", "skin", "-", "sparing", "mastectomy", ",", "skin", "-", "reducing", "mastectomy", "c", ",", "lymphnode", "biopsy", "and", "axillary", "dissection", ";", "\n", "immediate", "sub", "-", "pectoral", "prosthetic", "reconstruction", ";", "\n", "signed", "informed", "consent", ".", "\n" ]

[ "Measurement", "Procedure", "Scope", "Condition", "Mood", "Value", "Qualifier", "Person" ]

YE1998 is a Protein, 2000 is a Protein, Plu0634 is a Protein, Plu0635 is a Protein, P. luminescens is a Organism, plu1330 is a Protein, 1369 is a Protein, plu3217 is a Protein, plu3324 is a Protein, plu4117 is a Protein, plu3668 is a Protein, Y. enterocolitica is a Organism, YE1322 is a Protein, P. luminescens is a Organism, Plu3209 is a Protein, X. nematophila is a Organism, Plu2288 is a Protein, Plu0359 is a Protein, YE2685 is a Protein, Y. enterocolitica is a Organism, YE2091 is a Protein, P. luminescens ssp . akhurstii strain W14 is a Organism, P. luminescens ssp . laumondii strain TT01 is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, Txp40 is a Protein, Xnp2 is a Protein, X. bovienii is a Organism, galA is a Protein, plu0840 is a Protein, Aeromonas hydrophila is a Organism, plu2400 is a Protein, plu2420 is a Protein, cipA is a Protein, cipB is a Protein, P. luminescens is a Organism, plu1537 is a Protein, Y. enterocolitica is a Organism, Pnf is a Protein, P. luminescens ssp . akhurstii strain W14 is a Organism, P. luminescens ssp . laumondii strain TT01 is a Organism, P. luminescens is a Organism, plu4092 is a Protein, plu4436 is a Protein, P. luminescens is a Organism, M. sexta is a Organism, mcf2 is a Protein, plu3128 is a Protein, Y. enterocolitica is a Organism, P. luminescens is a Organism, tobacco hornworm is a Organism, Y. enterocolitica is a Organism, Y. pestis is a Organism, YPO0339 is a Protein, Y. enterocolitica is a Organism, P. luminescens is a Organism, SopB is a Protein, human is a Organism, P. asymbiotica is a Organism, P. luminescens is a Organism, YE2447 is a Protein, SrfA is a Protein, PhoP is a Protein, S. typhimurium is a Organism, SrfA is a Protein, P. luminescens is a Organism, YE1604 is a Protein, 1606 is a Protein, ProP is a Protein, YE3594 is a Protein, YE4072 is a Protein, 4078 is a Protein, YE3228 is a Protein, 3235 is a Protein, AHL is a Chemical, ADP is a Chemical, ye2124 is a Protein, ye2123 is a Protein, Yersinia is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, Y. enterocolitica is a Organism

21_task0

Sentence: Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Organism, Chemical, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5.

[ "Repeats", "-", "in", "-", "toxin", "(", "RTX", ")", "and", "other", "toxins", "\n", "RTX", "proteins", "constitute", "another", "family", "of", "toxins", "that", "may", "contribute", "to", "the", "insecticidal", "activity", "of", "the", "two", "pathogens", ".", "A", "putative", "RTX", "-", "family", "toxin", "transporter", "is", "common", "to", "both", "pathogens", "(", "YE1998", "-", "2000", ",", "Plu0634", "/", "Plu0635", ")", ".", "The", "P.", "luminescens", "genome", "comprises", "a", "gene", "cluster", "encoding", "RTX", "proteins", ",", "namely", "plu1330", "-", "1369", ".", "Further", "RTX", "toxins", "are", "encoded", "by", "plu3217", ",", "plu3324", "(", "both", "RTX", "A", "-", "family", ")", ",", "plu4117", "(", "own", "family", ")", ",", "and", "plu3668", "(", "RTX", "cytotoxin", ")", ",", "none", "of", "which", "is", "present", "in", "Y.", "enterocolitica", ".", "This", "pathogen", "produces", "only", "one", "RTX", "protein", "(", "YE1322", ")", "for", "which", "a", "truncated", "homologue", "is", "found", "in", "P.", "luminescens", "(", "Plu3209", ")", ".", "Other", "examples", "of", "toxins", "common", "for", "both", "bacterial", "species", "compared", "here", "are", "homologues", "of", "XaxAB", ",", "an", "apoptotic", "AB", "toxin", "of", "X.", "nematophila", "[", "68", "]", ",", "and", "proteins", "encoded", "by", "the", "macrophage", "toxin", "(", "mt)-like", "genes", "Plu2288", "and", "Plu0359", "with", "high", "similarity", "to", "YE2685", ".", "cnf", "encoding", "the", "cytonecrosis", "factor", "-", "like", "toxin", "is", "present", "in", "Y.", "enterocolitica", "(", "YE2091", ")", "and", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", "(", "Fig", ".", "4", ")", ".", "P.", "luminescens", "produces", "a", "series", "of", "proteins", "similar", "to", "toxins", "that", "have", "been", "identified", "in", "other", "bacteria", ",", "but", "are", "absent", "in", "Y.", "enterocolitica", ".", "Examples", "identified", "are", "Txp40", ",", "a", "40", "kD", "insecticidal", "toxin", "[", "69", "]", ",", "the", "nematicidal", "toxin", "(", "Xnp2", ")", "first", "described", "in", "X.", "bovienii", "(", "accession", "number", "AJ296651.1", ")", ",", "galA", "(", "plu0840", ")", "similar", "to", "the", "enterotoxin", "Ast", "of", "Aeromonas", "hydrophila", "which", "is", "involved", "in", "carbohydrate", "transport", "and", "metabolism", "[", "70", "]", ",", "and", "two", "dermonecrotizing", "toxin-(dnt-", ")", "like", "factors", "(", "plu2400", "and", "plu2420", ")", ".", "In", "addition", ",", "neither", "the", "crystal", "proteins", "encoded", "by", "cipA", "and", "cipB", "in", "P.", "luminescens", "nor", "a", "Bt", "-", "like", "toxin", "(", "plu1537", ")", "could", "be", "found", "in", "Y.", "enterocolitica", ".", "A", "cytonecrosis", "factor", "(", "CNF)-like", "protein", ",", "Pnf", ",", "was", "identified", "in", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", ".", "In", "P.", "luminescens", ",", "the", "two", "paralogs", "plu4092", "and", "plu4436", "encode", "juvenile", "hormone", "esterases", "(", "JHE", ")", "for", "which", "insect", "toxicity", "has", "already", "been", "demonstrated", "[", "24", "]", ".", "Additionally", ",", "neither", "the", "locus", "mcf", "that", "confers", "insecticidal", "activity", "of", "P.", "luminescens", "towards", "M.", "sexta", "[", "71", "]", "by", "inducing", "apoptosis", "[", "72", "]", ",", "nor", "the", "homologous", "gene", "locus", "mcf2", "(", "plu3128", ")", "[", "73", "]", "are", "present", "in", "the", "genome", "of", "Y.", "enterocolitica", ".", "Most", "of", "these", "toxins", "probably", "contribute", "to", "the", "higher", "insect", "toxicity", "of", "P.", "luminescens", "against", "the", "tobacco", "hornworm", "in", "comparison", "with", "Y.", "enterocolitica", ".", "No", "homologues", "of", "the", "Y.", "pestis", "gene", "coding", "for", "enhancin", "(", "YPO0339", ")", "could", "be", "found", "for", "which", "a", "role", "in", "flea", "colonization", "was", "predicted", "[", "74", "]", ".", "We", "also", "identified", "several", "virulence", "genes", "and", "operons", "that", "are", "present", "in", "Y.", "enterocolitica", ",", "but", "not", "in", "P.", "luminescens", ",", "suggesting", "that", "they", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", "from", "other", "bacteria", "and", "do", "not", "play", "a", "role", "in", "bacteria", "-", "insect", "association", ".", "Examples", "are", "SopB", ",", "a", "host", "cell", "invasion", "factor", "translocated", "via", "the", "type", "-", "III", "secretion", "system", "that", "is", "present", "in", "the", "emerging", "human", "pathogen", "P.", "asymbiotica", ",", "but", "not", "in", "the", "insect", "pathogen", "P.", "luminescens", "[", "14", "]", ",", "a", "putative", "effector", "protein", "(", "YE2447", ")", "with", "proteolytic", "activity", ",", "and", "a", "homologue", "of", "SrfA", "which", "is", "negatively", "regulated", "by", "PhoP", "in", "S.", "typhimurium", "[", "75", "]", ".", "The", "SrfA", "homologue", "has", "been", "demonstrated", "to", "be", "up", "-", "regulated", "by", "environmental", "temperature", "[", "67", "]", ".", "Other", "virulence", "factors", "absent", "in", "P.", "luminescens", "are", "the", "opg", "cluster", "(", "YE1604", "-", "1606", ")", "and", "ProP", "(", "YE3594", ")", ",", "both", "involved", "in", "osmoprotection", "[", "76", "]", ",", "cellulose", "biosynthesis", "(", "YE4072", "-", "4078", ")", "associated", "with", "protection", "from", "chemical", "and", "mechanical", "stress", "[", "60", "]", ",", "the", "methionine", "-", "salvage", "pathway", "(", "YE3228", "-", "3235", ")", "also", "involved", "in", "AHL", "production", "[", "23", "]", ",", "the", "putative", "ADP", "-", "ribosyltransferase", "toxin", "encoded", "by", "ytxAB", "(", "ye2124", "/", "ye2123", ")", "[", "77", "]", ",", "and", "the", "Yersinia", "heat", "-", "stable", "toxin", "Yst", "[", "78", "]", "which", "is", "stronger", "expressed", "at", "28degreesC", "than", "at", "37degreesC", "(", "Table", "1", ")", ".", "Summarizing", ",", "the", "large", "variety", "of", "diverse", "toxins", "present", "in", "P.", "luminescens", ",", "but", "absent", "in", "Y.", "enterocolitica", ",", "might", "contribute", "to", "the", "higher", "toxicity", "towards", "insects", "of", "P.", "luminescens", "in", "comparison", "to", "Y.", "enterocolitica", ".", "Toxins", "only", "present", "in", "Y.", "enterocolitica", "are", "assumed", "to", "play", "a", "major", "role", "in", "its", "pathogenicity", "towards", "mammalians", ",", "and", "some", "of", "them", "might", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", ".", "Examples", "of", "those", "factors", "are", "shown", "in", "Fig", ".", "5", ".", "\n" ]

[ "Organism", "Protein", "Chemical" ]

YE1998 is a Protein, 2000 is a Protein, Plu0634 is a Protein, Plu0635 is a Protein, P. luminescens is a Organism, plu1330 is a Protein, 1369 is a Protein, plu3217 is a Protein, plu3324 is a Protein, plu4117 is a Protein, plu3668 is a Protein, Y. enterocolitica is a Organism, YE1322 is a Protein, P. luminescens is a Organism, Plu3209 is a Protein, X. nematophila is a Organism, Plu2288 is a Protein, Plu0359 is a Protein, YE2685 is a Protein, Y. enterocolitica is a Organism, YE2091 is a Protein, P. luminescens ssp . akhurstii strain W14 is a Organism, P. luminescens ssp . laumondii strain TT01 is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, Txp40 is a Protein, Xnp2 is a Protein, X. bovienii is a Organism, galA is a Protein, plu0840 is a Protein, Aeromonas hydrophila is a Organism, plu2400 is a Protein, plu2420 is a Protein, cipA is a Protein, cipB is a Protein, P. luminescens is a Organism, plu1537 is a Protein, Y. enterocolitica is a Organism, Pnf is a Protein, P. luminescens ssp . akhurstii strain W14 is a Organism, P. luminescens ssp . laumondii strain TT01 is a Organism, P. luminescens is a Organism, plu4092 is a Protein, plu4436 is a Protein, P. luminescens is a Organism, M. sexta is a Organism, mcf2 is a Protein, plu3128 is a Protein, Y. enterocolitica is a Organism, P. luminescens is a Organism, tobacco hornworm is a Organism, Y. enterocolitica is a Organism, Y. pestis is a Organism, YPO0339 is a Protein, Y. enterocolitica is a Organism, P. luminescens is a Organism, SopB is a Protein, human is a Organism, P. asymbiotica is a Organism, P. luminescens is a Organism, YE2447 is a Protein, SrfA is a Protein, PhoP is a Protein, S. typhimurium is a Organism, SrfA is a Protein, P. luminescens is a Organism, YE1604 is a Protein, 1606 is a Protein, ProP is a Protein, YE3594 is a Protein, YE4072 is a Protein, 4078 is a Protein, YE3228 is a Protein, 3235 is a Protein, AHL is a Chemical, ADP is a Chemical, ye2124 is a Protein, ye2123 is a Protein, Yersinia is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, P. luminescens is a Organism, Y. enterocolitica is a Organism, Y. enterocolitica is a Organism

21_task1

Sentence: Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5. Instructions: please typing these entity words according to sentence: YE1998, 2000, Plu0634, Plu0635, P. luminescens, plu1330, 1369, plu3217, plu3324, plu4117, plu3668, Y. enterocolitica, YE1322, P. luminescens, Plu3209, X. nematophila, Plu2288, Plu0359, YE2685, Y. enterocolitica, YE2091, P. luminescens ssp . akhurstii strain W14, P. luminescens ssp . laumondii strain TT01, P. luminescens, Y. enterocolitica, Txp40, Xnp2, X. bovienii, galA, plu0840, Aeromonas hydrophila, plu2400, plu2420, cipA, cipB, P. luminescens, plu1537, Y. enterocolitica, Pnf, P. luminescens ssp . akhurstii strain W14, P. luminescens ssp . laumondii strain TT01, P. luminescens, plu4092, plu4436, P. luminescens, M. sexta, mcf2, plu3128, Y. enterocolitica, P. luminescens, tobacco hornworm, Y. enterocolitica, Y. pestis, YPO0339, Y. enterocolitica, P. luminescens, SopB, human, P. asymbiotica, P. luminescens, YE2447, SrfA, PhoP, S. typhimurium, SrfA, P. luminescens, YE1604, 1606, ProP, YE3594, YE4072, 4078, YE3228, 3235, AHL, ADP, ye2124, ye2123, Yersinia, P. luminescens, Y. enterocolitica, P. luminescens, Y. enterocolitica, Y. enterocolitica Options: Organism, Chemical, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5.

[ "Repeats", "-", "in", "-", "toxin", "(", "RTX", ")", "and", "other", "toxins", "\n", "RTX", "proteins", "constitute", "another", "family", "of", "toxins", "that", "may", "contribute", "to", "the", "insecticidal", "activity", "of", "the", "two", "pathogens", ".", "A", "putative", "RTX", "-", "family", "toxin", "transporter", "is", "common", "to", "both", "pathogens", "(", "YE1998", "-", "2000", ",", "Plu0634", "/", "Plu0635", ")", ".", "The", "P.", "luminescens", "genome", "comprises", "a", "gene", "cluster", "encoding", "RTX", "proteins", ",", "namely", "plu1330", "-", "1369", ".", "Further", "RTX", "toxins", "are", "encoded", "by", "plu3217", ",", "plu3324", "(", "both", "RTX", "A", "-", "family", ")", ",", "plu4117", "(", "own", "family", ")", ",", "and", "plu3668", "(", "RTX", "cytotoxin", ")", ",", "none", "of", "which", "is", "present", "in", "Y.", "enterocolitica", ".", "This", "pathogen", "produces", "only", "one", "RTX", "protein", "(", "YE1322", ")", "for", "which", "a", "truncated", "homologue", "is", "found", "in", "P.", "luminescens", "(", "Plu3209", ")", ".", "Other", "examples", "of", "toxins", "common", "for", "both", "bacterial", "species", "compared", "here", "are", "homologues", "of", "XaxAB", ",", "an", "apoptotic", "AB", "toxin", "of", "X.", "nematophila", "[", "68", "]", ",", "and", "proteins", "encoded", "by", "the", "macrophage", "toxin", "(", "mt)-like", "genes", "Plu2288", "and", "Plu0359", "with", "high", "similarity", "to", "YE2685", ".", "cnf", "encoding", "the", "cytonecrosis", "factor", "-", "like", "toxin", "is", "present", "in", "Y.", "enterocolitica", "(", "YE2091", ")", "and", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", "(", "Fig", ".", "4", ")", ".", "P.", "luminescens", "produces", "a", "series", "of", "proteins", "similar", "to", "toxins", "that", "have", "been", "identified", "in", "other", "bacteria", ",", "but", "are", "absent", "in", "Y.", "enterocolitica", ".", "Examples", "identified", "are", "Txp40", ",", "a", "40", "kD", "insecticidal", "toxin", "[", "69", "]", ",", "the", "nematicidal", "toxin", "(", "Xnp2", ")", "first", "described", "in", "X.", "bovienii", "(", "accession", "number", "AJ296651.1", ")", ",", "galA", "(", "plu0840", ")", "similar", "to", "the", "enterotoxin", "Ast", "of", "Aeromonas", "hydrophila", "which", "is", "involved", "in", "carbohydrate", "transport", "and", "metabolism", "[", "70", "]", ",", "and", "two", "dermonecrotizing", "toxin-(dnt-", ")", "like", "factors", "(", "plu2400", "and", "plu2420", ")", ".", "In", "addition", ",", "neither", "the", "crystal", "proteins", "encoded", "by", "cipA", "and", "cipB", "in", "P.", "luminescens", "nor", "a", "Bt", "-", "like", "toxin", "(", "plu1537", ")", "could", "be", "found", "in", "Y.", "enterocolitica", ".", "A", "cytonecrosis", "factor", "(", "CNF)-like", "protein", ",", "Pnf", ",", "was", "identified", "in", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", ".", "In", "P.", "luminescens", ",", "the", "two", "paralogs", "plu4092", "and", "plu4436", "encode", "juvenile", "hormone", "esterases", "(", "JHE", ")", "for", "which", "insect", "toxicity", "has", "already", "been", "demonstrated", "[", "24", "]", ".", "Additionally", ",", "neither", "the", "locus", "mcf", "that", "confers", "insecticidal", "activity", "of", "P.", "luminescens", "towards", "M.", "sexta", "[", "71", "]", "by", "inducing", "apoptosis", "[", "72", "]", ",", "nor", "the", "homologous", "gene", "locus", "mcf2", "(", "plu3128", ")", "[", "73", "]", "are", "present", "in", "the", "genome", "of", "Y.", "enterocolitica", ".", "Most", "of", "these", "toxins", "probably", "contribute", "to", "the", "higher", "insect", "toxicity", "of", "P.", "luminescens", "against", "the", "tobacco", "hornworm", "in", "comparison", "with", "Y.", "enterocolitica", ".", "No", "homologues", "of", "the", "Y.", "pestis", "gene", "coding", "for", "enhancin", "(", "YPO0339", ")", "could", "be", "found", "for", "which", "a", "role", "in", "flea", "colonization", "was", "predicted", "[", "74", "]", ".", "We", "also", "identified", "several", "virulence", "genes", "and", "operons", "that", "are", "present", "in", "Y.", "enterocolitica", ",", "but", "not", "in", "P.", "luminescens", ",", "suggesting", "that", "they", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", "from", "other", "bacteria", "and", "do", "not", "play", "a", "role", "in", "bacteria", "-", "insect", "association", ".", "Examples", "are", "SopB", ",", "a", "host", "cell", "invasion", "factor", "translocated", "via", "the", "type", "-", "III", "secretion", "system", "that", "is", "present", "in", "the", "emerging", "human", "pathogen", "P.", "asymbiotica", ",", "but", "not", "in", "the", "insect", "pathogen", "P.", "luminescens", "[", "14", "]", ",", "a", "putative", "effector", "protein", "(", "YE2447", ")", "with", "proteolytic", "activity", ",", "and", "a", "homologue", "of", "SrfA", "which", "is", "negatively", "regulated", "by", "PhoP", "in", "S.", "typhimurium", "[", "75", "]", ".", "The", "SrfA", "homologue", "has", "been", "demonstrated", "to", "be", "up", "-", "regulated", "by", "environmental", "temperature", "[", "67", "]", ".", "Other", "virulence", "factors", "absent", "in", "P.", "luminescens", "are", "the", "opg", "cluster", "(", "YE1604", "-", "1606", ")", "and", "ProP", "(", "YE3594", ")", ",", "both", "involved", "in", "osmoprotection", "[", "76", "]", ",", "cellulose", "biosynthesis", "(", "YE4072", "-", "4078", ")", "associated", "with", "protection", "from", "chemical", "and", "mechanical", "stress", "[", "60", "]", ",", "the", "methionine", "-", "salvage", "pathway", "(", "YE3228", "-", "3235", ")", "also", "involved", "in", "AHL", "production", "[", "23", "]", ",", "the", "putative", "ADP", "-", "ribosyltransferase", "toxin", "encoded", "by", "ytxAB", "(", "ye2124", "/", "ye2123", ")", "[", "77", "]", ",", "and", "the", "Yersinia", "heat", "-", "stable", "toxin", "Yst", "[", "78", "]", "which", "is", "stronger", "expressed", "at", "28degreesC", "than", "at", "37degreesC", "(", "Table", "1", ")", ".", "Summarizing", ",", "the", "large", "variety", "of", "diverse", "toxins", "present", "in", "P.", "luminescens", ",", "but", "absent", "in", "Y.", "enterocolitica", ",", "might", "contribute", "to", "the", "higher", "toxicity", "towards", "insects", "of", "P.", "luminescens", "in", "comparison", "to", "Y.", "enterocolitica", ".", "Toxins", "only", "present", "in", "Y.", "enterocolitica", "are", "assumed", "to", "play", "a", "major", "role", "in", "its", "pathogenicity", "towards", "mammalians", ",", "and", "some", "of", "them", "might", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", ".", "Examples", "of", "those", "factors", "are", "shown", "in", "Fig", ".", "5", ".", "\n" ]

[ "Organism", "Protein", "Chemical" ]

YE1998, 2000, Plu0634, Plu0635, P. luminescens, plu1330, 1369, plu3217, plu3324, plu4117, plu3668, Y. enterocolitica, YE1322, P. luminescens, Plu3209, X. nematophila, Plu2288, Plu0359, YE2685, Y. enterocolitica, YE2091, P. luminescens ssp . akhurstii strain W14, P. luminescens ssp . laumondii strain TT01, P. luminescens, Y. enterocolitica, Txp40, Xnp2, X. bovienii, galA, plu0840, Aeromonas hydrophila, plu2400, plu2420, cipA, cipB, P. luminescens, plu1537, Y. enterocolitica, Pnf, P. luminescens ssp . akhurstii strain W14, P. luminescens ssp . laumondii strain TT01, P. luminescens, plu4092, plu4436, P. luminescens, M. sexta, mcf2, plu3128, Y. enterocolitica, P. luminescens, tobacco hornworm, Y. enterocolitica, Y. pestis, YPO0339, Y. enterocolitica, P. luminescens, SopB, human, P. asymbiotica, P. luminescens, YE2447, SrfA, PhoP, S. typhimurium, SrfA, P. luminescens, YE1604, 1606, ProP, YE3594, YE4072, 4078, YE3228, 3235, AHL, ADP, ye2124, ye2123, Yersinia, P. luminescens, Y. enterocolitica, P. luminescens, Y. enterocolitica, Y. enterocolitica

21_task2

Sentence: Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Protein", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Chemical", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "B-Organism", "I-Organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Repeats-in-toxin (RTX) and other toxins RTX proteins constitute another family of toxins that may contribute to the insecticidal activity of the two pathogens. A putative RTX-family toxin transporter is common to both pathogens (YE1998-2000, Plu0634/Plu0635). The P. luminescens genome comprises a gene cluster encoding RTX proteins, namely plu1330-1369. Further RTX toxins are encoded by plu3217, plu3324 (both RTX A-family), plu4117 (own family), and plu3668 (RTX cytotoxin), none of which is present in Y. enterocolitica. This pathogen produces only one RTX protein (YE1322) for which a truncated homologue is found in P. luminescens (Plu3209). Other examples of toxins common for both bacterial species compared here are homologues of XaxAB, an apoptotic AB toxin of X. nematophila [68], and proteins encoded by the macrophage toxin (mt)-like genes Plu2288 and Plu0359 with high similarity to YE2685. cnf encoding the cytonecrosis factor-like toxin is present in Y. enterocolitica (YE2091) and P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01 (Fig. 4). P. luminescens produces a series of proteins similar to toxins that have been identified in other bacteria, but are absent in Y. enterocolitica. Examples identified are Txp40, a 40 kD insecticidal toxin [69], the nematicidal toxin (Xnp2) first described in X. bovienii (accession number AJ296651.1), galA (plu0840) similar to the enterotoxin Ast of Aeromonas hydrophila which is involved in carbohydrate transport and metabolism [70], and two dermonecrotizing toxin-(dnt-) like factors (plu2400 and plu2420). In addition, neither the crystal proteins encoded by cipA and cipB in P. luminescens nor a Bt-like toxin (plu1537) could be found in Y. enterocolitica. A cytonecrosis factor (CNF)-like protein, Pnf, was identified in P. luminescens ssp. akhurstii strain W14, but not in P. luminescens ssp. laumondii strain TT01. In P. luminescens, the two paralogs plu4092 and plu4436 encode juvenile hormone esterases (JHE) for which insect toxicity has already been demonstrated [24]. Additionally, neither the locus mcf that confers insecticidal activity of P. luminescens towards M. sexta [71] by inducing apoptosis [72], nor the homologous gene locus mcf2 (plu3128) [73] are present in the genome of Y. enterocolitica. Most of these toxins probably contribute to the higher insect toxicity of P. luminescens against the tobacco hornworm in comparison with Y. enterocolitica. No homologues of the Y. pestis gene coding for enhancin (YPO0339) could be found for which a role in flea colonization was predicted [74]. We also identified several virulence genes and operons that are present in Y. enterocolitica, but not in P. luminescens, suggesting that they have been acquired by horizontal gene transfer from other bacteria and do not play a role in bacteria-insect association. Examples are SopB, a host cell invasion factor translocated via the type-III secretion system that is present in the emerging human pathogen P. asymbiotica, but not in the insect pathogen P. luminescens [14], a putative effector protein (YE2447) with proteolytic activity, and a homologue of SrfA which is negatively regulated by PhoP in S. typhimurium [75]. The SrfA homologue has been demonstrated to be up-regulated by environmental temperature [67]. Other virulence factors absent in P. luminescens are the opg cluster (YE1604-1606) and ProP (YE3594), both involved in osmoprotection [76], cellulose biosynthesis (YE4072-4078) associated with protection from chemical and mechanical stress [60], the methionine-salvage pathway (YE3228-3235) also involved in AHL production [23], the putative ADP-ribosyltransferase toxin encoded by ytxAB (ye2124/ye2123) [77], and the Yersinia heat-stable toxin Yst [78] which is stronger expressed at 28degreesC than at 37degreesC (Table 1). Summarizing, the large variety of diverse toxins present in P. luminescens, but absent in Y. enterocolitica, might contribute to the higher toxicity towards insects of P. luminescens in comparison to Y. enterocolitica. Toxins only present in Y. enterocolitica are assumed to play a major role in its pathogenicity towards mammalians, and some of them might have been acquired by horizontal gene transfer. Examples of those factors are shown in Fig. 5.

[ "Repeats", "-", "in", "-", "toxin", "(", "RTX", ")", "and", "other", "toxins", "\n", "RTX", "proteins", "constitute", "another", "family", "of", "toxins", "that", "may", "contribute", "to", "the", "insecticidal", "activity", "of", "the", "two", "pathogens", ".", "A", "putative", "RTX", "-", "family", "toxin", "transporter", "is", "common", "to", "both", "pathogens", "(", "YE1998", "-", "2000", ",", "Plu0634", "/", "Plu0635", ")", ".", "The", "P.", "luminescens", "genome", "comprises", "a", "gene", "cluster", "encoding", "RTX", "proteins", ",", "namely", "plu1330", "-", "1369", ".", "Further", "RTX", "toxins", "are", "encoded", "by", "plu3217", ",", "plu3324", "(", "both", "RTX", "A", "-", "family", ")", ",", "plu4117", "(", "own", "family", ")", ",", "and", "plu3668", "(", "RTX", "cytotoxin", ")", ",", "none", "of", "which", "is", "present", "in", "Y.", "enterocolitica", ".", "This", "pathogen", "produces", "only", "one", "RTX", "protein", "(", "YE1322", ")", "for", "which", "a", "truncated", "homologue", "is", "found", "in", "P.", "luminescens", "(", "Plu3209", ")", ".", "Other", "examples", "of", "toxins", "common", "for", "both", "bacterial", "species", "compared", "here", "are", "homologues", "of", "XaxAB", ",", "an", "apoptotic", "AB", "toxin", "of", "X.", "nematophila", "[", "68", "]", ",", "and", "proteins", "encoded", "by", "the", "macrophage", "toxin", "(", "mt)-like", "genes", "Plu2288", "and", "Plu0359", "with", "high", "similarity", "to", "YE2685", ".", "cnf", "encoding", "the", "cytonecrosis", "factor", "-", "like", "toxin", "is", "present", "in", "Y.", "enterocolitica", "(", "YE2091", ")", "and", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", "(", "Fig", ".", "4", ")", ".", "P.", "luminescens", "produces", "a", "series", "of", "proteins", "similar", "to", "toxins", "that", "have", "been", "identified", "in", "other", "bacteria", ",", "but", "are", "absent", "in", "Y.", "enterocolitica", ".", "Examples", "identified", "are", "Txp40", ",", "a", "40", "kD", "insecticidal", "toxin", "[", "69", "]", ",", "the", "nematicidal", "toxin", "(", "Xnp2", ")", "first", "described", "in", "X.", "bovienii", "(", "accession", "number", "AJ296651.1", ")", ",", "galA", "(", "plu0840", ")", "similar", "to", "the", "enterotoxin", "Ast", "of", "Aeromonas", "hydrophila", "which", "is", "involved", "in", "carbohydrate", "transport", "and", "metabolism", "[", "70", "]", ",", "and", "two", "dermonecrotizing", "toxin-(dnt-", ")", "like", "factors", "(", "plu2400", "and", "plu2420", ")", ".", "In", "addition", ",", "neither", "the", "crystal", "proteins", "encoded", "by", "cipA", "and", "cipB", "in", "P.", "luminescens", "nor", "a", "Bt", "-", "like", "toxin", "(", "plu1537", ")", "could", "be", "found", "in", "Y.", "enterocolitica", ".", "A", "cytonecrosis", "factor", "(", "CNF)-like", "protein", ",", "Pnf", ",", "was", "identified", "in", "P.", "luminescens", "ssp", ".", "akhurstii", "strain", "W14", ",", "but", "not", "in", "P.", "luminescens", "ssp", ".", "laumondii", "strain", "TT01", ".", "In", "P.", "luminescens", ",", "the", "two", "paralogs", "plu4092", "and", "plu4436", "encode", "juvenile", "hormone", "esterases", "(", "JHE", ")", "for", "which", "insect", "toxicity", "has", "already", "been", "demonstrated", "[", "24", "]", ".", "Additionally", ",", "neither", "the", "locus", "mcf", "that", "confers", "insecticidal", "activity", "of", "P.", "luminescens", "towards", "M.", "sexta", "[", "71", "]", "by", "inducing", "apoptosis", "[", "72", "]", ",", "nor", "the", "homologous", "gene", "locus", "mcf2", "(", "plu3128", ")", "[", "73", "]", "are", "present", "in", "the", "genome", "of", "Y.", "enterocolitica", ".", "Most", "of", "these", "toxins", "probably", "contribute", "to", "the", "higher", "insect", "toxicity", "of", "P.", "luminescens", "against", "the", "tobacco", "hornworm", "in", "comparison", "with", "Y.", "enterocolitica", ".", "No", "homologues", "of", "the", "Y.", "pestis", "gene", "coding", "for", "enhancin", "(", "YPO0339", ")", "could", "be", "found", "for", "which", "a", "role", "in", "flea", "colonization", "was", "predicted", "[", "74", "]", ".", "We", "also", "identified", "several", "virulence", "genes", "and", "operons", "that", "are", "present", "in", "Y.", "enterocolitica", ",", "but", "not", "in", "P.", "luminescens", ",", "suggesting", "that", "they", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", "from", "other", "bacteria", "and", "do", "not", "play", "a", "role", "in", "bacteria", "-", "insect", "association", ".", "Examples", "are", "SopB", ",", "a", "host", "cell", "invasion", "factor", "translocated", "via", "the", "type", "-", "III", "secretion", "system", "that", "is", "present", "in", "the", "emerging", "human", "pathogen", "P.", "asymbiotica", ",", "but", "not", "in", "the", "insect", "pathogen", "P.", "luminescens", "[", "14", "]", ",", "a", "putative", "effector", "protein", "(", "YE2447", ")", "with", "proteolytic", "activity", ",", "and", "a", "homologue", "of", "SrfA", "which", "is", "negatively", "regulated", "by", "PhoP", "in", "S.", "typhimurium", "[", "75", "]", ".", "The", "SrfA", "homologue", "has", "been", "demonstrated", "to", "be", "up", "-", "regulated", "by", "environmental", "temperature", "[", "67", "]", ".", "Other", "virulence", "factors", "absent", "in", "P.", "luminescens", "are", "the", "opg", "cluster", "(", "YE1604", "-", "1606", ")", "and", "ProP", "(", "YE3594", ")", ",", "both", "involved", "in", "osmoprotection", "[", "76", "]", ",", "cellulose", "biosynthesis", "(", "YE4072", "-", "4078", ")", "associated", "with", "protection", "from", "chemical", "and", "mechanical", "stress", "[", "60", "]", ",", "the", "methionine", "-", "salvage", "pathway", "(", "YE3228", "-", "3235", ")", "also", "involved", "in", "AHL", "production", "[", "23", "]", ",", "the", "putative", "ADP", "-", "ribosyltransferase", "toxin", "encoded", "by", "ytxAB", "(", "ye2124", "/", "ye2123", ")", "[", "77", "]", ",", "and", "the", "Yersinia", "heat", "-", "stable", "toxin", "Yst", "[", "78", "]", "which", "is", "stronger", "expressed", "at", "28degreesC", "than", "at", "37degreesC", "(", "Table", "1", ")", ".", "Summarizing", ",", "the", "large", "variety", "of", "diverse", "toxins", "present", "in", "P.", "luminescens", ",", "but", "absent", "in", "Y.", "enterocolitica", ",", "might", "contribute", "to", "the", "higher", "toxicity", "towards", "insects", "of", "P.", "luminescens", "in", "comparison", "to", "Y.", "enterocolitica", ".", "Toxins", "only", "present", "in", "Y.", "enterocolitica", "are", "assumed", "to", "play", "a", "major", "role", "in", "its", "pathogenicity", "towards", "mammalians", ",", "and", "some", "of", "them", "might", "have", "been", "acquired", "by", "horizontal", "gene", "transfer", ".", "Examples", "of", "those", "factors", "are", "shown", "in", "Fig", ".", "5", ".", "\n" ]

[ "Organism", "Protein", "Chemical" ]

Monitoring is an umlsterm, pressure is an umlsterm

DerRadiologe.80380624.eng.abstr_task0

Sentence: Purpose : Monitoring of intraluminal pressure in standardized enteroclysis . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Purpose : Monitoring of intraluminal pressure in standardized enteroclysis .

[ "Purpose", ":", "Monitoring", "of", "intraluminal", "pressure", "in", "standardized", "enteroclysis", "." ]

[ "umlsterm" ]